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ABSTRACT 
Transgenic mice overexpressing Cx43 in specific regions of the vasculature were 
generated to examine the hypothesis that vascular function ( specifically blood pres$ure) 
is influenced by increased connexin (Cx) 43 expression. The creation of a DNA 
construct containing a restricted portion of the SM22a promoter (SM22a I Cx43) to 
drive Cx43 gene expression, met the tissue specific requirement of the mice. 
Unfortunately, the establishment of a temporal and tissue specific transgenic mouse line 
to ensure that the mouse would not succumb to embryonic or neo-natal mortality, 
exceeded the time limitations of the current project. 
When tested in vitro in murine aortic smooth muscle cells (prior to 
transformation into BALB/c embryonic stem cells), this DNA construct (SM22a / Cx43 
I pBs KSII-) produced inconclusive results. This construct was, however, used to 
generate a transgenic mouse line with a truncated-promoter in the germ-line. It was 
found that only 204 to 103 bp of the SM22a promoter was present and so the functional 
capability of the truncated-promoter was unknown. Subsequently, this mouse line was 
interbred to increase the gene copy number and hence, the Cx43 expression level. A 
second attempt produced mice with the full-promoter in the germ-line. 
Preliminary analyses on both mouse lines revealed the following: the aortic and 
tail artery tissues of all transgenic mice were more fragile than the control mouse; and 
the blood pressures of all mice, as determined by tail-cuff plethysmography, were within 
the normal range. Western blotting was used to determine the Cx43 protein levels in the 
aortae and tail arteries of the mice. In the single transgenic-promoter mice, there was no 
significant increase in Cx43 expression in either the aorta or tail artery. The double 
transgenic truncated-promoter mice had significantly increased Cx43 protein levels in 
the aorta, with no change in the tail artery, which indicates that the truncated-promoter 
was minimally functional. In the single transgenic full-promoter mice, aortic Cx43 
protein levels were significantly increased with a trend towards increased Cx43 in the 
tail arteries, which demonstrated that the SM22a / Cx43 construct was functional in 
VIVO. 
V 
Together, the Cx43 expression data and the blood pressure measurements. 
suggest that increased Cx43 expression does not cause hypertension or hypotension in 
the mouse. The results obtained from this thesis provide the groundwork for further 
experimentation into the physiological effects of Cx43 overexpression in the vasculature 
and changes in vascular reactivity. 
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Chapter 1 - Introduction 
This thesis examines the hypothesis that vascular function is influenced by 
connexin expression by specifically determining the effects of increased connexin (Cx) 
4 3 expression on blood pressure. To date, over fourteen individual mammalian 
connexins have been described (Beyer et al. 1990; Goodenough et al. 1996; Kumar and 
Gilula, 1992, 1996; Lo, 1999), with three having been identified in vascular smooth 
muscle: Cx43, Cx40 (Beyer et al. 1992; Little et al. 1995a; Christ et al. 1996; Severs et 
al. 1996; Xie et al. 1997; Hill et al. 2002) and Cx37 (Nakamura et al. 1999; Hill et al. 
2002). 
The characteristics of gap junctions, as determined by the properties of their 
component Cx properties, permit the selective intercellular passage of various ions, 
metabolites and small molecules ( < 1 kD) between adjacent coupled cells (Loewenstein, 
1981; Beyer et al. 1990; Bennett et al. 1991; Beny and Pacicca, 1994; Bruzzone et al. 
1996; Goodenough et al. 1996; Veenstra, 1996). Such coupling can vary both within, 
and between, vascular beds. Changes in the distribution and expression of the vascular 
connexins have been correlated with a number of disease states such as hypertension, 
atherosclerosis, coronary heart disease and renal failure (Brink, 1998; Severs, 1999; 
Kwak et al. 2002). 
In order to investigate aspects of some of these disease states, and in particular 
hypertension, the primary aim of this thesis was to produce a transgenic mouse model 
that would selectively overexpress Cx43 in the arterial system. This would enable an 
examination of the physiological effects of such overexpression on a number of aspects 
of vascular function, in particular the effect on blood pressure. 
1.1 The Circulatory System 
1.1.1 General overview 
The circulatory system consists of the heart and an extensive system of arteries, 
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veins and lymph vessels that are responsible for the supply of essential substances, such 
as oxygen and nutrients, and the removal of metabolic by-products. In this regard, the 
circulatory system is essential for the maintenance of homeostasis, including 
temperature regulation, systemic humoral communication, and adjustments to oxygen 
and nutrient supply in different physiological states (Berne and Levy, 1988; Tortora and 
Grabowski, 1993). 
The vascular system consists of three general types of vessels that can be 
subdivided on a functional basis: the aorta and arteries (a distributing system), the 
microcirculation (a diffusion and filtration system), and the veins (a collecting system). 
1.1.2 Types of arteries 
Arteries have traditionally been classified into three types: large or elastic 
arteries ( eg. the aorta), medium or muscular arteries ( eg. the coronary, mesenteric and 
middle cerebral arteries), and small arteries and arterioles. In general, large diameter 
vessels with a media consisting of smooth muscle cells and elastic laminae, are referred 
to as elastic arteries, whilst vessels with a much reduced or absent medial elastic lamina 
are referred to as muscular arteries (Duling et al. 1991; Luff, 1991 ). The latter generally 
decrease in diameter as they approach the periphery at which point, the media consists 
of only 1 to 2 smooth muscle cell layers, and where the vessel is commonly referred to 
as an arteriole (Mulvany and Aalkjaer, 1990). Elastic arteries may give rise to elastic or 
muscular branches, although the reverse does not occur (Bunce, 1970). Functionally, 
elastic arteries serve as conduction tubes that facilitate the passage of blood (Berne and 
Levy, 1989). 
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1.1.3 Arterial morphology 
In all arteries, the vessel wall is divided into three distinct layers: the intima, 
media and adventitia (Gutterman, 1999). Although variations in the characteristics of 
each layer have been observed in different vascular beds, the general arrangement of the 
endothelial and smooth muscle cells is similar in all arteries. A description of the 
morphology based upon several publications is presented in Figure 1.1 and Section 
1.1.3.1 (Rhodin, 1967, 1980; Gabella, 1981; Ross and Reith, 1985; Deitweiler, 1989; 
Mulvany and Aalkjaer, 1990; Duling et al. 1991; Luff, 1991), with the latter 
concentrating on the vascular smooth muscle cells, which are of particular relevance to 
the current study. 
1.1.3 .1 Vascular smooth muscle cells 
Vascular smooth muscle cells, the predominant cell type in the media, are 
mononucleate and are arranged in helical or circular layers around the larger blood 
vessels with a generally decreased pitch ( defined as the degree of angle in relation to the 
parallel arrangement of the vessel) in more peripheral vessels (Rhodin, 1967; Luff, 
1991 ). The structural arrangement of vascular smooth muscle cells reflects both 
functional and regulatory variations between different blood vessels, both in different 
parts of the vasculature and within the same vascular region (Jacobsen et al. 1966; 
Bevan and Torok, 1970; Shiraishi et al. 1986; Frid et al. 1997). 
The size of vascular smooth muscle cells varies considerably in different 
vascular beds ranging from 30 to approximately 2000 µm in length (Bumstock, 1970; 
Gabella, 1981) and from 3 to 20 µmin width (Komuro et al. 1982; Todd et al. 1983; 
Shiraishi et al. 1986). The overall shape of vascular smooth muscle cells has been 
shown to vary along the one vascular bed, between different vascular beds and between 
different animals (Gabella, 1981 ; Todd et al. 1983; Shiraishi et al. 1986; Gabella, 1991 ; 
adventitia 
media 
intima 
Figure 1.1 Schematic representation of the X-sectional appearance of an artery 
The intima consists of a tubular lining of endothelial cells which are joined by tight 
( occluding) junctions and gap ( communicating) junctions, with the specific arrangement of 
junctions varying in different blood vessels, tissues and animal species. In elastic arteries, the 
intima is usually relatively thick, consisting of the lining endothelium with its basal lamina, a 
subendothelial layer of connective tissue with both collagenous and elastic fibres, and the 
concentrically arranged internal elastic lamina. In muscular arteries, the subendothelial 
connective tissue is sparse and in some arteries, the basal lamina of the endothelium contacts 
the internal elastic membrane. 
The medial layer consists of either single or multiple layers of smooth muscle cells 
that vary in size, shape and arrangement in different blood vessels. These cells are connected 
by tight and gap junctions, with collagen fibres often being present in the region between 
smooth muscle cells. In both elastic and muscular arteries, the smooth muscle cells produce 
extracellular collagen and elastic fibres. Arterioles have one layer of smooth muscle cells 
and a small artery may have up to about eight layers of smooth muscle cells. Muscular 
arteries often have a distinct external elastic lamina. 
The adventitia confers structural support to the vessel, as well as connecting it to the 
surrounding tissues. It is composed of connective tissue and extracellular collagen fibres 
which contain cellular components such as fibroblasts, macrophages, and sympathetic, 
parasympathetic and sensory nerve fibres, and Schwann cells. The thickness of the adventitia 
varies considerably depending on the type and location of the blood vessel. 
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Kohler et al. 1999), as well as during development (Hill and Sandow, unpublished 
results) and maturation (Cliff, 1967; Miller et al. 1987). 
A variety off orms of vascular smooth muscle cells have been found to coexist 
within the vascular wall (Giuriato et al. 1995; Frid et al. 1997). Phenotypically distinct 
vascular smooth muscle cells, characterized by different patterns of ultrastructural 
morphology, cytoskeletal protein and ion channel expression, electrical responses, 
capacity for extracellular matrix synthesis, migration and growth, have been identified 
in the adult arterial media and in culture (Ko et al. 1999; Kohler et al. 1999; Halayko 
and Solway, 2001). Thus, specific types of vascular smooth muscle cells may be 
differentially involved in the processes associated with vascular disease (Frid et al. 
1997; Seidel, 1997). A characteristic property of vascular smooth muscle cells is their 
ability to modulate between the contractile phenotype and the synthetic phenotype, 
which is characterized by a reduction in myofilament content and an increase in 
synthetic organelles (Campbell et al. 1981 ), for the synthesis of extracellular matrix 
molecules (Blackbum et al. 1997). In the adult mammalian vascular system, vascular 
smooth muscle cells are found predominantly in the contractile state, but during vascular 
disease (in hypertension, for example) or following injury or during atherosclerotic 
plaque formation, the secretory synthetic type is expressed (Rennick et al. 1993; Lindop 
et al. 1995; Ross, 1996; Dzau et al. 1993; Severs, 1999). 
Abnormal growth of vascular smooth muscle cells plays an important role in the 
pathogenesis of many vascular diseases including atherosclerosis and hypertension 
(Jackson and Schwartz, 1992; Christ et al. 1996; Haefliger et al. 1997b; Shimokawa, 
1999). In hypertension, the vascular pathology is characterized by hypertrophy of the 
media, which in tum results in elevated blood pressure (Weissberg et al. 1995), whilst 
development of the intimal cells occurs in atherosclerosis (Blackbum et al. 1995; 
Schwartz et al. 1995; Schwartz, 1999). It has been suggested that these changes are 
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related to the position of the particular vessel in the vascular tree (Nakamura et al. 
1998). 
In hypertension, hypertrophy of the media is greater in the smaller arteries or 
arterioles than in the larger arteries, such as the coronary artery (Isoyama et al. 1992). 
Thus, in this state, the main pathological change in the vascular smooth muscle cells 
varies according to the size and position in the vasculature of the specific blood vessel. 
In the small arteries or arterioles, the smooth muscle cells undergo hyperplasia rather 
than hypertrophy (Mulvany et al. 1985; Berk et al. 1989) whilst in the larger arteries, 
they undergo hypertrophy rather than hyperplasia (Owens et al. 1981 ; Berk et al. 1989). 
Morphologically and biochemically there is little to distinguish these cells from normal 
vascular smooth muscle cells other than the hypertrophy / hyperplasia and a tendency to 
form multiple branches (Lindop et al. 1995; Weissberg et al. 1995). 
1.1.4 Arterial function 
As a functional whole, vascular smooth muscle cells contribute to the control of 
total peripheral resistance, and arterial and venous tone (Christ et al. 1996). These cells 
are in close contact with the endothelial cells which maintain the homeostatic state of 
the blood vessel by producing factors that regulate vessel tone, coagulation state, 
cellular responses ( eg. proliferation), and leukocyte movements (Kunsch and Medford, 
1999). 
Contraction of the smooth muscle cells assists in the maintenance of blood 
pressure (Sherwood, 1993; Tortora and Grabowski, 1993). Contraction is initiated by 
an increase in the cytoplasmic concentration of calcium resulting from the release of 
calcium from the sarcoplasmic reticulum and/or from the influx of calcium from the 
extracellular space though voltage-dependent calcium channels (VDCC: L-type and T-
type, of which the L-type VDCC is a major contributor to vascular tone) or receptor 
operated nonselective channels (Tortora and Grabowski, 1993; Martens and Gelband, 
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1998). The specific mechanisms involved in the entry and activity of calcium vary 
amongst vascular beds (van Breemen et al. 1995; Hirst and Edwards, 1989; Jagger and 
Ashmore, 1999). Calcium increase in the cytosol activates myosin light chain kinase, an 
enzyme that uses ATP to phosphorylate the myosin so that it can bind to actin for 
contraction to occur. Smooth muscle tone, which is integral for the maintenance of 
vascular tone and tension, is maintained by the continual entry and removal of calcium 
from the cytosol of smooth muscle cells, resulting in the preservation of a state of 
continual partial contraction (Sherwood, 1993; Tortora and Grabowski, 1993). 
1.1.5 Gap junctions 
The coupling of vascular smooth muscle cells via gap junctions is essential for 
the co-ordination, modulation and propagation of the contractile activity of vascular 
smooth muscle cells (Segal and Duling, 1986; Hirst and Edwards, 1989; Duling et al. 
1991; Christ et al. 1993a,b; Segal, 1994; Brink et al. 2000). The absence or reduction in 
gap junctions in tumours or transformed cells (Loewenstein, 1979; Ruch et al. 1998) 
and their corrective effects on cell proliferation when connexins, their constituent 
proteins, are transfected into these cells (Mehta et al. 1991; Rose et al. 1993 ), suggests 
that gap junctions also play an important role in the control of cell growth and 
development (Loewenstein, 1987; Bennett et al. 1991; Loewenstein and Rose, 1992; 
Warner, 1992; Goodenough et al. 1996; Lo, 1996). 
Analysis of connexin gene knockout animals and naturally occurring connexin 
mutations, has indicated that gap junctional communication has diverse functions in the 
development and physiological activity of not only the vascular system, but also of 
several organ systems (Lo, 1996; Martyn et al. 1997; Chanson et al. 1999; Waldo et al. 
1999). 
Gap junctions are dynamic structures, continually undergoing the process of 
formation and degradation (Christ et al. 1996; Spray, 1998). Compared with many 
other membrane proteins, this appears to be rapid in normal adult vascular tissues with, 
for example, Cx43 half-life between 1.5 and 3 hours in primary cultures of neonatal 
myocytes (Beardslee et al. 1998) as well as in other cultured cells (Fallon and 
Goodenough, 1981; Yancey et al. 1981 ; Laird et al. 1991; Darrow et al. 1995; Laing 
and Beyer, 1995; Darrow et al. 1996; Laing et al. 1997). Regulation of gap junction 
function and structure by various means, including via the activity of growth and 
differentiation factors, has been extensively reported (Meda et al. 1993; Brissette et al. 
1994) and will be discussed further in Section 1.1.5.4. 
1.1.5 .1 Gap junction structure 
Dye-tracer studies, high resolution electron microscopy and nuclear resonance 
imaging (NMR) electron microscopy have enabled the morphological structure of gap 
junctions to be well characterized (Brightman and Reese, 1969; Makowski et al. 1977, 
1984; Lampe et al. 1991; Yeager and Gilula, 1992; Yeager, 1995). Cell-to-cell contact 
through gap junctions occurs at sites of close apposition (2 to 3 nm apart) of plasma 
membranes of adjacent cells (Goodenough and Revel, 1970; Gabella, 1973; Caspar et 
al. 1977; Little, 1995a,b; Unger et al. 1999). These sites appear as electron dense 
pentalaminar structures (Luff, 1991) approximately 10 nm in width (Brink, 1998). 
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At the molecular level, gap junctions have been described as consisting of a 
highly conserved group of membrane protein subunits termed connexins; different types 
and combinations of which allow the selective intercellular passage of various ions, 
metabolites and small molecules(< 1 kD) in different vascular beds and tissues 
(Loewenstein, 1981 ; Beyer et al. 1990; Bennett et al. 1991; Beny and Pacicca, 1994; 
Bruzzone et al. 1996; Goodenough et al. 1996; Kumar and Gilula, 1996; Veenstra, 
1996; Simon, 1999; Falk, 2000). Each gap junction channel is composed of 12 
connexin protein subunits farmed by the association of two hemichannels ( connexons ), 
one in each opposing cell, comprising a hexagonal array of six connexin polypeptides 
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which together surround a central pore 1.5 to 2.0 run in diameter (Loewenstein, 1980, 
1987; Figure 1.2). 
The characteristic pentalaminar appearance of the gap junctions at the 
ultrastructural level, together with the arrangement of transmembrane connexins, is 
illustrated in Figure 1.3. Electron micrographs have shown that gap junctions have 
variable numbers of closely packed membrane channels, ranging from a few to many 
thousands (also called gap junct.ion plaques) (Goodenough and Revel, 1970), with the 
packing morphology varying between different tissues (Shivers and Mc Vicar, 1995). 
Since the first connexin cloning studies of Kumar and Gilula ( 1986) and Paul 
(1986) that demonstrated the full length amino acid sequences for specific connexins, 
over fourteen distinct mammalian connexins have been cloned and designated according 
to their molecular mass (in the range 26 to 60 kD) (Beyer et al. 1990; Willecke et al. 
1991; Kumar and Gilula, 1992; Goodenough et al. 1996) or into three major subclasses, 
a or type II,~ or type I and y or type III (Gimlich et al. 1990; Kumar and Gilula, 1996; 
O'Brien et al. 1998). Their presence has been demonstrated in a large variety of 
organisms (Bennett et al. 1995; Waltzman and Spray, 1995; Morley et al. 1997), as well 
as in various mammalian cell types and tissues (Paul, 1986; Waltzman and Spray, 1995; 
Coppen et al. 1999; Lo, 1999). Although connexin expression is conserved among 
species, it has been shown to be both tissue- and cell-specific, with some cell types 
expressing multiple connexins (Donaldson et al. 1997). Multiple connexins may also be 
present in the same gap junctional plaque (Nicholson et al. 1987). 
In vascular smooth muscle, two connexins have been identified - connexin (Cx) 
43 and Cx40 (Christ et al. 1996), whilst Cx43 , Cx40 and Cx37 have been demonstrated 
in vascular endothelial cells (Beyer et al. 1992; Christ et al. 1996; Delorme et al. 1997). 
Localization of Cx3 7 has recently been demonstrated in the medial layer of both the 
pulmonary artery and aorta (Nakamura, 1999) and in the rat tail artery (Hill and Hickey, 
Cell2 
Figure 1.2 Gap junction structure between smooth muscle cells 
High power electron micrograph from a 14 day rat iris 
arteriole showing a typical gap junction between smooth muscle cells 
and the appearance of connexins at the electron microscope level. 
The characteristic pentalaminar structure can be seen clearly. The 
lighter regions (arrows; 1-3) denote individual connexin channel 
pores. The distance between the connexins is 9 nm. The scale bar 
represents 5 nm. 
(Electron micrograph courtesy of Dr. Shaun Sandow, Division of 
Neuroscience, John Curtin School of Medical Research, Australian 
National University). 
Figure 1.3 Structure of gap junction channels 
Schematic diagram of the structure of gap junction channels between two cells 
A and B, demonstrating the position of the connexons in the cell membranes and their 
constituent connexins. Also shown are the lipid bilayers, the intercellular space and 
some of the molecules which are known to pass through the central pore of each gap 
junction. 
(Modified from Christ et al. 1996). 
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pers com). Connexins may also have overlapping or complementary expression patterns 
(Delorme et al. 1997). 
High resolution ultrastructural studies and sequencing data have shown that the 
connexins comprise a family of homologous proteins, all of which have four a-helical 
transmembrane domains that form the channel, two extracellular loops, a cytoplasmic 
loop, and cytoplasmic NH2_ and COOH- termini (Figure 1.4) (Bennett et al. 1991; 
Locke, 1998; Unger et al. 1999) which can influence or regulate the physical properties 
of the channel (Makowski et al. 1977; Kumar and Gilula, 1992; Paul, 1995; Sosinsky, 
1996; Yeager and Nicholson, 1996; Nicholson and Bruzzone, 1997; Yeager, 1998; 
Pumick et al. 2000). The extracellular loops of all connexins contain highly conserved 
cysteine residues, which are important in intercellular recognition and the docking of 
two hemichannels ( connexons) (Yeager and Nicholson, 1996). Studies of the carboxy 
terminal ( CT) tail have shown that it is an important site for channel gating in response 
to intracellular signalling (Moreno et al. 1994; Ek-Vitorin et al. 1996; Castro et al. 
1999) with each domain interacting with the other domains (Verselis et al. 1994). The 
CT tail also has a role in regulating connexin-mediated growth (Omori and Yamasaki, 
1999). 
Sequence similarity amongst the connexins is concentrated in the transmembrane 
domains and extracellular loops, whilst most of the sequence and length variation is in 
the cytoplasmic loop and CT tail (Beyer et al. 1990; Haefliger et al. 1992; Donaldson et 
al. 1997). Domain swapping experiments have determined that compatibility between 
the connexins (defined as the ability of adjacent cells expressing different connexins to 
communicate) is attributable to the second extracellular domain (White et al. 1994, 
1995). 
Figure 1.4 Structure of gap junction channels 
Two typical connexins, Cx43 and Cx32, are illustrated, showing the four 
membrane spanning domains - two extracellular loops, a cytoplasmic loop, and 
cytoplasmic amino (N) and carboxy (C) termini. 
(Modified from Yeager and Nicholson, 1996). 

10 
1.1.5.2 Gap junctions: homomeric, heteromeric, homotypic and heterotypic forms 
As alluded to above, each connexon (hemichannel) may be composed of either 
one type of connexin (homomeric) or multiple connexins (heteromeric). Theoretically, 
the heteromeric connexon can result in a variety of connexin combinations (Brink, 
1998; White and Paul, 1999) which would be physiologically advantageous, in terms of 
diversity, for intercellular communication. Adjacent cells can contribute different types 
of connexon to the intercellular channel giving rise to homotypic ( when the same 
connexin is present in both connexons ), heterotypic ( when each connexon is composed 
of a different connexin) or heteromeric (when different connexins mix in the 
connexons) intercellular channels (Figure 1.5) (Bukauskas et al. 1995; White and 
Bruzzone, 1996; Brink et al. 1997; Yeh et al. 1998; White and Paul, 1999). 
Some combinations of connexins, however, will not interact and consequently, 
are unable to form functional channels. Cx43 and Cx40, for example, are coexpressed 
in vascular smooth muscle and together, they form homomeric / homotypic channels 
with distinct permeability and gating properties but not functional homomeric / 
heterotypic channels (Kanter et al. 1993; He et al. 1999; Li and Simard, 1999). 
Conversely, He et al. (1999) demonstrated that in vascular smooth muscle cells in vitro, 
Cx43 and Cx40 can form functional channels with unique gating and conductance 
properties in the form of heteromeric channels, whilst Valiunas et al. (2000) have 
demonstrated that these connexins can form functional heterotypic channels in human 
HeLa cells. 
Electrophysiological studies of heterotypic channels have shown that some 
exhibit unique properties compared to homotypic channels (Barrio et al. 1991; Bruzzone 
et al. 1994; White et al. 1994; Darrow et al. 1996; Brink et al. 1997). Studies of 
homotypic Cx43, Cx40 and Cx37 gap junction channels (Brink et al. 1996; Veenstra, 
1996) have shown that they all display symmetric voltage dependence but different 
kinetics and voltage sensitivities (Brink, 1998). Furthermore, they are all permeable, 
Figure 1.5 Connexins in gap junctions 
The arrangement of connexins into connexons, intercellular channels and gap 
junctions is shown. Adjacent cells contribute different types of connexon to the 
intercellular channel giving rise to heteromeric, homomeric, heterotypic and homotypic 
channels. 
(Modified from White and Paul, 1999). 
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though at different levels, to fluorescent dye molecules in the range 350 to 450 Da such 
as Lucifer Yellow or carboxyfluorescein (Robinson et al. 1993; Moreno et al. 1994; 
Little et al. 1995b; Brink, 1996, 1997; Darrow et al. 1996), with Cx37-Cx40 having 
reduced permeability to 6-carboxyfluroscein compared to Cx43 (Veenstra et al. 1994). 
1.1.5.3 Gap junction expression 
The previous sections have alluded to the fact that different connexins and 
differences in the characteristics of connexins can confer specific physiological 
properties on gap junctions (Bruzzone et al. 1996; Beyer et al. 1990; Willecke et al. 
1991; Goodenough et al. 1996). Since most, if not all cells and tissues express at least 
two connexins (Nicholson et al. 1987; Kanter et al. 1992,1993; Darrow et al, 1995; 
Stauffer, 1995; Van Rijen et al. 1997; Coppen et al. 1999; Lo, 1999; Mehta et al. 1999), 
it follows that the properties of the gap junctions of any cell or tissue are complex. 
Physiological analysis of channel formation and gating has revealed unique 
patterns of connexin-connexin interaction, as well as unique functional characteristics of 
channels containing more than one type of connexin protein (White et al. 1995; White 
and Bruzzone, 1996). Each connexin has tissue-specific distributions, differential 
temporal expression and specific channel permeability properties, and is subject to 
unique types of biochemical regulation (Veenstra, 1992; Bruzzone et al. 1996; Kumar 
and Gilula, 1996; Bevans et al. 1998; Goodenough et al. 1996). Data from animal 
model studies and human disease states have shown that genetic defects in each 
connexin produce distinct developmental and/or physiological defects (Britz-
Cunningham et al. 1995; Paul, 1995; Anzini et al. 1997; Donaldson et al. 1997; Ewart 
et al. 1997; Huang et al. 1998; Chanson et al. 1999; Sullivan et al. 1999; ·White and 
Paul, 1999; Willecke et al. 1999). Specific mutations in Cx32 result in X-linked 
Charcot-Marie-Tooth disease, a demyelinating peripheral neuropathy (Bergoffen et al. 
1993; Anzini et al. 1997; Balice-Gordon et al. 1998; Abel et al. 1999; Fischbeck et al. 
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1999) whilst congenital hereditary bilateral cataracts have been associated with a 
missense mutation in Cx50 (White and Paul, 1999; Xu and Ebihara, 1999). 
Mutations in Cx43 (also referred to al connexin, and is the predominant gap 
junction gene in developing and adult heart tissue) have been shown to be associated 
with atrial defects ( eg. visceroatrial heterotaxia; Britz-Cunningham et al. 1995) and 
other congenital cardiac abnormalities (Reaume et al. 1995). In the transgenic 
( overexpressing Cx 4 3) and knockout Cx 4 3 mice, there are major right ventricular 
cardiac defects (Reaume et al. 1995; Ewart et al. 1997; Martyn et al. 1997; Ya et al. 
1998) leading to failure of pulmonary gas exchange and neonatal lethality at birth. 
Consequently, Cx43 appears to play an important role in cardiac morphogenesis with 
the precise level of Cx43-mediated gap junctional communication also being potentially 
critically important (Reaume et al. 1995; Ewart et al. 1997). 
Coexpression of multiple connexins enables cells to achieve levels of 
intercellular communication that could not be achieved by expression of a single 
connexin (Koval et al. 1995). Coexpression also enables functional compensation to 
occur (Minkoff et al. 1999) as has been demonstrated in Cx43 knockout mice. In this 
mouse, the absence of gross abnormalities, other than the ( critical) heart defect, has been 
taken as evidence that the loss of Cx43 can be compensated for by other connexins 
whose distributions overlap (De Sousa et al. 1997; Houghton et al. 1999). Furthermore, 
in preimplantation embryos lacking Cx43, a low level of intercellular coupling is 
maintained by gap junction channels having characteristics of Cx45 ( a6 connexin; De 
Sousa et al. 1997). Cx32 has also been suggested to compensate for the absence of 
Cx43 in some instances (Houghton et al. 1999). The ability of one type of connexin to 
either induce or suppress the expression of other connexins during development (van 
Kempen et al. 1995) has been demonstrated with respect to Cx45 in the Cx43 knockout 
mice (De Sousa et al. 1997) as well as with other connexin combinations. 
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Depending on the surrounding microenvironment to which cells are exposed, the 
extent of intercellular communication may also vary during development and aging 
(Mombouli and Vanhoutte, 1999). Modification of the Cx43 gene in mice has 
highlighted the importance of this connexin in heart morphogenesis (Reaume et al. 
1995; Ewart et al. 1997; Huang et al. 1998; Sullivan et al. 1999). In the Cx43 knockout 
mouse, abnormal cardiac tissue growth has been observed during development (Sullivan 
et al. 1999). Responses to other stimuli (pharmacological, hormonal or oncogenic) may 
also be distinct to a particular connexin or group of connexins (Mehta et al. 1999). 
1.1.5.4 Regulation of gap junction function 
Many aspects of the regulatory processes of gap junctions have been elucidated 
as a result of physical, biochemical and cloning studies. Regulation of gap junction 
function, and hence gap junction-mediated communication, can occur both acutely 
(gating) and over a longer time period. In the latter, overall connexin expression levels 
are altered, with or without switching to functionally different connexin isoforms 
(Bennett et al. 1991; Beyer, 1991). 
Dye coupling experiments and dual whole-cell voltage-clamp experiments 
(Flagg-Newton et al. 1979; Schwarzmann et al. 1981; Little et al. 1995b; White et al. 
1995; Darrow et al. 1996; Kwak and Jongsma, 1996; Bevans et al. 1998; Ebihara et al. 
1999; Manthey et al. l 999; Srinivas et al. 1999) have been used extensively to 
determine the functional state of gap junctions. Dye coupling studies have provided 
information about the extent of diffusional coupling and permeability of the channels, 
whilst dual whole-cell voltage-clamp experiments have allowed the gap junctional 
conductance (gj), which depends on the number of channels present, the conductance of 
each channel (yj) and their probability of being ' open' , to be determined (Kwak and 
Jongsma, 1996). As the majority of these studies have been done in the adult animal, 
there is a lack of comparable data for the immature and developing animal. 
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Gap junctions can 'open' and 'close' ( or be in an 'intermediate' state) rapidly in 
response to various stimuli (Moreno et al. 1994; Morley et al. 1997); an ability which 
may enable cells to adapt quickly to different physiological conditions. In human 
corporal cells, for example, the mean open time for Cx 4 3 channels ranged from O. 43 to 
5.25 seconds while the mean closed time was in the range of 0.21 to 1.49 seconds 
(Brink et al. 1997). At any one time, the proportion of channels open depends on the 
characteristics of the constituent connexin/s in conjunction with such variables as the 
calcium concentration, transjunctional voltage, phosphorylation state, cytoplasmic pH 
and levels of cAMP (Laing and Beyer, 1995). These are briefly discussed below. 
In prolonged transjunctional voltage, where the voltage differs between two 
cellular interiors (Revilla et al. 1999), vascular smooth muscle cell Cx43 gap junction 
channels are prone to prolonged closures (Brink et al. 1996). Phosphorylation (Kwak et 
al. 1995a,b; Kwak and Jongsma, 1996) and changes in intracellular pH (Bennett et al. 
1991; Morley et al. 1997; Francis et al. 1999) are known to be important regulators of 
gap junctional communication. Phosphorylation has been implicated in connexin 
trafficking, assembly, insertion into membranes, degradation and retrieval from the 
plasma membrane (Laird, 1996; White and Bruzzone, 1996; Stahl and Sies, 1998). It 
also influences the gating of gap junction channels, as do changes in intracellular pH 
and the concentration of calcium (Obaid et al. 1983). The effect phosphorylation exerts 
on junctional coupling is dependent on two factors: the type of connexin and the type of 
kinase involved (Kwak et al. 1995a,b; Kwak and Jongsma, 1996). Phosphorylation is 
associated with both increases and decreases in junctional coupling (Musil and 
Goodenough, 1991; Kwak and Jongsma, 1996; Hertlein et al. 1998), probably in 
consequence to conformational changes in the connexin/s that make up the channel. 
Changes in the phosphorylation state of Cx43, for example, appear to correlate with 
changes in the functional state of the gap junctions formed by this protein (Saez et al. 
1993, 1997; Moreno et al. 1994; Lau et al. 1996; Warn-Cramer et al. 1998). Saez et al. 
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(1997) showed reduced functional coupling of neonatal rat cardiac myocytes after 
treatment with staurosporine, a protein kinase inhibitor. In contrast, Crow et al. (1990) 
demonstrated that in transformed mammalian fibroblasts, phosphorylation of Cx43 on 
tyrosine in the presence of v-src is correlated with inhibited communication. 
With respect to the regulation of gap junctions and changes in pH, Morley et al. 
(1997) showed that the closure of Cx43 channels is significantly impaired by the 
truncation of the CT domain at amino acid 257, with a loss of pH sensitivity. This 
implies that the pH gating of Cx43 results from an interaction between the CT domain 
and the rest of the channel. Trexler et al. (1999) demonstrated that the CT domain of 
Cx43 enhanced the pH sensitivity of truncated Cx40, and that the CT domain of Cx40 
restored the pH sensitivity of truncated Cx43. Similar results have also been obtained 
by Gu et al. (2000). Thus, the regulatory domain of one connexin can specifically 
interact with a channel formed by another connexin, which may be an important factor 
in the regulation of heteromeric channels (Section 1.1.5.2). 
Functional differences between the various connexins are likely to be 
physiologically relevant (Peters, 1997) with respect to the selective permeabilities to 
small signalling and regulatory molecules, such as cAMP and cGMP (Spray and 
Bennett, 1985; Spray and Burt, 1990; Moreno et al. 1994; Veenstra et al. 1995; 
Nicholson et al. 2000). cAMP and cGMP play important roles in the mediation of the 
contractile process and can alter the functional status of gap junctions (Burt and Spray, 
1988; Burt, 1990; Bevans and Harris, 1999). Peters (1997) and Brink (1998) have 
suggested that cAMP and cGMP are of a size, charge and conformation that may cause 
them to diffuse selectively and thus exert their effects differentially between cells with 
different connexin expression. Other studies however, have shown that as a whole, gap 
junction channels appear to be poorly selective (Tsien and Weingart, 1976; Beblo and 
Veenstra, 1997; Wang and Veenstra, 1997) allowing the diffusion of small solutes, 
including second messenger molecules, to occur relatively easily. 
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Other regulatory factors influencing gap junction function include the number, 
size and spatial distribution of gap junctions; these being important determinants of 
passive electrophysiological properties (Beblo et al. 1995). In cultured smooth muscle 
cells, gap junctions are numerous between cells with a synthetic phenotype but few are 
observed between contractile cells (Rennick et al. 1993). This may be important for 
vessel development, following injury, or in various vascular disease states (Christ et al. 
1996). Increased expression of Cx43 has been observed in some forms of hypertension 
(Bastide et al. 1993; Gabriels et al. 1998) and atherosclerosis (Blackbum et al. 1995). 
Recent advances in the cloning of connexins have made it possible to manipulate 
the regulation of cellular growth and neoplastic transformation associated with 
intercellular communication (Ruch et al. 1998). It has been proposed that the loss of 
gap junctional communication leads to uncontrolled cell growth (Pitts et al. 1988; 
Loewenstein and Rose, 1992). Support for this contention comes from a number of 
studies (Mehta et al. 1991; Zhu et al. 1991; Rose et al. 1993; Hirschi et al. 1996; 
Temme et al. 1997; Naus, 1998; Rae et al. 1998; Mehta et al. 1999). In general, an 
inverse relationship exists between cell growth and connexin expression and 
intercellular coupling (Bennett et al. 1991; Beyer, 1991; Loewenstein and Rose, 1992). 
In Cx32 (~ 1) knockout mice, susceptibility to spontaneous and chemically induced 
hepatocarcinogenesis is increased (Temme et al. 1997). In mouse and human lung 
carcinoma cell lines, Ruch et al. (1998) have shown that expression of Cx43 is reduced 
compared to control. However, conflicting evidence is provided by Sia et al. (1999) in 
their study of gap junctional communication in quiescent mammary epithelial cells, 
where Cx43 expression was reduced but a high level of intercellular communication was 
maintained. 
A number of other factors have been shown to influence gap junctional activity. 
These include: hormonal regulation (parathyroid hormone, isoproterenol, oestrogens), 
17 
anaesthetics (halothane, isoflurane ), calmodulin binding, cadherins (the calcium-
dependent cell-cell adhesion molecules), neurotransmitters (dopamine, acetylcholine 
and y-aminobutyric acid), and selective pharmacological agents (heptanol, Gap 27 
mimetic peptide, 18a- and 18~-glycyrrhetinic acid (GA) and tetraethylammonium) 
(Davidson et al. 1986; Peracchia, 1991; Schiller et al. 1992; Hertig et al. 1996; Proulx 
et al. 1997; Wang and Rose, 1997; Chaytor et al. 1998; Yamamoto et al. 1999; He and 
Burt, 2000). 
1.1.6 Gap junctions and arterial function 
Gap junctions enable coupling between smooth muscle cells, between 
endothelial cells and in some cases, between adjacent smooth muscle and endothelial 
cells (Rhodin, 1967; Somlyo and Somlyo, 1968; Gabella, 1981; Duling et al. 1991; 
Luff, 1991; Beny, 1999). Dye tracer studies performed in isolated arterioles indicate 
that in some vessels, gap junctional coupling between endothelial cells is more 
extensive than that between the underlying medial smooth muscle cells (Little et al. 
1995b ). Connections between endothelial cells and the innermost smooth muscle cells 
have been suggested to occur through discontinuities in the internal elastic lamina of 
smaller coronary arteries and arterioles, with heteromeric gap junctions (Section 1.1.5 .2) 
sometimes being present at these sites (Severs, 1999). In such cases, communication 
occurs mainly in a unidirectional fashion from the endothelium to the smooth muscle 
layer (Little et al. 1995b; Beny, 1999), although bi-directional coupling is possible (Hill 
et al. 2001 ). 
Whilst the full functional gamut of gap junctional coupling remains to be 
elucidated, it has been established that this coupling is important for the regulation and 
co-ordination of blood flow both within and into tissue beds. The localized application 
of various vasoconstrictor and vasodilator substances ( acetylcholine and norepinephrine, 
for example) onto the arteriolar surface has been shown to induce both a local and a 
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generalized response (vasoconstriction or vasodilation) which is propagated proximally 
and distally along the vessel (Duling and Berne, 1970; Segal and Duling, 1986; Segal et 
al. 1989; Delashaw and Duling, 1991; Gustafsson and Holstein-Rathlou, 1999). This 
response is referred to as the conducted vasomotor response. However, not all 
substances that are capable of inducing local vasoconstriction or vasodilation initiate a 
propagated vascular response - sodium nitroprusside, for example (Segal et al. 1989). 
The ability of local vasomotor responses ( constriction or dilation) to be 
conducted relates to the stimulus (Delashaw and Duling, 1991 ), whilst the actual 
conduction of the response has been shown to be due to electrotonic transmission of the 
signal along the vascular wall through gap junctions between adjacent cells in some 
vessels (Segal and Duling, 1989; Xia and Duling, 1995; de Wit et al. 2000; Emerson 
and Segal, 2000). Basically, vasomotor responses may originate in either the 
endothelial or smooth muscle cell layer, with the expression of the final mechanical 
response depending on the specific signal transduction pathway involved (Hill et al. 
2001). 
The connexin knockout mice models have demonstrated the important role 
played by gap junctions in the vasomotor response, particularly in cardiac conduction 
and morphogenesis. Cx40-deficient mice have impaired conduction of endothelium-
dependent vasodilator responses along intact skeletal muscle arterioles ( de Wit et al. 
2000), and cardiac conduction abnormalities (Kirchhoff et al. 1998; Simon et al. 1998). 
Cx40 has been proposed to be important in the heteromeric coupling of the endothelium 
and vascular smooth muscle (de Wit et al. 2000). Cardiac conduction abnormalities 
have also been observed in the Cx40 and Cx43 double-deficient knockout mice 
(Kirchhoff et al. 2000). In Cx45-deficient mice, vascular development is defective 
(Kruger et al. 2000; Kumai et al. 2000), whilst in the Cx37 knockout mice, females are 
infertile due to failure of intercellular signalling (Simon et al. 1997). Overall, these 
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results support the contention that connexins play a vital role in intercellular 
communication in the vasculature, and hence the conducted vasomotor response. 
Antagonism of gap junction activity by pharmacological agents provides a useful 
tool for examining gap junction function although, to date, no agent has been shown to 
be universally effective. The specificity of action of these agents has been questioned 
and is indeed variable at best. The long chain alcohols, heptanol and octanol, for 
example, have been shown to block gap junction activity in a variety of tissues and cell 
cultures (Burt and Spray, 1989; Takens-Kwak et al. 1992; Bastiaanse et al. 1993; Christ 
et al. 1993b; Deutsch et al. 1995; Zhang et al. 1996; Largo et al. 1997; Proulx et al. 
1997). Christ et al. (1993b, 1999), for example, have shown that alpha-adrenoceptor 
agonist stimulated contraction is inhibited by heptanol in rat aortic smooth muscle cells, 
whilst in the rabbit superior mesenteric artery, heptanol abolishes rhythmic contractile 
activity and inhibits contractions evoked by phenylephrine (Chaytor et al. 1997). In 
myoblasts, 1-octanol and P-glycyrrhetinic acid inhibit gap junctional intercellular 
communication (Proulx et al. 1997). Inhibition of gap junction activities by P-
glycyrrhetinic acid has also been observed in rat hepatocytes (Eugenin et al. 1998) and 
guinea-pig mesenteric arterioles (Yamamoto et al. 1999). In rabbit jugular veins, 18a-
glycyrrhetinic acid blocks heterocellular endothelium-vascular smooth muscle coupling 
(Griffith and Taylor, 1999) and in immature rat irideal arterioles, it blocks spontaneous 
depolarisations and contractions (Hill et al. 1999). 
Another putative gap junction antagonist, Gap 27, a synthetic peptide possessing 
sequence homology with the extracellular loop 2 of Cx43, has been shown to block the 
acetylcholine induced endothelium-dependent relaxation in rabbit mesenteric arteries 
(Chaytor et al. 1998; Dora et al. 1999; Hutcheson et al. 1999) and jugular veins (Griffith 
and Taylor, 1999). Other synthetic peptides consisting of regions of the connexin 
extracellular loop sequences have been shown to inhibit gap junctional activity between 
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smooth muscle cells in mesenteric arteries (Chaytor et al. 1997). Calero et al. (1998), 
for example, showed that a synthetic l 7mer peptide formed by amino acids 271 to 287 
of Cx43 interfered, in a sequence specific manner, with the acidification-induced 
uncoupling of Cx43. Similarly, dye coupling and dual whole-cell voltage clamp have 
been used to demonstrate, via the synthetic oligopeptide P 180-195 which corresponds to 
a segment of the second extracellular loop of Cx43 , selective inhibition of Cx43 gap 
junction channels (Kwak and Jongsma, 1999). The selective block of gap junction 
channel expression with connexin-specific antisense oligodeoxynucleotides has also 
been documented (Moore and Burt, 1994; Minkoff et al. 1999). 
A variety of pharmacological agents ( agonists) have been used to study the 
activation or promotion of gap junction activity. Two examples are the potassium 
channel inhibitors tetraethylammonium (TEA) and 4-aminopyridine ( 4-AP) (Jones et al. 
1978; Kannan and Daniel, 1978; Peracchia, 1991). These agents are nonselective 
inhibitors of K+ channels. In vascular smooth muscle, it has been suggested that 
tetraethylammonium induces rhythmic contractions by promoting gap junction activity 
(Takens-Kwak et al. 1992; Christ et al. 1996). 
Thus, both in vivo and in vitro, diverse mechanisms of gap junction regulation 
exist that can vary between vascular beds and within vascular beds and for different 
connexins, that are susceptible to manipulation via a number of mechanisms. 
1.2 Vascular Control Mechanisms 
The control of blood flow in the vasculature is mediated by a variety of 
mechanisms, which can result in either arterial constriction or dilation. Such 
mechanisms include neural, humoral, myogenic, metabolic, endothelial-derived and 
physical factors (Wilson, 1979; Tortora and Grabowski, 1993 ; Bylund, 1995). 
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Differences in the activity of one or more of these mechanisms can result in 
specific control of different regions of the vasculature (Bylund, 1995), which can result 
in both systemic and localized control of blood flow and vascular resistance (tone) 
(Bevan and Purdy, 1973; Johnson, 1978; Bumstock and Ralevic, 1994). Control of 
vascular tone is important in the small arteries and arterioles, as they are the major 
resistance vessels, containing more than 50% of the total systemic vascular resistance 
(Berne and Levy, 1989; Sherwood, 1993). The integration of the vascular response 
occurs through electrical and mechanical coupling of vascular smooth muscle cells 
(Hirst and Edwards, 1989); factors that are moderated by the autonomic nervous system 
(Janssen and Smits, 2002). 
Neurotransmitters released from the autonomic nervous system act on specific 
receptors located on the smooth muscle cells and/or endothelial cells to modify vascular 
tone (Todd, 1980; Bevan, 1988). Contraction or relaxation of many blood vessels 
occurs in response to either an increase or decrease in intracellular calcium (Walsh et al. 
1995), initiated via various pathways and signalling mechanisms. However, nerve-
mediated vascular responses vary between vascular beds and between different regions 
along the one blood vessel (Bylund, 1995), as well as within the same vascular bed 
during development (Sandow and Hill, 1999). Not only can signalling pathways vary, 
but the type of neurotransmitter released, their associated pre- and post-synaptic 
receptors and pathways associated with such receptors, and mechanisms of intracellular 
calcium, may also vary. 
Thus, in order to understand the implications of variable gap junctional activity 
in the vasculature, an understanding and recognition of other factors associated with 
vascular control is required. One such entity that is relevant to this thesis, in terms of its 
influence on the vascular smooth muscle cells, is the neurovascular control provided by 
the endothelium. 
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1.2.1 Endothelium derived factors 
The endothelium plays an important role in maintaining vascular resistance and 
blood flow in many vascular beds (Griffith and Henderson, 1989; Mombouli and 
Vanhoutte, 1999), by releasing a variety of vasodilator mediators, including nitric oxide, 
endothelium-derived hyperpolarizing factor (EDHF) and prostaglandins (Moncada et al. 
1991; Fleming and Busse, 1999; Shimokawa, 1999). In some cases, this function may 
be hampered by the release of vasoconstrictors. Nitric oxide and EDHF activity 
(release) have also been linked to the activity of various neurotransmitters (Griffith et al. 
1988; Toda and Okamura, 1998). 
Nitric oxide is synthesized from L-arginine via the enzyme nitric oxide synthase 
(Palmer and Moncada, 1989; Vanhoutte and Feletou, 1998). In smooth muscle cells, 
nitric oxide mediates vasodilation via the activation of guanylate cyclase and cyclic 3', 
5'-guanosine monophosphate ( cGMP) signaling pathways (McDonald and Murad, 
1995). In endothelial cells, activation of nitric oxide synthase, which is calcium / 
calmodulin dependent (Bredt and Snyder, 1992), may occur via receptor activation, by 
shear stress and/or aggregating platelets (Fleming and Busse, 1995; Amal et al. 1999; 
Takamura et al. 1999). Nitric oxide synthase has been shown to co-localize with 
acetylcholine and vasoactive intestinal peptide (VIP) in parasympathetic nerves (Lumme 
et al. 1996; Yoshida and Toda, 1997), and to be present in sensory nerves (Lumme et al. 
1996). 
The labile substance EDHF (Feletou and Vanhoutte, 1999) induces 
hyperpolarization of smooth muscle cells due to an increase in potassium conductance 
(Komori and Suzuki, 1987), which in turn leads to reduced intracellular calcium and 
relaxation (Walsh et al. 1995). The exact nature and mechanisms of action of EDHF are 
unknown to date (Mombouli and Vanhoutte, 1997, 1999; Feletou and Vanhoutte, 1999). 
Although both EDHF and nitric oxide cause endothelium-dependent dilation, the 
dilatory response is often tissue specific. In most vascular diseases, the vasodilator 
function of the endothelium is attenuated (Mombouli and Vanhoutte, 1999). 
1.2.2 Endothelial influences in vascular disease 
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Furchgott and Zawadzki (1980) first demonstrated the role of the endothelium in 
the acetylcholine induced relaxation of isolated rabbit aorta where a factor, subsequently 
shown to be nitric oxide, caused relaxation of vascular smooth muscle (Ignarro et al. 
1987; Palmer et al. 1987; Moncada and Palmer, 1991 ; Feletou and Vanhoutte, 1999). 
Subsequently, it has been shown that the endothelium can control vascular 
smooth muscle tone primarily by the release of mediators of vasodilation (prostacyclin 
and EDHF, for example) in response to factors such as increases in the level of shear 
stress, neurotransmitters ( such as acetylcholine and noradrenaline), endothelial produced 
autacoids, platelet products and coagulation derivatives (including serotonin and 
thrombin) and hormones (angiotensin II) (Vanhoutte and Miller, 1989; Vanhoutte and 
Boulanger, 1995; Shimokawa, 1998; Boulanger, 1999; Burnstock, 1999; Feletou and 
Vanhoutte, 1999; Fleming and Busse, 1999; Mombouli and Vanhoutte, 1999; Takamura 
et al. 1999). 
In a number of blood vessels, selective a 2-adrenergic agonists can cause 
endothelium-dependent relaxations and stimulate post-junctional a 2-adrenoceptors on 
vascular smooth muscle cells to result in a contraction (Vanhoutte and Miller, 1989; 
Aburto et al. 1993). Although these receptors are more abundant in hypertensive blood 
vessels, the responses they evoke are very sensitive to functional agonists such as nitric 
oxide (Vanhoutte and Miller, 1989). 
A summary of the effects of the main endothelium-derived vasodilators (nitric 
oxide, endothelium-derived hyperpolarizing factor and prostacyclin) and endothelium-
derived contracting factors (vasoconstrictor prostaglandins, endothelin and reactive 
oxygen species) on vascular smooth muscle cells, is shown in Figure 1.6. 
Figure 1.6 Activity of endothelial vasodilators and vasoconstrictors 
Summary of the effects of endothelial-derived vasoconstrictors and vasodilators 
on the contraction and proliferation of the underlying vascular smooth muscle cells. 
The figure also demonstrates coupling between adjacent endothelial cells (1), between 
adjacent smooth muscle cells (2) and between endothelial and smooth muscle cells (3). 
Modified from Shimokawa, 1999. 
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Under normal conditions, an accurate and balanced release of relaxing and 
contracting factors contribute to vascular perfusion (Tortora and Grabowski, 1993). In 
disease states however, such as hypertension, atherosclerosis, coronary artery disease, 
diabetes and heart failure, this balance is shifted (Sherwood, 1993). Arteries obtained 
from hypertensive animal models have demonstrated, for example, that endothelium-
dependent vasodilation is reduced (Vanhoutte and Miller, 1989; Vanhoutte and 
Boulanger, 1995; Shimokawa, 1998), with the mechanisms underlying this dysfunction 
being variable between different types of hypertension. 
Endothelial dysfunction in most arterial diseases is characterized by either 
decreased secretion of vasodilator mediators, increased production of endothelium-
derived vasoconstrictors, and/or resistance of vascular smooth muscle to endothelium-
derived vasodilators (Vanhoutte and Boulanger, 1995; Shimokawa, 1998; Mombouli 
and Vanhoutte, 1999). Endothelial dysfunction differentially affects shear stress- or 
hormone-induced endothelium-dependent vasodilation in vascular beds for two reasons: 
firstly, the distribution of endothelial receptors for acetylcholine, ADP, UTP, 
bradykinin, serotonin, vasopressin and catecholamines ( stimulators of endothelial 
vasodilators) may vary, as well as the signal transduction pathway/s to which they are 
coupled, within an artery or be modified by the physiological conditions present in the 
artery (Furchgott, 1983; Vanhoutte and Miller, 1989; London and Safar, 1996; 
Mombouli and Vanhoutte, 1999). 
1.3 Vascular Disease and Gap Junctions 
1.3 .1 Gap junctions in injury and vascular disease 
Remodelling of vascular structures in response to haemodynamic signals 
associated with changes in blood flow readily occurs as a result of changes in a variety 
of physiological, developmental and pathological stimuli. Such changes are often 
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reflected by changes in the properties of the vascular connexins. Under selected disease 
processes that result in vascular cell injury and prolif era ti on, such as many forms of 
hypertension, atherosclerosis and ischaemia, altered expression levels of various 
connexins, in particular Cx40 and Cx43, have been observed (Bastide et al. 1993; Peters 
et al. 1994; Kwak et al. 2002). As this thesis is primarily concerned with the role of 
connexins in vascular disease, a summary of the role of vascular connexins in disease 
processes will now be presented. 
Vascular tissues are known to respond to changes in the mechanical loads 
imposed on them by changes in blood pressure (stretch) and thus, changes in blood flow 
(shear stress), with adjustments in vasomotor tone in the short term and then structural 
remodelling when these loads persist (De Paola et al. 1992; Langille, 1993; Davies, 
1995; Hayoz and Brunner, 1997; Cowan et al. 1998; Mulvany, 1999). This transition 
involves the expression of various genes that affect cell proliferation, cell death, and 
connective tissue proliferation and reorganization (Sutcliffe and Davidson, 1990; Malek 
et al. 1993; Birukov et al. 1995; Davies, 1995; Hayoz and Brunner, 1997; Cowan et al. 
1998; Mulvany, 1999). In vascular smooth muscle cells, stretch force has been shown 
to enhance cell proliferation, modulate cell phenotype (Birukov et al. 1995) and change 
the expression of contractile proteins (Reusch et al. 1996). Furthermore, Inoue et al. 
(1998) showed that stretch force on rat aortic smooth muscle cells enhanced cell-
mediated low density lipoprotein oxidation via superoxide anion production; a potential 
mechanism in the theoretical link between hypertension and atherosclerosis (Kunsch 
and Medford, 1999). 
Tissue remodelling due to changes in mechanical load has been shown to involve 
extensive changes in intercellular communication. Cowan et al. (1998) found that both 
mechanical and fluid shear stress caused increased expression of the gap junction 
protein Cx 4 3 in vascular smooth muscle cells exposed to stretch, and in endothelial cells 
exposed to fluid shear stress. As discussed below, the smooth muscle cells are largely 
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responsible for effecting the remodelling responses by activation of the stretch-sensitive 
expression of connexins. Stretch-sensitive expression of connexins has been shown to 
be related to the activity of selected ion channels (Ou et al. 1997; Ziambaras et al. 
1998); low dose progesterone, for example, induces the gravid rat myometrium to 
contract and hence, increases myometrial Cx43 expression (Ou et al. 1997). 
Stretch-activated nonselective ion channels are present on arterial smooth muscle 
cells (Ohya et al. 1997; Setoguchi et al. 1997). The opening of these channels causes 
Ca2+ and Na+ influx and membrane depolarization, which contribute to the myogenic 
contractile response. Ohya et al. (1998) showed that activation of stretch-activated 
channels was enhanced in vascular smooth muscle in small mesenteric arteries from 
spontaneously hypertensive rats compared with control. It was suggested that this 
phenomenon may contribute to increased myogenic responses to mechanical stress in 
spontaneously hypertensive rats, as well as to the generation of hypertrophy and 
remodelling of arterial tissues in hypertension. Other mechanisms, however, may also 
contribute to this vascular remodelling. 
Further changes in the activity of ion channels are illustrated by the activity of L-
type Ca2+ currents which are present in normal vascular smooth muscle cells (Welsh et 
al. 1998) and have been shown to be larger in vascular smooth muscle cells from 
spontaneously hypertensive rats compared with responses in control rats (Rusch and 
Hermsmeyer, 1988; Ohya et al. 1993; Wilde et al. 1994). Other stretch-dependent 
mechanisms could include phospholipases A and C (Sadoshima and Izumo, 1993 ), 
voltage-dependent Ca2+ channels (including L-type Ca2+ channels) (Langton, 1993; Arii 
et al. 1999) and Ca2+ -dependent K+ channels (D'Angelo and Meininger, 1994; Dopico et 
al. 1994; Takamura et al. 1999). 
The neural, hormonal and other control mechanism/s responsible for the altered 
activity of stretch-activated channels have yet to be elucidated. However, Ohya et al. 
(1997), in their study of spontaneously hypertensive rats (SHR), proposed three 
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possibilities: 1) that increased expression of the channel proteins would explain the 
increased opening (greater availability) of the stretch-activated channels; 2) that changes 
in the expressed phenotype of channel protein or its regulatory protein for stretch-
activated channels may differ between the SHR and control rat; and 3) that differences 
in lipid characteristics of vascular smooth muscle cells between SHR and control rats 
may contribute to enhanced activation of stretch-activated channels in the hypertensive 
animal model (Tsuda et al. 1988a,b; Dominiczak et al. 1991; Andreeva et al. 1995). 
Indeed, an increased viscosity of the lipid bilayer in hypertension has been suggested to 
be responsible for the multiple abnormalities of membrane transport systems that exist 
in genetic (inherited) hypertension (Bohr et al. 1991b; Dom~niczak et al. 1991). 
Generally, in vascular smooth muscle cells, up-regulation of Cx43 gap junctions 
occurs after injury to arteries (Yeh et al. 1997; Severs, 1999) and in the early stages of 
atherosclerosis (Blackburn et al. 1995), where phenotypic transformation of the smooth 
muscle cells occurs concurrently. With further growth and accumulation of 
extracellular matrix material, the number of gap junctions decreases (Blackbum et al. 
1995) in line with the reduced intercellular communication reported in cultured smooth 
muscle cells isolated from atherosclerotic lesions (Andreeva et al. 1995). The initial 
increase in gap junctional communication between vascular smooth muscle cells 
appears to be linked both to the phenotypic transition process itself and subsequent 
maintenance of the synthetic state (Blackbum et al. 1995; Severs, 1999). 
Whilst the conditions of vascular cell coupling in culture often differ from that in 
vivo (Christ et al. 1996; Hill et al. 2001), such studies are useful for demonstrating some 
of the fundamental activities of vascular smooth muscle cell coupling in normal and 
diseased states. In cultured smooth muscle cells, immunodetectable Cx43 expression is 
high between synthetic phenotype cells but low between contractile cells (Rennick et al. 
1993; Ko et al. 1999). Upregulation of Cx43 gap junctions in vivo has also been 
associated with the transition of contractile vascular smooth muscle cells to the synthetic 
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state (Rennick et al. 1993 ), which may be an important factor during atherosclerotic 
plaque formation, blood vessel development or following injury. 
Endothelial responses to mechanical stress related to repair of injury, may also 
result in upregulation of Cx43 channels (Gabriels and Paul, 1998). In addition, this 
upregulation may facilitate communication with other Cx43-expressing cell types, such 
as monocytes and macrophages (Beyer and Steinberg, 1991; Polacek et al. 1993), 
polymorphonuclear leukocytes (Jara et al. 1995) and lymphocytes (Krenacs and 
Rosendaal, 1995). 
The influence of growth factors and cytokines on the expression of connexins in 
cultured smooth muscle cells has emerged (Mensink et al. 1996; Yeh et al. 1996). 
Mensink et al. (1996) demonstrated that the magnitude and nature of the observed 
effects on the primary human smooth muscle cell gap junctions, were growth factor- and 
cytokine-specific; some causing a transient increase (basic fibroblast growth factor), a 
transient decrease (interleukin-6) or a persistent decrease (interferon gamma), in 
intercellular communication. This raises the possibility of co-operative interactions 
between extracellular signalling and direct intercellular communication in the 
modulation of vascular smooth muscle cell function in arterial disease and injury. 
1.3 .2 Hypertension 
Hypertension has been identified as the most important risk factor in both 
coronary heart disease and cerebrovascular disease in human populations (World Health 
Organization, 2000). Chronically elevated blood pressure induces degenerative arterial 
disease predominantly affecting the heart, brain and kidneys (Sherwood, 1993; Tortora 
and Grabowski, 1993; Baldwin et al. 1999; Neutel et al. 1999). In humans, blood 
pressure over 120 / 80 (normal) is considered indicative of hypertension (Berne and 
Levy, 1989). A summary of the control mechanisms of blood pressure and the types and 
causes of hypertension is presented below. 
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1.3 .2.1 Blood pressure control mechanisms 
Regulation of blood pressure is complex, involving both multiple environmental 
and intrinsic ( eg. genetic) factors. In both normal and hypertensive individuals, several 
interconnected negative feedback systems control blood pressure by adjusting cardiac 
output and peripheral vascular resistance. These systems include the cardiovascular 
centre in the medulla, which influences the parasympathetic and sympathetic divisions 
of the autonomic nervous system and other neural systems (baroreceptors and 
chemoreceptors ), hormonal ( epinephrine, norepinephrine, antidiuretic hormone, 
angiotensin II, atrial natriuretic peptide, histamine and kinins) and local (physical 
changes and chemical mediators) negative feedback systems (Tortora and Grabowski, 
1993; Janssen and Smits, 2002). 
1.3.2.2 Types and causes of hypertension 
There are two types of hypertension: primary and secondary. In humans, about 
90% of hypertensive cases are primary ( essential) and idiopathic, with the remaining 
10% being secondary to renal disease or less commonly, to narrowing of the renal artery 
by an atheromatous plaque (renovascular hypertension). Both essential and secondary 
hypertension may be either benign or malignant depending on the clinical course 
(Robbins and Kumar, 1987). A number of disease states also display hypertension, such 
as primary aldosteronism, Cushing' s disease (hyperadrenocorticism) and 
pheochromocytoma. 
Elevated blood pressure is usually caused by a combination of several 
abnormalities. Epidemiological evidence suggests that genetic inheritance, 
psychological stress, and environmental and dietary factors ( excess body weight, 
increased salt and perhaps decreased calciu1n and potassium intakes) contribute to an 
increased prevalence of hypertension (Robbins and Kumar, 1987; Detweiler, 1989; 
Kreutz et al. 1992; Sherwood, 1993; Shimkets and Lifton, 1996; Redon, 2001). 
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Over fifty different genes have now been identified as having an important role 
in the regulation of blood pressure (Garbers and Dubois, 1999). Interestingly, males are 
at greater risk than females of developing hypertension as demonstrated by ambulatory 
blood pressure measurements in human patients (Wiinberg et al. 1995) and hypertensive 
rat models (Chen and Meng, 1991; Reckelhoff et al. 1998, 1999). Also, elderly people 
have a higher cardiovascular risk, which may be the result of age-associated functional 
and structural changes to the arterial tree (Lakatta and Mitchell, 1987; Bortolotto et al. 
1999). Aging decreases the distensibility of large elastic arteries independently of blood 
pressure changes (Bortolotto et al. 1999). 
Manipulating components of the mechanisms controlling blood pressure has 
generated a number of animal models of experimental hypertension. Based on their 
phenotypic traits, models exhibiting the following have been generated: elevated cardiac 
output ( essential hypertension), renal hypertension, neurogenic hypertension, increased 
salt loading and reduced renal mass, increased adrenal steroids ( aldosterone and 
corticosterone ), angiotensin II stimulation, and genetic (hereditary) hypertension (Bohr 
and Dominiczak, 1991; De Paola et al. 1992, 1999; Johns et al. 1996). Computer 
models, together with animal experimentation, have also been used to elucidate the 
conceptual bases of hypertensive mechanisms (Guyton et al. 1988). Data obtained from 
studies on these models indicate that the most likely contributors to the primary defects 
in the pathogenesis of hypertension are alterations in neurohumoral regulatory 
mechanisms (sympathetic nervous system, renin-angiotensin system and endothelium-
derived vasoactive factors), cellular growth control, steroid action, lipid metabolism, 
and cell membrane function (ion transport, signal transduction and cell calcium 
handling) (Zicha and Kunes, 1999; Cvetkovic and Sigmund, 2000). 
T4e initial haemodynamic response to increased blood pressure is an increase in 
cardiac output (Benowitz and Bourne, 1989). Functional and morphological changes in 
the resistance vessels have been suggested to result from a chronic elevation in blood 
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pressure. Changes in vascular morphology such as hypertrophy of the muscular arterial 
walls, occur through vascular autoregulation, increasing the peripheral resistance to a 
level sufficient to maintain hypertension despite the cardiac output and extracellular 
fluid volume returning to normal (Detweiler, 1989; Haefliger et al. 1997b, 1992; Bohr et 
al. 1991a,b; Schiffrin and Deng, 1999). 
Sympathetic innervation also contributes to the maintenance of elevated blood 
pressure (Folkow, 1978); adrenergic factors representing one of the mechanisms that 
determine variability in blood pressure (Koepke et al. 1988; Umemura et al. 1992; 
Lembo et al. 1998; Altman et al. 1999; Baldwin et al. 1999; Makaritsis et al. 1999a,b ). 
The adrenergic receptors are G-protein coupled receptors located in the cell membranes 
of such tissues as the brain, kidney, sympathetic neurones and blood vessels (Tavares et 
al. 1996). Animal and human studies have demonstrated that sympathetic activation 
directly promotes cardiac and vascular alterations that are associated with hypertension, 
independently of the rise in blood pressure (Mancia, 1997). This has been shown to 
occur, for example, in the hypertrophication or remodelling process of the vascular 
smooth muscle cells (Heagerty et al. 1993; Giannattasio et al. 1995) during the 
development of hypertension. 
Since hypertension is a complex multifactorial disease, specific causes of 
hypertension are difficult to determine. However, morphological changes occur in the 
small arteries of hypertensive animals and humans that have been positively correlated 
with elevated blood pressure (Cowan et al. 1998; Mulvany, 2002a). 
1.3 .2.3 Vascular morphology in hypertension 
As mentioned above, vascular tissues respond to changes in blood pressure and 
flow by adjusting vasomotor tone. When these loads or variations there-of persist, 
structural remodelling often occurs. Fluid dynamic studies in vitro have shown a close 
relationship between flow characteristics and altered morphology and function (Davies 
et al. 1986; De Paola et al. 1992, 1999; Malek et al. 1993; Bumstock, 1999; Mulvany, 
2002b). 
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Although the determinants of remodelling in hypertensive vascular disease have 
yet to be completely characterized, examples found to date include growth factors and 
vasoactive peptides, such as angiotensin II (Chung and Unger, 1999; Romero and 
Reckelhoff, 1999; Kim and Iwao, 2000), endothelin (Schiffrin, 1995; Rosendorff, 1997), 
and pulse pressure ( the difference between peak systolic and minimum diastolic 
pressure; Baumbach et al. 1991; Christensen, 1991; Baumbach, 1996; Schiffrin and 
Deng, 1999). Schiffrin and Deng (1999), for example, have shown changes in systolic, 
diastolic and mean blood pressure to be closely correlated with the remodelling present 
in the small gluteal subcutaneous arteries of hypertensive humans. Furthermore, a 
complex interaction between endothelin, angiotensin II, a 1-adrenergic agonists, calcium 
and other growth factors has been described (Rosendorff, 1996). 
The morphological remodelling that occurs in small arteries of hypertensive 
animals and humans is well documented, and is largely attributable to changes in the 
vascular smooth muscle cells (Huttner et al. 1982; Lee et al. 1983; Mulvany and 
Aalkjaer, 1990; Heagerty et al. 1993). Hypertrophy of the vascular smooth muscle of 
the arterial wall leads to thickening of the vessel wall and a decrease in lumen diameter, 
resulting in an increase in the media to lumen ratio (Aalkjaer and Mulvany, 1995; 
Cooper and Heagerty, 1997; Sharifi et al. 1998; Schiffrin and Deng, 1999) and an 
augmented cross-sectional media area (Mulvany et al. l 996; Sharifi et al. 1998). 
Resistance to blood flow is subsequently increased, which contributes to the elevated 
peripheral resistance seen in essential hypertension (Folkow, 1982; Komer and Angus, 
1992). Medial growth may also occur as a result of deposition of increased intercellular 
matrix due to a greater than normal collagen to elastin ratio (Sharifi et al. 1998). 
The remodelling process involves the expression of many genes which influence 
cell growth, cell death, and connective tissue elaboration and reorganization (Sutcliffe 
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and Davidson, 1990; Malek et al. 1993; Davies, 1995) and consequently, extensive 
intercellular communication. Sutcliffe and Davidson (1990) have shown that in vitro 
stretching alone does not cause hypertrophy or hyperplasia of the vascular smooth 
muscle cells of the porcine aorta. In this study, transduction of mechanical force into 
elastin gene expression by vascular smooth muscle cells contributed to the development 
of a thickened arterial media, characteristic of hypertensive blood vessels. 
In terms of intercellular communication, it has been suggested that in endothelial 
cells, hypertension may either increase the ratio of gap junctions to the lateral 
endothelial membrane surface area, or alternatively, may result in abnormal gap junction 
morphology (Huttner et al. 1982). Studies on vascular smooth muscle cells from 
hypertensive animals and humans have concluded that since the cells have abnormal 
contractile oscillations, hypertension alters gap junctional communication (Webb et al. 
1992; Sunano et al. 1994; Watts et al. 1994; Watts and Webb, 1996). This altered gap 
junctional communication has reportedly been associated with increased abundance and 
size of gap junctions (Grunwald et al. 1982). It has been suggested that in hypertension 
gap junctional communication may be enhanced by one or more of the following: an 
increase in the transcription of genes encoding for connexins, an increase in the 
translation of connexin mRNA, an increase in plaque size or by increasing processes 
such as protein phosphorylation (Bennett et al. 1991 ). 
Early in the hypertensive process, expression of the gap junction protein Cx43 in 
the vascular smooth muscle has been shown to increase (Grunwald et al. 1982; Peters et 
al. 1994), as does expression of Cx40 in the endothelium (Bastide et al. 1993). 
Recently, however, Rummery et al. (2002) demonstrated that in the SHR rat, the 
development of hypertension is accompanied by a decrease in Cx 40 expression. 
A mediator of vascular smooth muscle hypertrophy, cAMP, has been shown to 
increase both conduction velocity and Cx43 expression via a signalling cascade (Peters 
et al. 1997). The expression of Cx43 is increased specifically in regions of blood 
34 
vessels where the blood flow becomes non-laminar and the endothelial cells are 
subjected to shear stress (Bastide et al. 1993; Gabriels and Paul, 1998; De Paola et al. 
1999). Increased Cx43 plaque size has also been reported. It has been suggested that 
the localized release of basic fibroblast growth factor after endothelial cell injury may 
result in these increases in Cx43 expression (Lau et al. 1996; Gabriels and Paul, 1998). 
Haefliger et al. (1997a,b), De Paola et al. (1999) and Haefliger and Meda (2000) 
concluded that Cx43 expression, organization and function are regionally mapped to 
haemodynamic forces, and that localized mechanical forces ( stretch and shear forces) 
induced by hypertension are major tissue-specific regulators of Cx 4 3 expression. 
Alterations in the structure and function of the vascular smooth muscle cells and 
associated gap junctions, in particular Cx43, are correlated with the increased peripheral 
vascular resistance characteristic of hypertension in animals and humans. The 
functional vascular changes that occur with elevated blood pressure are complex and 
variable. 
1.4 Thesis Aims and Outline 
1.4.1 General overview 
The properties of gap junctions, together with those of the autonomic nervous 
system, pacemaker cells, myogenic mechanisms, and electrotonic current spread 
(hyperpolarizing and depolarizing mechanisms and their associated currents passing 
though gap junctions), confer physiological advantages throughout the vascular tree, in 
terms of adaptability and flexibility to both local and systemic influences (Christ et al. 
1996). It is these attributes that most likely explain the observed diversity in the 
regulation and function of all vascular tissues throughout the cardiovascular system, in 
both homeostatic and disease states. The integration and co-ordination of responses 
amongst vascular smooth muscle cells are vital to the local modulation of vasomotor 
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tone, and to the maintenance of circulatory homeostasis (Simon, 1999; Brink et al. 
2000). 
A thorough knowledge of intercellular communication between vascular smooth 
muscle cells and, to a degree, between endothelial cells, is essential to understanding not 
only the pathogenesis of hypertension, but also a wide variety of other vascular 
pathologies. The nature and regulation of the gap junction channel proteins, the 
connexins, and the signals that pass between the cells, are of great interest as they 
represent potential targets for the modification of blood flow and for repair and growth 
of blood vessels. 
The preceding literature survey reveals the need for experimental work to 
provide more information on the relationship between vascular structure and function. 
Although reliably identified, functional characterization of gap junction channels 
formed by connexins in vascular tissue is limited (Li and Simard, 1999). 
Increased expression of the gap junctional protein Cx43 has been observed in 
hypertensive subjects (Blackburn et al. 1997; Haefliger et al. 1997a), although the cause 
and significance of this increase and its function in relation to hypertension, remains to 
be elucidated. Connexins have been shown to be important in the co-ordination of 
mechanical contraction of vascular smooth muscle cells (Segal and Duling, 1986; Segal 
1994). It is possible that Cx43 has a role in the mediation and modulation of vascular 
tone in the resistance arteries. In fact, the increased expression of Cx43 in vascular 
smooth muscle cells during hypertension suggests that they are involved in the adaptive 
response to elevated blood pressure (Blackburn et al. 1997; Donaldson et al. 1997; 
Haefliger et al. 1997b ). How the change in Cx43 expression participates in the adaptive 
process remains to be elucidated, as does the question of whether the increase in Cx43 
expression is due to or causes, high blood pressure. 
Further studies are currently required to determine the role of Cx43 in 
hypertensive states. The general aim of this study is to initiate studies in this area. 
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1.4.2 Thesis aims 
The primary aim of this thesis was to determine the effect on blood pressure of 
selectively overexpressing Cx43 in blood vessels, specifically in the media. In order to 
achieve this, a DNA construct was made, containing a restricted portion of the SM22a 
promoter from. the murine SM22a gene, to direct specific arterial expression in order to 
avoid overexpression of Cx43 in the heart, which has been shown to be lethal. 
Following the development of the DNA construct, a transgenic mouse line was 
produced by firstly, expressing the construct in vitro and then injecting into blastocysts, 
the construct with embryonic stem cells. 
The SM22a / Cx43 transgenic mice would be expected to exhibit tissue 
specificity but not temporal specificity. This circumvents any congenital cardiac 
abnormalities caused by Cx43 overexpression, but will not prevent or ameliorate any 
developmental complications from occurring, both in the vascular smooth muscle and 
systemically. The physiological effect of overexpressing Cx43 or any connexin in the 
vasculature, apart from the heart, has not as yet been reported. Thus, the results 
obtained from this study using control and transgenic SM22a I Cx43 mice will enable 
some conclusions concerning the overexpression of Cx43 in the smooth muscle cells of 
the vasculature to be drawn. The rest of this thesis reports this work and is divided into: 
The general methods ( Ch. 2) 
The design, development and evaluation of the DNA construct (Ch. 3) 
The generation and assessment of the SM22a / Cx43 transgenic mouse (Ch. 4) 
and the final discussion is presented in Ch. 5. 
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Chapter 2 - Materials and Methods 
A variety of molecular biology techniques were used in the design, construction 
and verification of the DNA construct for the generation of the transgenic mice. 
Evaluation of the construct prior to injection into murine blastocysts was performed 
using cell cultures of murine vascular smooth muscle cells and murine embryonic 
fibroblasts, which were transfected and analyzed by immunohistochemistry and 
fluorescence microscopy. Chimaeric mice were generated from embryonic stem cells 
and bred to produce germ-line transgenic mice. These mice were analyzed by PCR, 
immunohistochemistry, blood pressure measurements and Western blotting. 
2.1 Recombinant DNA Techniques 
The following experimental protocols were used in the design, construction and 
evaluation of the DNA constructs. 
2.1.1 Oligonucleotide design and preparation 
The design of the various oligonucleotides will be discussed in the relevant 
chapters. A summary of the general approach is presented here. 
The sequences for the genes and cDNAs used in this thesis were downloaded 
from GenBank and converted into a text file suitable for reading on a Power MacIntosh 
(7200/90) computer with the Microsoft programme Word 6. The programmes Amplify 
(Bill Engels, University of Wisconsin, USA) and Mac Vector (Stratagene) were also 
used. After the region of interest of each gene was selected, it was imported into 
Mac Vector and a restriction enzyme analysis performed to obtain the restriction enzyme 
cutters and non-cutters list, and also an annotated sequence. Using Amplify, two 
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primers ( one forward and one reverse) were designed, one on either side of the selected 
region, and subsequently checked for stability, primer dimer, loops, primability of match 
and fragment size. The primers were compared against the Genebank database to test 
their specificity (ie: their ability to anneal to other non-required sequences) before 
ordering their synthesis from Life Technologies ( GIBCO-BRL ), SigmaGenosys or the 
Biomolecular Resource Facility at the John Curtin School of Medical Research, 
Australian National University (ANU). A summary of the oligonucleotides used is 
presented in Table 2.1. 
Primers were supplied in either ammonium hydroxide or as purified lyophilised 
powder. Purification of the former group of primers was carried out by n-Butanol 
precipitation. A small volume of the oligonucleotide (100 µl) was diluted in 1 ml butan-
1-ol and mixed well by vortexing, before centrifugation for one minute at 13 000 rpm. 
The supernatant was removed and the tube inverted on a clean tissue to fully drain the 
remaining butan-1-ol. The pelleted oligonucleotide was then rinsed carefully with ether, 
centrifuged for 1 minute, the ether removed and the pellet dissolved in 100 µl of T 10E0.1 
(10 mM Tris-HCl, 0.1 mM EDTA pH 8). After spectrophotometric analysis, aliquots of 
the oligonucleotide (5 pmol / µI in 200 µl MilliQ water (UF final filter, Millipore) were 
made and stored at -20°C for future use. 
Lyophilised primers were made up according to the manufacturer's directions by 
adding 0.5 ml T 10Eo.1 buffer to each and mixing well. After spectrophotometric analysis 
to check the supplied concentration, aliquots of the oligonucleotide were made ( 5 pmol / 
µl) and stored at -20°C for future use. 
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Gene or No. 
Primer Name 
Plasmid bases 
Sequence Tm 
SM22exlf SM22a 24 AAG ACT AGT TCC CAC CAA CTC GAT 70 
SM22exlr SM22a 24 CGT TTG TGG ACT GGA AGG AGA GTA 72 
mSM22F2 SM22a 24 AGC CTT GCA AGA AGG TGG CTT GTT 72 
mSM22F6 SM22a 24 CAA AAT ATG GAG CCT GTG TGG AGT 72 
mSM22F7 SM22a 23 ACATCACTGCCTAGGCGGCCTTT 72 
mSM22exlfb SM22a 23 GAC TAG TTC CCA CCA ACT CGA TT 68 
CnxF Cx43 24 TGG CTT GGG TTG AAA CTG CCT TAT 70 
CnxR Cx43 24 TCC TCC ACA ATC GAT TGG CAG CTT 72 
mCnx43R Cx43 24 GAT ATT CAG AGC GAG AGA CAC CAA 70 
CxF Cx43 24 AAA CGT CTG CTA TGA CAA GTC CTT 68 
Cx43F Cx43 24 GAG ATG CAC CTG AAG CAG ATT GAA 70 
Cx43R Cx43 24 GAT GTT CAA AGC GAG AGA CAC CAA 70 
Cx43R2 Cx43 24 GAG CAG CCA TTG AAG TAG GCG TAT 72 
Cx43R3 Cx43 24 CGA TGG CTA ATG GCT GGA GTT CAT 72 
mCx435'R Cx43 23 CAT GTC TGG GCA CCT CCT AAG AA 70 
pBi5F pBi5 22 TTC GAG CTC GGT ACC CGG GGA T 72 
pBi5R pBi5 23 CAA GGG ACA TCT TCC CAT TCT AA 66 
HOTT3 pBSKSII- 23 CGC GCA ATT AAC CCT CAC TAA AG 68 
HOTT? pBSKSII- 23 ACG ACT CAC TAT AGG GCG AAT TG 68 
Table 2.1 Summary of oligonucleotides used in the present study 
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2.1.2 The polymerase chain reaction (PCR) 
In order to amplify each DNA fragment, PCR was performed in a capillary tube 
cycler (Corbett Research) in a total reaction volume of 20 µl containing 5 µl of the DNA 
sample ( diluted as necessary), 2 µl of 10 x PCR buffer (Promega), 0.8 µl of each 
deoxynucleotide triphosphate (dNTP; 5 mM of each dATP, dTTP, dCTP and dGTP), 
1.0 µl of each primer (5 pmol / µl) and 1 U of Taq DNA polymerase (Promega). The 
PCR reaction mixtures were pipetted into positive displacement pipette tips using a 
Cycle Prep automatic pipetter, and the ends either plugged or heat-sealed. In summary, 
the PCR cycling conditions used to amplify each fragment of DNA were: 94°C for 3 
minutes for DNA denaturation (1 cycle), then 10 seconds for annealing followed by the 
appropriate extension time for each DNA fragment at 72°C (35 to 38 cycles). The final 
cycle was 72°C for 5 minutes followed by 25°C for 5 minutes. Annealing temperatures 
and extension times were determined by the melting temperatures of the individual 
primer pairs and predicted fragment lengths. The PCR conditions for specific primer 
pairs are listed (Table 2.2). 
2.1.3 Restriction endonuclease digests 
Restriction endonuclease digests (in a 20 µl total volume) were performed to 
verify the plasmids and the DNA constructs at each stage of their construction, and prior 
to larger restriction digests (> 200 µl total volume) as part of the cloning process for 
each construct. Each restriction digest was carried out in the appropriate buffer 
(NewEnglandBiolabs (NEB)) (see Table AI.I) for each enzyme (NEB, Pharmacia or 
Promega). 
For each digest, the mix consisted of 2 µl of 10 x NEBuffer, 2 µl of 1 mg/ ml 
acetylated-bovine serum albumin (BSA), 100 ng of DNA or plasmid and MilliQ water 
to a total volume of 20 µI. To this mix, 0.5 µl (> 10 000 units/ ml) to 1.0 µl ( < 10 000 
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Annealing Extension Predicted Primer Gene I Plasmid temperature Time (s) I Fragment Pair 
TA(°C) (mins) size (kb) 
SM22exlf SM22a gene SM22exlr 65 30 s 0.493 
SM22exlf SM22a/pBs KSII-
HOTT3 63 30 s 0.586 
SM22exlr SM22a/pBs KSII- 64 30 s none HOTT3 
HOTT3 SM22a/pBs KSII- 64 30 s 0.635 HOTT7 
CnxF Cx43 gene 65 30 s 1.390 CnxR 
CnxF Cx43/pBs KSII- 65 2 1.018 CxR2 
CnxF Cx43/pBs KSII- 65 2 1.390 HOTT3 
HOTT3 Cx43/pBs KSII- 65 2 1.480 HOTT7 
HOTT7 Cx43/pBs KSII- 65 2 1.268 CxR2 
CnxF Cx43/pBi5 65 2 1.0kb Cx43R3 
mSM22F2 EGFP/Cx43/pBi5 65 1.30 0.662 mCx435'R 
SM22exlf SM22a/Cx43/ 61 2 1.987 
pBi5R pBs KSII-
SM22exlf SM22a/Cx43/ 
61 2 none 
pBi5F pBs KSII-
SM22exlf SM22a/Cx43/ 
65 2 1.47 
Cx43R2 pBs KSII-
SM22exlf SM22a/Cx43/ 
65 2 1.3 
CnxR2 pBs KSII-
SM22exlf SM22a/Cx43/ 
65 2 1.334 
mCnx43R pBs KSII-
SM22exlf SM22a/Cx43/ 
63 2 3.0 
HOTT7 pBs KSII-
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Gene/ Annealing Extension Predicted Primer Pair temperature Time (s) I Fragment Plasmid TA(°C) (mins) size (kb) 
mSM22F2 SM22a/ Cx43/ 65 2 0.633 
mCx435'R pBs KSII-
mSM22F6 SM22a/ Cx43/ 65 2 0.374 
mCx435'R pBs KSII-
mSM22F7 SM22a/ Cx43/ 65 2 0.273 
mCx435'R pBs KSII-
mSM22F6 SM22a/ Cx43/ 61 2.20 1.699 
pBi5R pBs KSII-
mSM22F7 SM22a/ Cx43/ 61 2.20 _ 1.598 
pBi5R pBs KSII-
CnxF SM22a/ Cx43/ 61 2.20 1.469 
pBi5R pBs KSII-
Cx43F SM22a/ Cx43/ 61 2.20 0.9 
pBi5R pBs KSII-
Table 2.2 PCR conditions for specific primer pairs 
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units / ml) of the appropriate enzyme was added. The restriction digest was mixed and 
incubated for 1 hour at the appropriate temperature for each enzyme according to the 
NEBiolab catalogue. For larger restrictions used in cloning, the amounts of all reagents 
were increased proportionally and the incubation time/s increased as determined by 
regular monitoring on a 1.5 % agarose gel (see Section 2.1.4). 
2.1.4 Analytical and preparative separation of DNA fragments 
In order to visualize the result either of a restriction digest, PCR, or the purity 
and concentration of DNA present, gel electrophoresis was carried out at room 
temperature on 1.5% agarose gels. Each gel was prepared by dissolving 1.5 g of agarose 
(Difeo Laboratories) in 100 ml TAE (40 mM Tris-acetate and 2 mM EDTA pH 8.0) and 
allowing it to cool to 65°C in a water bath before pouring into a prepared gel tray. Once 
set, the gel was submerged in TAE in a Biorad Mini-Submarine electrophoresis tank and 
electrophoresis conducted at 80 V for 1 hour. For cloning purposes, the smaller 
Pharmacia electrophoresis tank was used and 1.0% agarose gels (0.6 g agarose in 60 ml 
T AE) made before electrophoresis at 60 V for 2 to 3 hours. 
To each 20 µl sample, 5 µl of 5 x loading dye (5 ml 1 M Tris-HCl pH 8.0, 20 ml 
0.5 mM EDTA, 7.5 g Ficoll 400, 1 g N-lauryl sarcosine and 50 mg dye (bromophenol 
blue, xylene cyanol, for example)) was added. The sample was then mixed by shaking 
and incubated for 5 minutes in a 65°C water bath before loading onto a prepared agarose 
gel. Appropriate volume adjustments were made for the larger samples loaded for gel 
purification. Lambda phage DNA digested with Accl or Hindill or pTz (Biorad) 
restricted with Alul (pTz I Alul) were run in parallel with the samples to serve as 
molecular size markers (see Table AI.2) and to enable quantitative analyses. The ADNA 
EcoRI I Hindill (GIBCO-BRL, LifeTechnologies) marker was also used later in the 
study (see Table AI.2). After electrophoresis, the gel was stained with the fluorescent 
dye ethidium bromide (500 ml TAE and 50 µl ethidium bromide) for 15 minutes, and 
the bands visualized under UV light and photographed with either a N ovaLine Gel 
Documentation System or the SpeedLight Platinum Gel Documentation System 
(Lightools Research). 
2.1.5 Gel purification of restricted DNA fragments 
Gel purification of restricted DNA was undertaken to isolate the required 
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fragment of DNA, and to remove unwanted DNA fragments and restriction enzymes. 
After the restriction step was complete, loading dye was added ( at 5 µl / 20 µl mix as 
described previously), and the whole mix heated in a 65°C water bath for 5 minutes 
before loading onto a gel ( 1 % agarose I 0. 00 l M guano sine) prepared for a Pharmacia 
tank. Transillumination of gels can damage the DNA present and compromise 
subsequent manipulations (Hartman, 1991; Maueler et al. 1994), however the 
incorporation of 1 mM guanosine in agarose gels has been shown to have a strong, 
albeit not absolute, protective effect on DNA against UV irradiation (Grundemann and 
Schomig, 1996). 
A small amount ( 5 µl) of an appropriate marker was also added to one lane of the 
gel before electrophoresis at 60 V for 2 to 3 hours. Gels were stained in fresh ethidium 
bromide solution for 15 minutes before being viewed under UV light, quickly 
photographed and the appropriate band removed using a new scalpel blade. The 
removed gel band was weighed before using the QIAquick Gel Extraction Kit (Qiagen), 
as the maximum amount of gel slice per QIAquick column is 400 mg. A small amount 
of the final eluted sample (1 µl with 9 µl MilliQ water and 2.5 µI loading dye) was 
subsequently run on a 1.5 % agarose gel to ascertain its purity and for quantitation 
purposes. 
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2.1.6 DNA concentration by ethanol precipitation 
DNA products were concentrated, as necessary, using ethanol precipitation. 
Briefly, the volume of each sample was estimated before adding 0.1 volume of 3 M 
sodium acetate (NaOAc, pH 7.5), followed by 2 volumes of ice-cold 100% ethanol. The 
mixture was vortexed and placed in a -20°C freezer for 3 hours ( or immersed in liquid 
nitrogen for 5 seconds). After centrifuging at 14 000 rpm for 30 minutes at 4°C, all 
traces of the supernatant were removed and the pellet rinsed with 1 ml 70% ethanol 
before further centrifugation at 4 °C for 2 minutes. The supernatant was removed and 
the tube inverted on a tissue to dry. The pellet was resuspended in T10E0_1 and stored at 
4°C. The new DNA concentration was determined by spectrophotometric analysis at 
OD260 (Sambrook et al. 1989). 
2.1.7 Dephosphorylation of vector DNA 
Dephosphorylation was undertaken on complementary ends ( also called 
compatible cohesive ends) of vector DNA using calf intestinal alkaline phosphatase 
(CIAP; Boehringer-Mannheim) to catalyze the removal of 5' -phosphate residues from 
the ends of the vector to prevent self-ligation. 
After the quantity of number ends (pmol) per mass (µg) of linear DNA was 
calculated, the dephosphorylation reaction was set up as follows: to the DNA (restriction 
digest to 200 µl total volume with MilliQ water), CIAP was added at 1 U per 1 - 2 pmol 
ends and the mix vortexed before being placed in a 3 7°C water bath for 15 minutes. The 
same quantity of CIAP was added again and the mix subsequently incubated at 55°C for 
15 minutes. Afterwards, 0.5% sodium dodecyl sulphate (SDS), 5 mM 
ethylenediaminetetraacetic acid (EDT A, pH 8) and proteinase K ( 100 µg / ml; to digest 
the CIAP) were added and the mix vortexed before incubation in a 5 5°C water bath for 
30 minutes. The mix was allowed to cool to room temperature and diluted to 300 µl 
with T 10E0_1 (pH 8) prior to phenol extraction to purify the dephosphorylated DNA. 
46 
To a 300 µl dephosphorylation mix volume, 150 µl phenol was added and the 
mix vortexed for 30 seconds before centrifugation at 13 000 rpm for 5 minutes. The 
upper aqueous supernatant was transferred to a new 1.5 ml eppendorftube and 150 µl of 
isoamyl alcohol (IAC) added to remove any remaining phenol. After vortexing the mix 
for 30 seconds, followed by centrifugation at 13 000 rpm for 5 minutes, the supernatant 
was transferred to a new 1.5 ml eppendorftube. Subsequent ethanol precipitation (see 
Section 2.1.6) removed salt contaminants, and agarose gel electrophoresis (using 1 µl of 
the sample with 9.0 µl MilliQ water and 2.5 µI loading dye) was undertaken as 
described previously. 
2.1.8 Blunt ending of DNA fragments with Klenow 
The Klenow fragment is a proteolytic fragment of Escherichia Coli DNA 
Polymerase I which retains polymerization and 3' to 5' exonuclease activity, but has lost 
5' to 3' exonuclease activity (Sambrook et al. 1989). Thus, the Klenow enzyme can be 
used to fill-in 3' recessed ends remaining after enzyme restriction to make restriction 
sites with incompatible ends blunt and hence complementary. Each reaction was 
performed in the restriction eppendorf tube (volume 60 µl) using the restriction buffer 
already present. The buffer was supplemented with 5 mM MgCli, 33 µM of each dNTP 
and 1 unit Klenow per µg DNA. The mix was incubated at 25°C for 15 minutes and the 
reaction stopped by the addition of EDT A to 10 mM final concentration, and heating at 
7 5°C for 10 minutes. 
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2.1.9 Purification of products 
Occasionally, purification of products from the various molecular cloning 
procedures ( eg. PCR, ligation reactions, and restriction digests) was performed using the 
High Pure PCR Product Purification Kit (Boehringer-Mannheim), according to the 
manufacturer's instructions. The products were always checked by agarose gel 
electrophoresis afterwards. 
2.1.10 Ligation of restriction fragments into vector DNA 
In a typical ligation mix, DNA insert, plasmid vector and 1 x T4 DNA Ligase 
buffer (50 mM Tris-HCl pH 7.8, 10 mM MgCh, 10 mM DTT, 1 mM dATP, 25 µg / ml 
of BSA) were added to a volume ofMilliQ water to make the final calculated total 
volume, then mixed before adding 1 µl T4 DNA Ligase (NEB). The ligation was again 
mixed thoroughly before incubation at room temperature for 30 minutes, followed by 
overnight incubation at 16°C. 
The ligated DNA was transformed into competent E. coli cells as described in 
Section 2.1.11. 
2.1.11 Transformation and selection of bacterial clones 
Electroporation was used to transform electrocompetent E. coli TOPI OF' cells, 
with ampicillin as the marker to indicate which populations were transformed. 
(a) Preparation of electrocompetent cells 
Electrocompetent cells were prepared according to standard techniques. Briefly, 
a 1 in 100 of a fresh overnight culture of TOP 1 OF' bacterial cells was diluted in 1 L of 
liquid medium (Luria Broth or LB; bacto-tryptone 5 g, bacto-yeast extract 2.5 g (Difeo 
Laboratories) and NaCl 5 gin 500 ml MilliQ water; adjusted to pH 7 with 5 mM NaOH 
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before autoclaving at 120°C for 20 minutes). Ampicillin (Sigma; 50 µg / ml) was added 
to cooled LB agar (50°C) or LB to select and maintain recombinant bacterial strains. 
The cells were grown at 3 7°C with vigorous shaking and the growth of the 
culture determined by monitoring the OD6oo regularly until an OD6oo of 0.5 to 1.0 was 
attained (the desired concentration; about 4 hours). After harvesting the cells by chilling 
the flask on ice for 15 - 30 minutes, the cells were centrifuged at 1 000 g at 4°C. The 
supernatant was removed and the pellet resuspended in a total volume of 1 L cold 
MilliQ water before further centrifugation. 
After removal of the supernatant, the pellet was resuspended in 0.5 L cold 
MilliQ water, re-centrifuged, and resuspended in 20 ml cold water before centrifuging 
again. Again the supernatant was removed, and the pellet resuspended in a final volume 
of 2 to 3 ml of cold 10% glycerol in MilliQ water. The solution was aliquotted into pre-
cooled sterile 1.5 ml eppendorf tubes in 40 µl lots and stored at -70°C. 
(b) Preparation of L-ampicillin agar plates 
The L-ampicillin (L-amp) agar plates were prepared as follows: liquid medium 
(400 ml of Lauria Broth (LB)) was prepared and 6.0 g ofbacto-agar (Difeo 
Laboratories) added before autoclaving at 120°C for 20 minutes. The media was 
swirled gently to distribute the melted agar evenly throughout the solution before 
cooling to 50°C in a water bath. Ampicillin (800 µl of 50 mg/ ml) was then added and 
about 20 ml of the media poured into each petri dish. Bubbles forming on the newly 
poured L-amp plates were removed by flaming the surface with a Bunsen burner before 
solidification of the agar. When the plates were set, they were air-dried for 60 minutes 
in a sterile laminar flow hood and stored inverted at 4 °C. 
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( c) Electroporation and plating 
Prior to electroporation, an eppendorf tube containing 40 µl of TOP 1 OF' cells 
was removed from the -70°C freezer and placed on ice to thaw. Then 1 µl of the ligation 
mix was added to the tube and the contents mixed thoroughly. The mixture was 
transferred into an ice-cold 0.2 cm micro-cuvette (Biorad) and electroporated (2.5 kV, 
25 µF and 200 ohms, with a resultant field strength of 12.5 kV/ cm) with a Biorad Gene 
Pulser. After pulsing, the cuvette was flushed with 1 ml of cool LB and the transformed 
cells transferred to a 15 ml Falcon tube to recover for one hour at 3 7°C with shaking at 
250 rpm. Several dilutions of this culture were plated onto L-amp agar plates using a 
sterile glass spreader to ensure an even distribution, and then dried before incubation at 
3 7°C overnight. In order to enhance potential growth, the cells were sometimes pelleted 
by centrifugation at 2 500 g for 3 minutes (after shaking), the supernatant removed and 
the cells resuspended in 300 µl of LB before plating out onto 2 or 3 L-amp plates. 
2.1.12 Screening cloned inserts 
The cloned inserts were screened by one or more of the following: a-
complementation (blue / white colony screening), cracking or PCR. 
(a) a-complementation (blue/ white colony screening) 
a-complementation is commonly used to identify bacterial colonies that contain 
recombinant plasmids. Deletion mutants of the operator-proximal segment of the lacZ 
gene of E. coli are complemented by ~-galactosidase-negative mutants that have an 
intact operator-proximal region (Ullmann et al. 1967). The Lac+ bacteria that result 
from a-complementation form blue colonies in the presence of the chromogenic 
substrate 5-bromo-4-chloro-3-indolyl-~-D-galactoside (X-gal). However, insertion of a 
fragment of foreign DNA into the multiple cloning site of the plasmid results in the 
production of an amino-terminal fragment that is not generally capable of a-
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complementation (Sambrook et al. 1989). Thus, bacteria carrying recombinant plasmids 
usually form white colonies. However, some blue colonies can have an insert if it is in 
frame with the lacZ gene and is usually < 1 kb (Matthaei, pers com). 
For blue / white screening of vectors capable of a-complementation ( eg. 
pBluescript (Stratagene )), 40 µl of a stock solution of isopropylthio-~-D-galactoside 
(IPTG; 1 M = 23 8 mg / ml in water) and 10 µl of a solution of X-gal ( 10% in 
dimethylformamide) per 20 ml L-amp plate were mixed, spread evenly over the entire 
surface of the plate using a sterile glass spreader, and allowed to dry prior to plating the 
transformed cells. L-amp plates were used to maintain antibiotic selection. 
(b) Colony cracking 
All transf ormants were analyzed by colony cracking. This method enables the 
size of the plasmid in individual colonies of transformed cells to be estimated quickly 
and simply by gel electrophoresis of total colony lysates. 
A gel of 1 % agarose in T AE buffer ( without ethidium bromide) was prepared 
and when set, placed in a Biorad Mini-Submarine electrophoresis tank to equilibrate 
with the T AE in the chamber before the samples were loaded. A well-isolated colony 
( white if screening) was sampled with a sterile toothpick, replicated onto a fresh L-amp 
agar plate, and resuspended in 25 µl of cracking solution (MilliQ water, 50 mM NaOH 
(fresh), 0.5% SDS, 5 mM EDTA, 10% glycerol and 0.01 % bromocresol green). This 
procedure was repeated for each colony sampled after which, the replica plate was 
placed in an incubator at 3 7°C until the colonies were about 1 to 2 mm in diameter. 
All of the cracking samples were subsequently placed in a water bath at 65°C for 
30 minutes, allowed to cool to room temperature and loaded onto the prepared 
electrophoresis gel. Positive clones were identified by their increased band size when 
compared with uncut vector and with a Supercoiled DNA ladder (GIBCO-BRL, Life 
Technologies; 0.25 µg / µl). 
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(c) PCR 
All possible positives were identified (pen marked by hand) on the replica plate 
and sampled with a sterile toothpick as previously. The toothpicks were then twirled in 
the appropriately labelled eppendorf tube containing 100 µl MilliQ water. All samples 
were thoroughly mixed and heated for 5 minutes at 65°C; 5 µl of each sample was used 
in a PCR with the selected plasmid primers to determine the presence and size of the 
required insert. PCR positives were re-analyzed with gene specific primers, again under 
standard conditions, to identify whether or not the inserts present were the correct ones 
for the DNA construct. 
A combination of gene specific and plasmid primers was used to deduce the 
orientation of the insert in the vector. PCR positives thus identified were selected and 
grown overnight in liquid culture as described below (Section 2.1.13) before 
purification using the QIAprep Spin Miniprep Kit (Qiagen) according to the 
manufacturer's directions. This enabled subsequent verification of positive clones by 
restriction enzyme digestion and sequencing. 
2.1.13 Plasmid preparation 
Overnight cultures of 3 to 5 positives (Section 2.1.12) were prepared using, for 
each positive, 2 ml of L-broth and 4 µl (50 mg/ ml) of ampicillin in a labelled Falcon 
tube (replicates of each plasmid were usually made). The tubes were mixed well by 
hand before the positive colonies from the replica plate were sampled with sterile 
toothpicks; each of which was swirled in the appropriately labelled liquid media prior to 
all tubes being placed in an incubator at 37°C with vigorous shaking (280 rpm) 
overnight. 
Each plasmid was purified according to the manufacturer' s instructions for the 
QIAprep Spin Mini prep Kit. To estimate the plasmid yield, 1 µl of the eluted DNA 
(with 9 µl MilliQ water and 2.5 µI loading dye) was electrophoresed on a 1.5% agarose 
gel, with standard markers, and visualized under UV light. The remainder of each 
overnight culture (850 µl) was pipetted into an appropriately labelled sterile tube and 
150 µl of sterile glycerol added to each to form glycerol cultures. The tubes were 
thoroughly mixed by vortexing and stored at - 70°C. 
For larger plasmid preparations, the EndoFree Plasmid Maxi and Mega Kits 
(Qiagen), and the QIAfilter Maxi Kit (Qiagen) were used, according to the 
manufacturer's instructions. 
2.1.14 DNA sequencing 
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Dye Terminator Sequencing (ABI PRISM BigDye Terminator Cycle Sequencing 
Ready Reaction Kit, PE Applied Biosystems) was used for DNA sequencing in a 
capillary cycler. The 20 µl reaction mixture consisted of Terminator Ready Reaction 
Mix (8 µl), DNA (200 to 500 µg), primer (3.2 pmol / µl) and MilliQ water to 20 µl total 
volume. The mix was pipetted into a capillary tip and capped. The cycling conditions 
were as follows: 25 cycles of DNA denaturation for 30 seconds at 96°C, annealing for 
15 seconds at 50°C and extension for 4 minutes at 60°C, and then 1 cycle of 25°C for 5 
minutes. 
Excess dye terminator was removed before sequencing by ethanol / sodium 
acetate extraction and the DNA concentrated as follows. To a 1.5 ml eppendorftube, 
2.0 µl 3 M sodium acetate (pH 4.6) was added followed by 50 µl of 95% ethanol. The 
contents of each extension reaction were then pipetted into the appropriately labelled 
tube, mixed thoroughly and vortexed before leaving at room temperature ( to remove 
unincorporated nucleotides and dye terminator) for 10 minutes to precipitate the 
extension products. After centrifugation for 15 to 20 minutes at 13 000 rpm, the 
supematants were aspirated and the pellets rinsed with 250 µl of 70% ethanol before 
briefly vortexing and centrifugation for 5 minutes at maximum speed. The supematants 
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were aspirated and the pellets dried in a vacuum centrifuge for 10 to 15 minutes or until 
dry. 
DNA products from the dye terminator cycle reaction were sequenced by the 
Biomolecular Resource Facility, Australian National University. Results were imported 
into a file suitable for reading on a MacIntosh computer with the program Mac Vector. 
The sequence of bases was checked against known sequences of the gene insert and the 
plasmid. 
2.2 Generation of the DNA Construct 
During the course of this study, four DNA constructs were generated: SM22a / 
Cx43 I pBs KSII- (Chapters 3-5), and a smooth muscle specific construct (SM22a I 
pTetOn) and two temporal specific constructs (Cx43 / pBi5; EGFP / Cx43 / pBi5) (see 
Appendix II). The design, analysis and use of each construct is presented in the 
appropriate chapter. This Chapter deals solely with the SM22a / Cx43 / pBs KSII-
construct. 
2.3 Evaluation of the DNA Construct in Cell Culture 
Evaluation of the construct was performed using cell cultures of murine aortic 
smooth muscle cells and fibroblasts (murine embryonic feeder cells), and 
immunohistochemistry. 
2.3 .1 Dissection and culture of aortic smooth muscle cells 
Six adult mice, of either sex, were anaesthetized by ether inhalation and killed by 
cervical dislocation. Each thoracic aorta was excised and placed in a dish containing 
Dulbecco modified Eagles medium (DMEM; Sigma), with 5% foetal calf serum (FCS), 
3.7 g IL NaHCO3, 6 mg penicillin, 10 mg streptomycin and MilliQ water; pH 7.4 and 
54 
filter sterilized (complete medium). Adipose and connective tissues were removed and 
the aorta placed in a fresh dish of PCS/ DMEM. The aorta was then cut open to 
produce a flat sheet and the endothelial cells rubbed off with a sterile cotton bud. The 
smooth muscle cell layers were subsequently dissected from the adventitia and washed 
in incomplete medium (DMEM; no PCS) before digestion with collagenase II (3 mg / 
ml)/ DMEM (mixed by gentle trituration to avoid air bubbles forming) in a 37°C water 
bath, with shaking, for 10 minutes. The supernatant was discarded and a second 
digestion undertaken with collagenase II (3 mg I ml) and elastase II (3 mg I ml), in a 
3 7°C shaking water bath for 20 minutes. The supernatant was collected into a tube 
containing 500 µl PCS. 
The double enzyme digestion was repeated, again with careful trituration, with a 
15 minute incubation time and the supernatant collected into a second tube of PCS. 
Both tubes were then centrifuged at 1 000 rpm for 3 minutes and the supernatants 
subsequently discarded. The cells were resuspended in 1 ml of complete medium (PCS 
I DMEM) by gentle trituration. 
Cell viability and number were checked by mixing a small aliquot (10 µl) of the 
cells with trypan blue (0.01 % in distilled water) and loading 10 µl onto a Neubauer 
haemocytometer. The cells were subsequently diluted and seeded onto glass coverslips 
previously placed in the bottom of the 24 well plates ( 500 µl / well; at an estimated 106 
cells per well) and incubated in complete medium at 37°C in an incubator with an 
atmosphere of 5% CO2 in air. After leaving the plates for 72 hours to allow the cells to 
settle on the coverslips, the culture medium was changed daily. Cells were grown for 6 
to 7 days to a confluence level of approximately 60%, before transfection with 
Lipofectamine Plus (1 mg/ ml; GIBCO-BRL, Life Technologies). 
This method was later modified as follows as it was found to enhance cell 
growth: briefly, the peeled smooth muscle cells were washed with Hanks ' Solution (800 
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mg NaCl, 35 mg NaHCO3, 40 mg KCl, 6 mg KH2PO4, 6.5 mg Na2HPO4, 100 mg D-
Glucose and 1 mg Phenol Red; in 100 ml MilliQ water) without calcium and 
magnesium, to wash off the 5% PCS in DMEM. Digestion with collagenase II (3 mg/ 
ml diluted in Hanks' Solution) in fresh Hanks' Solution at 37°C in a shaking water bath 
for 10 minutes followed. The solution and tissue were gently triturated, and the 
supernatant aspirated and discarded before triple enzyme digestion with collagenase II 
(3 mg I ml), elastase II (3 mg/ ml in Hanks' Solution) and trypsin (2 mg/ ml) in Hanks' 
Solution. The mix was incubated for 10 to 15 minutes with shaking in a 37°C water 
bath. The tissue was gently triturated, then incubated and the supernatant collected as 
previously described, and the triple enzyme digestion repeated for 5 minutes in a 3 7°C 
water bath. After collecting the second supernatant, centrifugation and seeding 
proceeded as per normal. 
The specificity of these cultures was confirmed using positive staining with 
antibodies against smooth muscle cell myosin (Figure 2.1; see Table AI.3). Briefly, the 
adhered cells were rinsed in PBS, fixed in paraformaldehyde and then rinsed again in 
PBS before the addition of the primary antibody (rabbit anti-myosin; 1: 1000) and 
incubation overnight in a humidified chamber at room temperature. After rinsing in 
PBS, the cells were incubated with fluorescein (FITC)-conjugated affinity-purified 
donkey anti-rabbit (1 :40; Dako) or goat anti-rabbit oregon green (1: 100; Molecular 
Probes) for one hour as previously described, then rinsed in PBS, mounted in buffered 
glycerol and stored at -20°C. 
2.3 .2 Culture of fibroblasts 
Fibroblasts were used to test the specificity of the construct. They were grown 
from embryonic mouse cells ( derived from 13 day old mouse embryos without the livers 
and heads) in tissue culture flasks. When 70 to 80% confluent, the cells were 
trypsinized (Trypsin/ Hanks; 1 x Sterile Hanks to Trypsin-EDTA (0.25% trypsin and 
Figure 2.1 Confocal micrograph of smooth muscle cells 
Confocal images of murine aortic smooth muscle cell. Immunohistochemistry 
with antibodies against smooth muscle myosin confirmed the specificity of the smooth 
muscle cell cultures. Scale bar represents 500 µm. 
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0.02% EDTA; GIBCO-BRL, Life Technologies) to break the seal between the bottom of 
the culture flask and the cells, and seeded onto glass coverslips in 24 well plates. 
Incubation was in DMEM (Sigma) containing 1 U / ml penicillin/ streptomycin 
(GIBCO-BRL, LifeTechnologies), 0.1 mM ~-mercaptoethanol and 3.4 g NaHCO3; pH 
7, and 15% FCS (TRACE) in 1 L sterile water and filter sterilized. Glutamine was 
replenished weekly (L-Glutamine-200mM; Sigma). Cells were incubated at 37°C in a 
humidified atmosphere of 10% CO2 in air and allowed to grow on the coverslips for 2 
days ( to 60% confluence) before transfection with Lipofectamine Plus. 
2.3 .3 Transfection of cultured cells 
As electroporation was not unsuccessful, transfection of the construct into the 
cultured cells was undertaken using the transfection reagent Lipofectamine Plus, 
following the manufacturer's instructions. Preliminary testing was undertaken with this 
reagent and others: CellFectin (1 mg/ ml; GIBCO-BRL, LifeTechnologies), SuperFect 
Transfection Reagent (3 mg/ ml; Qiagen), Lipofectamine (2 mg/ ml; GIBCO-BRL, 
LifeTechnologies), FuGENE 6 (Boehringer Mannheim) and Lipofectamine 2000 (1 mg/ 
ml; GIBCO-BRL, LifeTechnologies)) both in smooth muscle cell cultures and 
fibroblasts using the control plasmid pJWLacZ (Dr Klaus Matthaei, JCSMR), to 
determine the best reagent. Two days after transfection, immunohistochemical analysis 
was performed on the cells. 
2.3 .4 Immunohistochemistry 
Immunohistochemical studies were undertaken using antibodies against Cx43. 
Briefly, the cells were rinsed in PBS and fixed in 4% (w/v) paraformaldehyde in 0.1 M 
sodium phosphate buffer pH 7.3, for 5 minutes at room temperature. After washing 
three times in PBS (5 minutes each), the cells were pre-incubated for 30 minutes with 
PBS containing 1 % (w/v) BSA, 0.3% (v/v) Triton X-100 and 0.04% (w/v) sodium azide 
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(pre-incubation solution). , The primary antibody (mouse anti-Cx43 (1 :250; Chemicon or 
rabbit anti-Cx43 , 1 :250, Zymed) diluted in the pre-incubation solution was added, and 
the cells incubated overnight at room temperature in a humidified chamber. After 
washing three times in PBS (5 minutes each), the cells were washed three times in 
washing solution containing 1 % (v/v) Triton X-100 and 0.04% (w/v) sodium azide in 
PBS (10 minutes each) before incubation with biotinylated horse anti-mouse (1 :500, 
Jackson Immuno-Research Laboratories Inc.) or biotinylated donkey anti-rabbit mouse 
(1 :500, Jackson Immuno-Research Laboratories Inc.) at room temperature for one hour 
in a humidified chamber. 
Following repeat washing in PBS and in washing solution, the cells were 
incubated in Texas Red conjugated to streptavidin (1 :200, Amersham) for 60 minutes at 
room temperature in a humidified chamber. After more PBS and washing solution 
rinses, the cells were mounted in buffered glycerol and stored at -20°C if necessary. 
Preparations were examined using either a fluorescence microscope (BH2-RFL, 
Olympus) fitted with the appropriate filters for fluorescein (excitation filter IF-190 + 
EY455, dichroic mirror DM500, barrier filter 0-515) and Texas Red (excitation filter IF-
545 + BG-36, dichroic mirror DM580, barrier filter R-610), or a confocal laser scanning 
microscope (Leica TCS 4D), and the number of Cx43 and EGFP labelled cells counted. 
Total cell counts were performed directly using either a phase-contrast 
microscope (for the fibroblasts) or by fluorescence microscopy after staining the cells 
(smooth muscle cells) in propidium iodide (40 µg / ml diluted in PBS) for 40 minutes, 
followed by several PBS washes. 
Statistical analyses of the total cell counts were undertaken using the computer 
program GraphPad Prism 2.01 for Windows. A one-way analysis of variance 
(ANOV A) was performed on the data followed by individual pairwise t tests with 
Bonferroni correction for multiple group comparisons. Significance was assessed at the 
5% level. 
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2.4 Generation of the Transgenic Mice 
2.4.1 General outline 
Transgenic mice were generated as shown in Figure 2.2. The linear DNA 
construct ( either Pvul I Kpnl I SM22a I Cx43 or Pvul I PvuIT I SM22a I Cx43) was 
electroporated into BALB/c (white) embryonic stem (ES) cells (where it would 
recombine with the genome) with a circular selection plasmid (pMClNeoPolyA (pMCl 
Neo; Stratagene)) that is not integrated into the chromosome. After selection with G418 
(Geneticin; 200 µg / ml; GIBCO-BRL, Life Technologies), resistant (surviving) colonies 
were isolated and passaged for DNA extraction and storage in liquid nitrogen. Suitable 
methods for freezing and recovering clones of embryonic stem cells have been 
published (Chan and Evans, 1991; Ure et al. 1992; Ramirez-Solis et al. 1993; Hogan et 
al. 1994; Udy and Evans, 1994). 
Positive colonies were identified by PCR and subsequently microinjected into 
blastocysts from a black mouse strain (C57BL/6), which were then reimplanted into the 
. uteri of pseudo-pregnant foster mothers. The chimaeras thus contain cells which have 
originated from both the introduced transgenic white BALB/c ES cells and the black 
C57BL/6 cells indigenous to the recipient blastocyst. Chimaeric offspring are therefore 
black and white. 
Confirmation of germ-line chimaeras was achieved by crossing the mice to 
BALB/c mice and then screening the white progeny (indicating germ-line transmission) 
by PCR using gene specific primers. Single transgenic mice were interbred to obtain 
single transgenic, double transgenic and wild type progeny. Breeding germ-line 
chimaeras gives heterozygous mice that if desired, can be interbred to homozygousity, 
as is the case for knockout mice. 
Briefly, to a 800 µl aliquot of the cell suspension, 10 µg of the linearized DNA 
and 10 µg of the circular selection plasmid (pMCl Neo) were added, followed by room 
Figure 2.2 Generation of transgenic mice 
Schematic diagram showing how transgenic mice were generated. In this thesis, 
the linear DNA construct was electroporated into cultured BALB/c embryonic stem 
cells with a circular selection plasmid (pMCl Neo ), which was not integrated into the 
chromosome. Selection with G418 followed, and the resistant ( surviving) colonies 
were passaged; ultimately for freezing and for DNA extraction. Positive colonies were 
identified by PCR and one to two microinjected into C57BL/6 blastocysts. The latter 
were then reimplanted into the uteri of pseudo-pregnant foster mothers. The chimaeras 
were therefore, black and white. Transgenic "founder" mice were identified by PCR 
. 
screemng. 
(Modified from a slide provided by Dr Klaus Matthaei, Division of Biochemistry and 
Molecular Biology, John Curtin School of Medical Research, Australian National 
University) 
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temperature incubation for 5 minutes before transfer to a 0.4 mm electrode gap 
electroporation cuvette. The cells were pulsed at 0.25 kV, 500 µFin a BioRad gene 
pulser and collected into a clean tube. After rinsing the cuvette with 800 µl knockout 
medium (KO DMEM; 500 ml KO DMEM, 0.5 U / ml penicillin/ streptomycin; 5 ml 
non-essential amino acids, 0.1 mM ~-MeEtoh, 500 µI leukaemia inhibitory factor (LIF; 
1000 U / ml final concentration) and 2 mM L-glutamine) and collecting the medium, an 
additional 4 ml of KO DMEM was added and mixed into the cell suspension. The cells 
were seeded onto 5 plates previously seeded with mouse embryonic (feeder) fibroblasts 
at 1 ml / 100 mm diameter plate, and incubated at 3 7°C in a humidified incubator with 
an atmosphere of 10% CO2 in air. 
Twenty-four hours later, cell selection was undertaken every day for about 10 
days with G418. The surviving resistant colonies were then individually isolated and 
passaged in duplicate to 6 well plates: one for DNA isolation and one for passaging for 
long term storage in liquid nitrogen. By Day 3 non-G418 resistant clones were dying-
off, with extensive cell death around days 3 to 5 after starting the selection process. 
For each clone, the medium from the well(,..., 1 ml) was removed and placed into 
a labelled tube, centrifuged to pellet the floating cells and the supernatant removed. The 
well was rinsed twice with PBS, which was added to the tube containing the pelleted 
cells, before trypsinizing (200 µl / well) for 5 minutes at room temperature. Then 1 ml 
of warmed KO DMEM with G418 (in a 37°C water bath) was added to the well, mixed 
by pipetting, and transferred to the same tube. This was repeated with another 1 ml KO 
DMEM I G418. Finally, the tubes were centrifuged for 10 minutes, the liquid removed 
and the cells resuspended in 200 µl PBS. The cells were then transferred to a clean 
eppendorf and stored at 4°C for a maximum of 2-3 hours before DNA extraction. 
DNA extraction was performed using the QIAamp Blood Kit (Qiagen) following 
the protocol for Blood and Body Fluid. Afterwards, the concentration of DNA present 
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in each clonal sample was measured using a spectrophotometer and calculated. PCRs 
were performed on 100 ng of DNA from each of the clones using gene specific primers, 
to identify which clones were positive for the insert. The PCR positives that gave the 
strongest bands (ie: contain multiple number of copies per cell) when electrophoresed 
on a 1.5 % agarose gel (see Section 2.1.4), were then frozen in preparation for injection 
into the blastocysts. 
2.4.2 The chimaeras and progeny 
Each male chimaera ( coat colour black and white) was mated to two female 
BALB/c mice and each female chimaera was mated to one male BALB/c mouse. 
Resultant progeny were white (indicating germ-line transmission) or brown (no 
transmission). Preparation of the tail DNA for PCR is described below, whilst the 
testing which was undertaken for the SM22a / Cx43 mice is detailed in Chapter 4. 
All mice were kept in micro isolator cages (Laboratory Products Inc.) in a 
controlled room with a 12 hour light / dark cycle. Food and water were available ad 
libitum. 
2.4.3 Preparation of tail DNA 
Three week old mice were ear marked for identification purposes, and the 
number recorded in the Gene Targeting mouse register. The tips of the tails were then 
excised (0.3 to 0.5 cm) and placed into eppendorf tubes containing 500 µl lysis buffer 
(100 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.2% SDS, 200 mM NaCl and MilliQ water 
to 990 ml; filter sterilized and aliquotted into 25 ml samples for storage at 4°C). 
Proteinase K (250 µl proteinase K to 25 ml buffer) was added to the lysis buffer just 
prior to use. All tubes were incubated at 56°C overnight, with rotation, in a 
hybridization oven. 
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The following day, the tubes were vortexed and then centrifuged at 6 000 rpm 
for 1 O minutes. The supernatant was poured into clean eppendorf tubes containing 500 
µl isopropanol, mixed well and using a sterile Pasteur pipette or ArtTip, the spooled 
DNA removed into a clean eppendorf tube. After rinsing with 70% ethanol and drying 
in a vacuum for a minimum of 10 minutes, the DNA was redissolved in 600 µl T 10Eo.1 
by heating to 65°C in a water bath for 30 minutes. The OD was then measured at 280 
and 260 nm and the DNA concentration calculated. Dilutions of each sample were 
made (5 µl of sample with 45 µl T10Eo.1) and 5 µl (,_,100 ng DNA) used in a PCR 
reaction. All samples were stored at 4°C. 
2.5 Analysis of the Transgenic Mice 
Transgenic and control mice were studied using immunohistochemistry, blood 
pressure measurements and W estem blots. 
2.5.1 Immunohistochemistry 
Two female mice ( one transgenic and one control in order to eliminate sex bias) 
were chosen from two age groups ( three and six weeks) and their weights recorded. 
They were anaesthetized by diluting 0.8 ml xylazine (20 mg/ ml; Ilium Veterinary 
Products) and 1.2 ml ketamine (100 mg/ ml; Ilium Veterinary Products) to 10 ml with 
PBS, and injected intraperitoneally using 100 to 150 µl per mouse. The mice were 
killed by cervical dislocation. The following tissues were dissected and processed for 
immunohistochemistry (see Table AI.5): aorta (thoracic and abdominal), mesenteric 
artery, tail artery, vena cava and ventricle. 
Briefly, the dissected tissues were cryo-frozen, sectioned and then placed on 
microscope slides before fixing in cold acetone. After air drying, the sections were pre-
incubated in 2% BSA/ 0.2% Triton-X / 0.04% sodium azide for 30 minutes and then 
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incubated with the primary antibody (anti-rabbit Cx43 polyclonal antibody (1 :250; 
Zymed) diluted in primary antibody solution (0.04% sodium azide, 2% BSA and 0.2% 
Triton-X) for one hour at room temperature in a humidified chamber. After rinsing and 
washing with PBS, the secondary antibody (1: 100; Cy-3-conjugated anti-rabbit 
immunoglobulins, Jackson Immunoresearch Laboratories Inc.) diluted in PBS/ 0.01 % 
Triton-X was applied for one hour and incubated as before. After rinsing and washing 
with PBS, the sections were mounted in buffered glycerol and examined using a 
fluorescence microscope with the appropriate filters. 
2.5.2 Western blots 
In the current study, Western blots were used to investigate the protein level of 
connexin 43 and actin in the tail artery and aorta of both control and transgenic mice of 
either sex. 
After recording its bodyweight, each mouse was anaesthetized by inhalation of 
ether and killed by severing the jugular veins in order to avoid injury to the tail artery. 
The aorta and tail artery were dissected out and placed into separate dishes containing 
cold PBS. Adipose and connective tissues were then carefully removed and the tissues 
placed in fresh dishes of cold PBS. The aorta was cut open so that the blood cells could 
be carefully removed. Due to its small size, blood in the tail artery was gently squeezed 
out using a pair of fine forceps. After determining the tissue weights on an analytical 
balance, the tissues were homogenized in separate pre-chilled homogenizers, containing 
1 ml of cold Tris swelling buffer (10 mM Tris-HCl pH 7.9, 10 mM KCl, 1 mM MgCh 
and distilled water to 100 ml) with 0.5 µl phenylmethylsulfonic acid (PMSF; 40 µg / ml 
in DMSO). This technique was latter modified for each mouse Group 2 to 4 as follows: 
the tissues were homogenized in 1000 µl of 0.25 mM cold sodium bicarbonate buffer 
(pH 7.2) with 0.5 µl PMSF. 
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After homogenization, the samples were pipetted into clean and chilled 
eppendorf tubes and centrifuged at 800 g for 3 minutes at 4 °C. The supematants were 
then aspirated into individually labelled clean eppendorf tubes and centrifuged at 17 400 
g for 20 minutes at 4 °C. The supematants were discarded and the pellets resuspended in 
appropriate volumes of either chilled RlP A buffer (Group 1; 150 mM NaCl, 50 mM 
Na2HPO4 pH 7.2, 1 % sodium deoxycholate, 1 % Triton-X, 0.5% sodium dodecyl 
sulphate (SDS), 1 mM sodium orthovanadate in distilled water) with added PMSF 
( 1: 1000), or 1 x sample buffer without dye ( other groups: 100 ml / L glycerol, 120 ml / 
L UpperTris (Table AI.6), 30 g / L SDS in distilled water). All samples were then 
stored at - 70°C until the protein assays were performed. 
The tissue samples were assayed for membrane protein using the Bio-Rad De 
Protein Assay (Bio-Rad Laboratories) according to the manufacturer's directions, and 
the appropriate dilutions for each sample were calculated. Preliminary testing with the 
XCell Surelock Mini-Cell System (Invitrogen) had shown that 12 mg of murine tail 
artery or 1 mg of aorta was the minimum tissue weight required per well in order to 
produce an adequate band. Subsequently, the proteins were separated on 12% SDS-
polyacrylamide gels using Mini-Cell System and the SeeBlue Pre-Stained Standards 
(Novel Experimental Technology) as a marker. The solutions used are shown in Table 
AI.6. The proteins were then transferred to nitrocellulose membranes using a Semi-
Phor (Hoeffer Scientific Instrumenta) followed by overnight incubation at 4°C (or one 
hour at room temperature) with 5% skim milk powder in 0.2% Tween20 in PBS (PBS-
T) to block non-specific binding. The blocking solution was removed by rinsing the 
membranes three times in PBS-T, before incubation in anti-connexin 43 rabbit 
polyclonal antibody (1 :500; Zymed) diluted in primary antibody solution (0.04% sodium 
azide, 1 % BSA and PBS-T to 2 ml) for one hour at room temperature or overnight at 
4°C on rollers. Control experiments with 10-fold excess of peptide to Cx43 antibody 
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(peptide block) were also undertaken. After washing in PBS-T for 60 minutes (3 x 10 
minutes, then transfer to a new tube for 3 x 10 minutes), the secondary antibody 
(1: 1000; donkey anti-rabbit horseradish peroxidase; Amersham Life Science) diluted in 
PBS-T was added, and the membranes incubated with agitation at room temperature for 
one hour, followed by one hour of washing in PBS-T at room temperature. Afterwards, 
the ECL Western Blotting detection agents (Amersham Pharmacia Biotech) or the 
Supersignal West Dura Extended Duration Substrate (Pierce) were used to complete the 
detection process. The membranes were then developed using Xray film and analyzed 
using the Analytical Imaging System (AIS; Imaging Research Inc.). 
2.5.3 Blood pressure recordings 
Systolic blood pressure and heart rate were measured in unanaesthetized male 
and female transgenic and control mice by tail-cuff plethysmography using a 
Programmed Electro-Sphygmomanometer PE-300 (Narco Bio-Systems), amplifier (to 
which the tail sensor was connected) and the HyperRat programme (SDR Clinical 
Technology) on a MacIntosh LC475 computer. Pressure corresponding to the systolic 
blood pressure is applied externally to the tail in the conscious but restrained mouse, and 
is measured by a manometer attached to a tail-cuff with blood flow in the tail being 
detected by a photoresistor (Hoit, 2001 ). All mice ( except one group) were acclimatized 
to the tail-cuff plethysmography equipment for the recommended 7 days prior to the first 
recording (Krege et al. 1995). 
After attaching a tail-cuff and a tail sensor, the mice were warmed to 37°C ± 1 °C 
(basal temperature for a mouse is 37°C) on a HyperRat Heated Baseplate (FUil PYZ4 
Controller) for 15 to 20 minutes. As restraint of some strains of mice is known to 
decrease tail (and body) temperature (Johnson et al. 2000), heating the base-plate to 
3 7°C is considered important as the tail artery dilates, facilitating blood pressure 
measurements. Readings were taken within 3 0 minutes, as heating on the plate may 
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stress mice, leading to a false elevation in the blood pressure reading. A blood pressure 
reading for each mouse was gained by averaging the figures for four blood pressure 
measurements that were within 10 mmHg of each other. All measurements were 
performed between 1300 and 1600 hours. 
Statistical analyses comparing blood pressure measurements in control and 
transgenic mice were undertaken using the computer program GraphPad Prism 2.01 for 
Windows. A three-way analysis of variance (ANOV A) was performed on the data. 
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Chapter 3 - Generation of the SM22a I Cx43 Construct and Mouse 
3.1 Introduction 
A transgenic mouse may be defined as an animal that contains a segment of 
exogenous DNA that is stably inherited and chromosomally integrated (Mullins and 
Ganten, 1990; Faraci and Sigmund, 1999). The DNA may originate from the host 
species, from an unrelated species, or from a combination of the two. The tissue-
specific and developmental expression of the gene construct depends upon the nature of 
the gene construct itself. Phenotypes resulting from such alterations are diverse and 
may even be phenotypically normal. The latter is due to redundancy in the genome 
and/or the expression of compensatory mechanisms. 
A number of stages are involved in the construction of a transgenic mouse. 
Briefly, in conventional experiments, pronuclear stage ( one cell) murine embryos are 
collected after fertilization, but before cleavage is initiated. Exogenous cloned 
linearized DNA is transferred into the genomes of mice by microinjection into the 
pronuclei (Gordon et al. 1980; Gordon and Ruddle, 1981, 1983). The embryos are then 
implanted into the oviduct or ovarian bursa of a pseudo-pregnant foster mother 
(previously mated with a sterile male) where they can develop into pups. Therefore, the 
chimaeras contain cells which will contribute to the germ-line, ensuring the inheritance 
of the altered gene in succeeding generations. 
Alternative methods for introducing genes into the mouse germ-line include, for 
example, retroviral infection (Nagano et al. 2000), nuclear transplantation/ transfer 
(Wakayama et al. 1999) and the insertion of genetically engineered embryonic stem 
cells (Bradley et al. 1992) into blastocysts (Hogan et al. 1994). The latter method was 
used in this thesis - chimaeric mice are shown in Figure 3 .1. 
Figure 3.1 The chimaeric mice 
Shown are two photos of two low grade male chimaeras (black and white 
colouring), each with two BALB/c (white) females. In the top photo, the pups are only 
a few days old and the female in the lower right comer is clearly gravid. Pink eyes in 
the BALB/c at birth mean germ-line (grow a white coat), whereas brown eyes (grow a 
brown coat) mean non-germ-line. In the bottom photo, three pups can be seen - two 
white (pink) indicating germ line transmission and one brown (no transmission). 
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Connexin 43 is the predominant gap jrmction gene in developing and adult 
cardiac tissue, and has been implicated in many cardiovascular pathologies. In order to 
develop a transgenic mouse model that selectively overexpresses Cx43 in the vascular 
system, it was necessary to express Cx43 specifically in vascular smooth muscle. A 
restricted portion of the smooth muscle (SM) 22a promoter ( a promoter confined to 
vascular smooth muscle cells) from the SM22a gene was used to direct specific arterial 
expression and thus, avoid cardiac overexpression of Cx43. SM22 is a 22-kDa protein 
that is expressed exclusively and uniformly in smooth muscle tissues of adult animals 
(Lees-Miller et al. 1987; Shanahan et al. 1993) and is one of the earliest markers of 
differentiated smooth muscle cells (Duband et al. 1993). 
Previous research by Solway et al. (1995) showed that only a 482 bp fragment in 
the 5'-flanking region of the SM22a gene (- 441 to+ 41 bp) was necessary and sufficient 
to program high level transcription of the SM22a / luciferase reporter gene in both 
primary rat aortic smooth muscle cells and the smooth muscle cell line A 7r5. 
Subsequent studies delineated a SM22a promoter region specific for expression in 
arterial smooth muscles in vivo (Li et al. 1996; Moessler et al. 1996). Moessler et al. 
(1996) showed that various promoter constructs of 445 to 2126 bp directed reporter 
expression initially (and transitorily) in embryonic somites and heart (presumptive right 
ventricle and outflow tract), and subsequently in the arterial vascular system where it 
persisted in the adult mouse. 
This Chapter describes the cloning of the SM22a / Cx43 / pBs KSII- (SM22a / 
Cx43) construct and the subsequent generation of the transgenic mice, whilst data 
obtained from analyses of the mice are presented in Chapter 4. The cloning strategies 
for the SM22a promoter and Cx43 cDNA are shown in Figures 3.2 and 3.3 respectively, 
and for the SM22a / Cx43 construct in Figures 3.4 and 3.5. 
3' 
(A) 
5' SM22a promoter 3' 
(B) 
EcoRI 712 Smal 699 BamHI 693 Spel 687 
iroBs KSII-
5
' SM22a promoter 3' 
Figure 3.2 Schematic diagram of the cloning of the SM22a promoter 
The cloning of the SM22a promoter is shown in (A) and (B). 
The promoter was amplified from a mouse genomic library by PCR 
(A). For the promoter to function, it had to be in the forward 
orientation in Smal I pBs KSII- (B). 
Figure 3.3 Schematic diagram of the cloning of the Cx43 cDNA 
The cloning of the Cx43 cDNA is shown in (A), (B) and (C). The cDNA was 
amplified from mouse genomic DNA by PCR (A). As the ensuing destination site of 
the Cx43 was in PvuII I Clal restricted pBi5 (B), the Cx43 gene fragment had to be in 
the reverse orientation in Clal I pBs KSII- (C). Thus, when the Cx43 / pBs KSII-
plasmid was cut with Clal and EcoRI, the Cx43 gene could be ligated into pBi5 in the 
correct orientation. 
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Figure 3.4 Schematic diagram of the cloning of SM22a / Cx43 / pBs KSII-
The cloning of the SM22a / Cx43 / pBs KSII- construct is shown in (A), (B) and 
(C). The Cx43 cDNA was excised from Cx43 / pBs KSII- with EcoRl and Clal and 
cloned into the multiple cloning site of Clal I Pvull pBi5. The Cx43 / ~-globulin poly A 
signal fragment was then excised from Cx43 / pBi5 with BamHI and Asel (A). The 
vector was further restricted with Sphl for ease of purification. The SM22a / pBs KSII-
plasmid was restricted with BamHI (B) before cloning the BamHI I Asel I Cx43 I poly A 
signal insert into the BamHI I SM22a I pBs KSII- vector (C). The figures are not to 
scale. The numbers refer to the designated pBs KSII- numbering. 
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PvuII 977 Kpnl 759 Small 699 BamHI 693 Spel 687 I PiluI 500 
3' Bs KSII-
I I I====== 
SM22a promoter 
(0.493 kb) 
Cx43 I poly A signal 
(2.510 kb) 
Figure 3.5 Preparation of the SM22a / Cx43 / pBs KSII- plasmid for electroporation 
The SM22a / Cx43 / pBs KSII- plasmid was restricted with Pvul and Kpnl to excise the SM22a / Cx43 
/ poly A fragment prior to electroporation into BALBI c murine embryonic stem cells. The numbers refer to the 
designated pBs KSII- nu1nbering system. Not drawn to scale. 
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PART I- Cloning of the SM22apromoter and Cx43 cDNA 
3.2 Additional Methods 
3.2.1 Cloning of the SM22a promoter 
3 .2.1.1 Isolation of the SM22a promoter 
The Mus mus cul us SM22a gene ( GenBank sequence accession number 268618) 
and SM22a cDNA sequences were downloaded from GenBank and the published 
restricted SM22a promoter region identified. The general features of the SM22 gene are 
shown in Figure 3.6A. Two primers, one forward (SM22exlf) and one reverse 
(SM22exlr) were designed on either end of the promoter (see Figure 3.6B; Table 2.2). 
The restricted SM22a promoter was amplified from a BALB/c mouse genomic 
library (LE392, provided by Mr David Mann) by PCR using the SM22exlf and 
SM22exlr primers (see Table 2.2) and Pfu DNA polymerase. After agarose gel 
electrophoresis to check for correct band size ( 493 bases), the product was generated a 
further six times using the same primers and PCR conditions to gain sufficient sample 
for cloning. All six PCR tubes were then combined before assessment by agarose gel 
electrophoresis. The product was purified and the concentration determined by OD at 
260 nm. 
3 .2.1.2 Construction of the SM22a / pBs KSII- plasmid 
The pBluescript plasmid (Figure 3. 7) was restricted with Smal and phosphatased 
by Mr David Mann (Biochemistry and Molecular Biology, JCSMR). The purified 
SM22a PCR product was blunt-end cloned into Smal I pBs KSII-. The ligation was 
performed in a 20 µl total reaction volume with 1 µl of T 4 DNA ligase ( 40 000 units / 
ml). The construct was subsequently electroporated into TOPl0F' cells and resulting 
colonies blue / white screened. 
All white colonies were analyzed by cracking and those containing an insert and 
some not containing an insert, were screened by PCR using the gene specific primers 
i 
Figure 3.6 The restricted SM22a promoter 
The position of the restricted promoter region in relation to the SM22a gene is 
shown in (A). The SM22 primers are indicated on the SM22a promoter sequence 
in (B). The Exon 1 start site and transcription start site is also marked. The 
mSM22exlf primer (GAC TAG TTC CCA CCA ACT CGA TT) is not marked as 
it was largely encompassed by the SM22exlf primer. 
f Start site of transcription 
•
11 Exons are boxed, with open boxes indicating non-coding regions 
C Restricted promoter region 
i SM22exlf 
i - i mSM22F2 
i 
i 
i 
I 
I 
i 
I 
i 
mSM22F6 
mSM22F7 
SM22exlr 
Start of Exon 1 and transcriptional start site 
End of Exon 1 (+ 65 bp) 
(A) 
500 bp 
-2126 t 
TAG 
+6030 
(B) 
taccatacct gtgggcagga tgacccatgt tctgccatgc acttggtagc cttggaaagg ccactttgaa cctcaatttt ctcaactgtt aaatggagtg gtaactgcta tctcataata 
c gtttlgatag tgcctggtt; c ~~cca;sct gcagt4iagal 
-430 ccaactc a t ::ctt: t i t gtcccttgca ttta agcct tgcaa aa~ ctcgggccaa actctagaat gcctccccct ttctttctca ttgaagagca gacccaagtc cgggtaacaa ggaagggttt cagggtcctg cccataaaag gtttttcccg gccgccctca gcaccgcccc gccccgaccc ccgcagcatc tccaaagcat gcagagaatg ctccggctg cccccgacag actgctccaa cttggtgtct atggagcct~ gtggagtga gtggggcggc ccgg t t g ggcagggagg ggcgccacgg ggcggcagag gggt · catc acccctcacc cccggcccgt ctgccccagc ccagacaccg aagatactct ccttccagt +47 cacaaac ac caagcct gt aagtgcaagt catgggagca gaagggctgt gggctcaatt agatccccta gtctcttcta gtttgctggg tggaattggg tccctagaga ccattctctg tgttagacaa aaagtctggg ttaaaatgcc taggatgatt tgactggggc aaaagaataa atggggtgag agggaggctc aaattcagtc actgtcccac ccataggtgt atgggctatg tgttaggccc aaagaggtga caaatgaggc caagggaaca actccatctt tggatctcca 
Figure 3. 7 The pBluescript (pBs KSII + / -) plasmid 
The 2.961 kb pBluescript plasmid, derived from pUC19 (GenBank), is shown 
opposite with selected restriction enzyme sites (A). The KS designation indicates that 
lacZ transcription proceeds from Kpnl to Sacl. The fl (-) origin is the filamentous 
phage origin of replication allowing the recovery of the antisense strand of the lacZ 
gene when a host strain containing the pBluescript II phagemid is co-infected with 
helper phage. Hence the minus designation (pBs KSII-). The lacZ promoter provides 
a-complimentation for blue/ white screening (see Section 2.1.12). The multiple 
cloning site (657 to 759 bp) is flanked by two promoters (HOTT3 (or T3) and HOTT7 
( or T7)) which are shown in (B), with selected restriction enzyme sites pertinent to this 
study. Amp\ the ampicillin resistance gene (1975 to 2832 bp ), allows antibiotic 
selection of the vector. The difference between pBs KSII- and pBs KS- is the addition 
of two BssH II restriction enzyme sites in pBs KSII-. 
(A) 
. Seal 2526~ 
PvuI 2416~ 
(B) 
Pvu II 529 
,. :·:,-.--Sac I 657 
Multiple cloning site :·; ._. 
-=' Kpn I 759 
Pvu II 977 
BssH II 
HOTT3 Kpnl Clal EcoRV EcoRI 
796 
AACAAAAGCTGGGTACCGGGCCCCCCCTCGAGGTCGACGGTATCGATAAGCTTGATATCG 
- TGTTTTCGACC~ATGCGCCGGGGGGGAGCTCCAGCTGCC,TAGCTATTCGAAClATAG~TTAA 
759 731 717 712 
Spel . S I Pstl Smal Bamffi Xbal Natl ac BssH II 
. 3' +) AATTCCIGCAGCCCGGGGGATCCACTAGTTCTAGAGCGGCCGCCACCGCGGTGGAGCTCC ATTCG GG CGTCGGGCCCCCTAGGTGATCAAGATCTCGCCGGCGGTGGCGCCACCTCGAGG TAAGC I I I I I I I HOTT? primer 
CGCG 
. GCIGC 
5' (-) 
705 699 693 687 681 675 657 624 
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SM22exlf and SM22exlr, and appropriate controls (pBs KSII- and genomic DNA). 
The HOTT3 and HOTT7 primers (Table 2.2) were made to the T3 and T7 promoter 
sites outside the multiple cloning site of pBs KSII-. Positive colonies were further PCR 
screened using various primer combinations, with two colonies ultimately chosen for 
restriction enzyme analyses and bi-directional sequencing using the SM22exlr, 
SM22exlf, HOTT3 and HOTT7 primers. 
3.2.2 Cloning of the Cx43 cDNA 
3 .2.2.1 Isolation of the Cx43 cDNA 
The Mus musculus connexin 43 gene (6.935 kb; Genbank sequence accession 
number L10388) was downloaded from GenBank. The start and stop codons for the 
gene were identified using published sequences for the rat and mouse, and sufficient 
bases added to either side (139 bp forward and 42 bp reverse) for flexibility during the 
cloning process, to give a fragment of 1.325 kb (344 7 to 4 772 bp ). The selected 
cloning sequence is shown in Figure 3.8A,B. One forward (CnxF) and one reverse 
(CnxR) primer were designed on either side of the designated region (Figure 3.8B; 
Table 2.2) and used to isolate the Cx43 gene fragment from a BALB/c mouse genomic 
DNA by PCR using PfuTurbo DNA polymerase (see Table 2.2). This PCR was 
repeated four times to generate enough product for cloning. The products were then 
combined into one sterile eppendorf tube and a small aliquot electrophoresed on an 
agarose gel to check for correct band size. The PCR product was purified and assessed 
by agarose gel electrophoresis. 
3.2.2.2 Construction of the Cx43 / pBs KSII- plasmid 
One hundred nanograms of pBs KSII- (previously quantitated at OD260) was 
restricted with EcoRV and Clal (Figure 3.7). After a four hour incubation (2 hours for 
the EcoRV restriction digest followed by 2 hours for the Clal restriction digest with 
Figure 3.8 The Cx 4 3 selected cloning sequence 
The position of the selected Cx43 cDNA region (1.325 kb) in relation to the 
entire Cx43 gene is shown in (A). The Cx43 primers are indicated on the Cx43 
cDNA sequence in (B). The Exon 2 start site is also marked, as are the start and 
stop codons, and the Clal restriction site. 
• Exon 1 
Exon 2 with coding region (green) 
Intron (10.5 kb) in the 5'-UTR (untranslated region) 
D Selected sequence for cloning 
_______ __.I CnxF primer 
_______ __.I mCx435'Rprimer 
::::::::::::1 Rat CxF primer position 
t 
I 
i 
i i 
I 
Rat Cx43F primer position 
mCnx43R primer & rat Cx43R primer position 
Rat Cx43R2 primer position 
Rat Cx43R3 primer position 
CnxRprimer 
Start and stop codons 
Exon 2 start site 
Clal restriction site 
(A) 
- I 
Transcription start site 
(B) 
3421 gccagatttg cccttggatt ctgtt ggc 
ccctgaaaaa agaaactata tatgt 
gttttcgtgg tttttgtttt tgtt ttctt 
gccttgggga agctgctgga caaggtccaa 
ctgtcggtgc tcttcatttt cagaatcctg 
tcgctgtaac 
cct ccccat ctctcacgtg 
cactcctgta cttggctcac 
ctgaacaaga aagaagagga gctcaaagtg 
cacctgaagc agattgaaat caagaagttc 
aagatgagag gtggcctgct gagaacctac 
gaggtggcct tcctgctgat ccagtggtac 
acctgcaaga gagatccctg cccccaccag 
aaaaccatct tcatcatctt catgctggtg 
attgagctct tctatgtctt cttcaagggc 
ccttaccac cccactgagc 
ct tact tea ctcaccaacg 
tacaagctgg cagaaacaat 
agcgagcaaa actgggcgaa ttacagcgca 
accatctcca 
aaagttgctg 
agagccagca 
ttgaacat 
4801 cacctqqqqt ttcccqtgga 
,,-·-::•- ,. 
ts£-.-~=...:· .: 
ttgggttgaa 
catcaattta 
ag ggtgcc 
gee actcca 
ctcctgggga 
actcaacaac 
cgcttctggg 
gtgttctatg 
gcgcagaccg 
aagtatggga 
atcatcagca 
atctatgggt 
gtggactgct 
gtgtcottgg 
gttaaggatc 
ccatccaaag 
gccccactct 
tcctcctgcc 
gagcaaaatc 
atttccct 
ttagctat 
ggtqgtactc 
I 
1000 bp 
actgcctta tttgactgac 
cagtctacaa tcactgagtt 
caga g tgactggagc 
cggccggagg gaaggtgtgg 
cagcggttga 
ccggttgtga 
tccttcagat 
tgatgagaaa ggaag a aag 
acggggtcaa cgtgg-agatg 
ttgaagaaca cggcaaggtg 
tcctcttcaa gtctgtcttc 
tcagcctgag tgcggtctac 
tcctctcacg 
tgtctctcgc 
gcgtgaaggg aagaa= 
actgcggatc tccaa ta 
cacctatgtc tcctcctggg 
gcaattacaa caagcaagcc 
gaatggggca ggccggaagc 
acgacagcca aaatgccaaa 
tggatcam ccttccagc 
acctgga t taaacaggc 
aagggtgctt gcagaacgtg 
aacaacctca gtaatqaqqc 
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added BSA, MilliQ water and new buffer), the unwanted plasmid fragment and 
restriction enzymes were removed by guanosine gel electrophoresis. The restricted 
plasmid was purified and a small aliquot checked by agarose gel electrophoresis. 
The blunt-end Cx43 PCR product was then restricted with Clal to make a 
complementary end for cloning into the EcoRV I Clal I pBs KSII- vector (Figure 3.3). 
After isolation and purification, two hundred and thirty-six ng of the Clal I Cx43 
fragment was cloned into 100 ng of EcoRV I Clal I pBs KSII- in a 80 µI ligation mix 
with 1 µl of T 4 DNA Ligase ( 400 000 units / ml; Section 2.1.10). The plasmid was 
electroporated into TOP 1 OF' cells and blue / white screened. 
White colonies were analyzed by cracking (predicted size of 4.326 kb). One 
possible positive clone, designated C3, was verified by PCR using various connexin and 
pBs KSII- forward and reverse primers, and by restriction enzyme digests. Bi-
directional sequencing with a combination of primers (HOTT3, HOTT7, CnxF, Cx43R, 
Cx43R2 and Cx43R3) so that each base was unambiguously determined at least twice, 
was also undertaken. The Cx43 forward primers Cx43F and CxF (provided by Dr Caryl 
Hill) were also used. 
3.3 Results 
3.3.1 SM22a I pBs KSII-
Three SM22a / pBs KSII- colonies (designated Clone #121, Clone #137 and 
Clone #139) amplified the requisite band (around 493 bases) on initial PCR screening 
with SM22exlf and SM22exlr. Subsequent screening on Clone #121 showed that the 
insert was present and in the correct orientation. As shown in Figure 3 .9 (Table 2.2), the 
HOTT3 I HOTT7 primers amplified a band around the predicted size of 0.635 kb, and 
insert orientation was determined by the HOTT3 / SM22exlr PCR (no band was 
amplified as expected) and the HOTT3 / SM22exlf PCR (amplified a band around the 
0.621 kb 
0.521 kb 
• 
• 
l 2 3 4 5 6 
• 0.635 kb band 
Figure 3.9 PCR screening of SM22a / pBs KSII- Clone # 121 
Three PCRs are shown, with the pTz / AluI marker in Lane 1. 
In Lane 2, Clone #121 was screened with HOTT3 and SM22exlf 
(positive for reverse orientation; purple arrow) and Lane 3, with 
HOTT3 and SM22exlr (negative for reverse orientation). In Lane 4, 
Clone #121 was screened with HOTT3 and HOTT7 (positive for 
insert; yellow arrow). The water controls are in Lanes 5 and 6. 
0.621 kb 
0.521 kb • • 
1 2 3 4 5 
• 
Figure 3.10 PCR screening of SM22a / pBs KSII- clones 
0.493 kb band 
PCR screening of Clone #137 and Clone #139 with the 
SM22exlf and SM22exlr primers ( expected band size of 0.493 kb) 
revealed that only Clone #137 was positive (Lane 2). Clone #139 is in 
Lane 3 (negative), followed by the water control in Lane 4, and 
SM22a DNA in Lane 5. The pTz / AluI marker is in Lane 1. 
71 
predicted size of 0.586 kb). Clones #137 and #139 were screened with the HOTT3 / 
HOTT7 primers (amplified a band around the predicted 0.635 kb) and the SM22exlf I 
SM22exlr primers (amplified a band around the predicted band size of 0.493 kb). Only 
Clone #137 was PCR positive for both sets of primers (Figure 3.10). 
Subsequently, the two PCR positive SM22a / pBs KSII- clones (#121 and #137) 
were subjected to restriction analyses: 1) the single pBs KSII- cutters EcoRI and Spel 
(both are non-cutters in the restricted SM22a promoter) each gave a band that 
corresponded with the predicted fragment size of 3.457 kb; 2) the combination of EcoRI 
and Spel excised the SM22a promoter from SM22a / pBs KSII- giving two fragments 
that approximated the predicted band sizes of 518 bp and 2.939 kb (Figure 3.11). 
Orientation of the SM22a promoter insert in Clones # 121 · and # 13 7 was 
confirmed by restriction with the Xbal enzyme. Xbal cuts once in pBs KSII- ( at position 
681) and once in the SM22a promoter ( at position 87), so an insert in the forward 
orientation should give bands which correspond with the predicted band sizes of 0.424 
kb and 3.033 kb (as in Clone #137). An insert in the reverse orientation when restricted 
withXbal, would produce two bands around the calculated band sizes of 0.105 kb and 
3.352 kb, as was the case with Clone #121. BamHI (a single cutter in pBs KSII- and a 
non-cutter in the SM22a promoter) restrictions on both clones gave linear bands which 
approximated the predicted band size of 3 .457 kb. 
The sequencing data showed that the SM22a / pBs KSII- clones had three (3) bp 
in the SM22a promoter which differed from the published database sequence (Figure 
3.12). 
3.3.2 Cx43 I pBs KSII-
The Clone designated C3 was verified by PCR screening (Table 2.2). Briefly, 
the HOTT3 and HOTT7 primers amplified a band around the predicted fragment size of 
1.480 kb, and the HOTT3 and CnxF primers amplified a single band which 
Figure 3.11 Verification of the SM22a / pBs KSII- Clones (#121 and #137) 
Restriction enzyme digests on Clone # 121 are shown in (A), whilst restriction 
enzyme digests on Clone #137 are shown in (B) and (C). The predicted size of the 
SM22a I pBs KSII- clone was 3.457 kb. 
In (A), EcoRI and Spel each gave a band which corresponded with the predicted 
fragment size of 3.457 kb, whilst EcoRI and Spel (Lane 5) excised the SM22a 
promoter, giving two fragments that approximated the predicted band sizes of 0.518 kb 
and 2.939 kb. An.Xbal restriction (Lane 6) produced two bands around the calculated 
band sizes of 0.105 kb and 3.352 kb (the former band could not be visualized on the 
gel), which confirmed the reverse orientation of the SM22a promoter insert in Clone 
# 121. A BamHI restriction ( a single cutter in pBs KSII- and a non-cutter in the SM22a 
promoter; Lane 8) gave a linear band which approximated the predicted band size of 
3.457 kb. 
A BamHI restriction on Clone # 13 7 also gave a linear band which corresponded 
with the predicted fragment size of 3.457 kb (B). Orientation (forward) of the SM22a 
promoter insert in this clone was confirmed by an .Xbal restriction, which produced two 
fragments corresponding with the predicted band sizes of 0.424 kb and 3.033 kb (C). 
,......, 
;::i 
~ (A) ~ f:--< 
0. 
6.557 kb 
4.373 kb 
2.322 kb 
2.027 kb 
0.621 kb 
0.521 kb 
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-430 
+47 
taccatacct 
ccactttgaa 
gacccaagtc 
gccgccctca 
tctccggctg 
tgtggagtga 
ggcgccacgg 
tgttaggccc 
KEY: 
i i 
' 
i 
gtgggcagga tgacccatgt 
ctcaactgtt 
aa c gtttggatag 
ccaactc a tttaaagcct 
ctcgggccaa actctagaat 
cgggtaacaa ggaag= t 
gcaccgcccc gcccc c 
cccccgacag actgctccaa 
gtggggcggc ccggggtggt 
ggcggcagag gggtgacatc 
cccggcccgt ctgccccagc 
caagccttgt aagtgcaagt 
gtctcttcta gtttgctggg 
aaagtctggg ttaaaatgcc 
agggaggctc aaattcagtc 
aaagaggtga caaatgaggc 
SM22ex 1 f primer 
SM22ex 1 r primer 
tctgccatgc acttggtagc 
aaatggagtg gtaactgcta 
tgcctggttg cggccaggct 
tgcaagaagg tggcttgttt 
gcctccccct ttctttctca 
cagggtcctg cccataaaag 
ccgcagcatc tccaaagcat 
cttggtgtct ttccccaaat 
gagccaagca gacttccatg 
actgcctagg cggcctttaa 
ccagacaccg aagc actct 
catgggagca gaagggctgt 
tggaattggg tccctagaga 
taggatgatt tgactggggc 
actgtcccac ccataggtgt 
caagggaaca actccatctt 
Figure 3.12 Sequencing of SM22a I pBs KSII- clones 
cttggaaagg 
tctcataata gcagtcfi#i4 
gtcccttgca 
ttgaagagca 
gtttttcccg 
gcagagaatg 
atggagcctg 
ggcagggagg 
acccctcacc 
ccttcca t 
gggctcaatt 
ccattctctg 
aaaagaataa 
atgggctatg 
tggatctcca 
Clones # 121 and # 13 7 were sequenced in both directions. The 
sequences differed from the published sequence by three bases, as 
indicated by the blue boxes. 
An extra C between the A and C 
[lJ Loss of the two As at the proximal end of the forward primer 
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approximated the predicted fragment size of 1.390 kb. The HOTT7 and CnxF primers 
did not amplify any band; the CxR3 and CnxF primers amplified a single band around 
the predicted fragment size of around 0.680 kb; the CxR2 and CnxF primers amplified a 
single band around the predicted fragment size of 1.018 kb, and the HOTT7 and CxR2 
primers amplified a single band of about 1.268 kb. 
Further verification of the C2 clone was by restriction enzyme digests, as shown 
in Figure 3.13. Clal (a single cutter in pBs KSII- and a Cx43 cDNA non-cutter) gave a 
linear band which corresponded with the predicted fragment size of 4.326 kb. Single 
BamHI (single cutter in pBs KSII- and a non-cutter in Cx43) and EcoRI (single cutter in 
pBs KSII- and a non-cutter in Cx43) restriction digests each gave a linear band, which 
approximated the predicted band size of 4.326 kb. The double restriction enzyme 
digests BamHI I Clal and EcoRI I Clal each excised the Cx43 gene fragment (single 
band sizes of about 1.417 kb for Clal I BamHI, and 1.384 kb for Clal I EcoRI). 
Finally, the sequence of the clone did not differ from the published sequence 
(Figure 3.8). 
PART II- Cloning of the Cx43 lpBi5 construct 
3.4 Additional Methods 
3 .4.1 Preparation and verification of the pBi5 plasmid 
A small aliquot of the pBi5 plasmid was quantified at OD260 and verified by 20 
µl restriction analyses using Aatll ( a single cutter in pBi5 which gave a linear band 
around the predicted size of 6.083 kb), Asel (cuts twice at 1.827 kb and 3.062 kb, and 
produced fragments around the predicted band sizes of 4.848 kb and 1.235 kb), Aatll I 
Asel (three fragments were generated around the predicted sizes of 4.086 kb, 1.235 kb 
and 0.762 kb), Clal (cuts once at 629 bp and produced a linear band approximating the 
predicted size of 6.083 kb), Pvull (a single cutter at 603 bp, so a linear band of about 
Figure 3.13 Restriction enzyme verification of Cx43 / pBs KSII-
The Clal restriction (a single cutter in pBs KSII- and a Cx43 cDNA non-cutter) 
digest on Cx43 / pBs KSII- gave an expected linear band around the 4.373 kb band of 
lliindIII (A). This corresponded with the predicted fragment size of 4.326 kb. In (B), 
the single cutters BamHI (Lane 4) and EcoRI (Lane 5) each gave a linear band, which 
approximated the predicted band size of 4.326 kb. The double restriction enzyme 
digests of BamHI I Clal and EcoRI I Clal are shown in Lanes 5 and 7 of (C). Both 
combinations excised the Cx43 gene fragment ( estimated band sizes of 1.417 kb for 
Clal I BamHI, and 1.384 kb for Clal I EcoRI). 
(A) 
l ... ·· ... . 11·· .'.'.•,. _.·., . .. ·•. -- . ..'•r, ,c;a: . • 5.581 kb • 4.373 kb 
= • 
4.326 kb band 3.574 kb 
2.720 kb • 2.180 kb • 
1.444 kb • 
(B) 
4.373 kb --•- ... •--- - 4.326 kb band 
2.180 kb ----1•-
(C) ,-.., ...... ~ ~ 
,-.., ,-.., u u ;:: ...... ;::::. 
-.. 
'B ::c ~ ~ ...... (..) s.: ~ (..) § 0 f--< ~ ~ (..) 0. CQ ~ 
3.574 kb • 
1.444 kb • • 1.3 84 kb band 
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6.083 kb was produced), and Clal I PvuII will remove 26 base pairs which will not be 
visible on a gel, giving a linear band around an estimated band size of 6.057 kb. 
One hundred nanograms of the plasmid was then restricted with Clal and PvuII 
to remove part of the multiple cloning site. The product was assessed by agarose gel 
electrophoresis before isolation, purification and assessment by agarose gel 
electrophoresis. 
3.4.2 Preparation of the Cx43 / pBs KSII- plasmid 
Cx43 I pBs KSII- (2 µg) was restricted with EcoRI at 37°C for 1.5 hours and 
then heat inactivated (65°C for 20 minutes) before blunt-ending with Klenow. The 
sample was purified and assessed by agarose gel electrophoresis. Two micrograms of 
EcoRI I Cx43 I pBs KSII- were restricted with Clal, isolated by guanosine gel 
electrophoresis and purified before agarose gel electrophoresis. 
3.4.3 Cloning of the insert into the vector 
The EcoRI I Clal I Cx43 I pBs KSII- insert was ligated into the Clal I PvuII I 
pBi5 vector with an insert to vector ratio of 5 to 1, and using 100 ng vector with 1 µl of 
T4 DNA Ligase. Colonies were screened by cracking, with ten positive for the Cx43 
insert when compared to the control plasmid. Verification of the Cx43 / pBi5 clones 
was by PCR using the Cx 4 3 R3 and CnxF primers ( this reverse primer was chosen as the 
Clal I Cx43 restriction had removed 13 bases from the original CnxR primer; Table 
2.2). The single clone giving the strongest band in the PCRs ( designated Clone 20) was 
chosen for restriction analyses, and together with one other clone ( designated Clone 3 
(Lane 5); Figure 3.14) was bi-directionally sequenced with the CnxF, CxF, Cx43F and 
Cx43R2 primers. Two new primers were designed using Mac Vector to sequence 
through the multiple cloning site ( designated pBi5R and pBi5F). Clone 20 was further 
verified by restriction analyses. 
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3.5 Results 
Nine Cx43 / pBi5 colonies were PCR positive with the Cx43R3 and CnxF 
primers, producing a fragment around the predicted band size of 1 kb (Figure 3 .14 ). 
The clone producing the strongest band (Clone 20) was then subject to restriction 
analyses (estimated plasmid size of 7.357 kb; Figure 3.15). Asel (cuts twice in pBi5 at 
1.827 kb and 3.062 kb, and is a non-cutter in the Cx43 gene fragment) gave fragment 
sizes which corresponded to the predicted values of 1.235 kb and 6.122 kb; Aatll (a 
single cutter in pBi5 at 3.809 kb) produced a linear band around 7.357 kb; Asel I Aatll 
gave fragment sizes which corresponded to the predicted bands of 1.234 kb, 0.763 kb 
and 5.359 kb; Sphl (a single cutter in pBi5 at 5.411 kb) gave a linear fragment around 
the predicted size of 7.357 kb), BamHI (a triple enzyme cutter in pBi5 at 0.591 kb, 4.344 
kb and 4.362 kb, produced the expected fragment sizes of2.312 kb, 3.753 kb and 0.018 
kb ( data not shown); and Sphl I BamHI produced three fragments which corresponded 
with the predicted sizes of 5.027 kb, 1.263 kb, 1.049 and 0.018 kb. In both cases, the 18 
bp band was too small to be visualized on the agarose gel. 
The sequencing data showed that no base changes had occurred during the 
cloning process, and the orientation of the construct in pBi5 was confirmed. 
PART III- Cloning of the SM22a/Cx43 /pBs KSII- construct 
3.6 Additional Methods 
3 .6.1 Cloning of the SM22a / Cx43 construct 
3.6.1.1 Preparation of the SM22a I pBs KSII- plasmid 
The SM22q / pBs KSII- plasmid Clone #137 (SM22a in the forward orientation) 
was verified by repeating the Spel, Xbal and BamHI restrictions. Three micrograms of 
the plasmid were then linearized using BamHI. After assessment by agarose gel 
1.444 kb • 
10 15 
I I 
PCR screening with the CnxF and Cx43R3 primers 
Figure 3.14 PCR testing of Cx43 / pBi5 colonies 
The CnxF and Cx43R3 PCR is shown. All colonies except 
the one in Lane 14 ( designated # 4 7) showed the expected PCR 
product size of 1 kb. The dye line is indicated by the yellow arrow. 
The clone in Lane 10 ( designated C20) was selected as the potential 
stock colony. Lane 15 was the water control. 
Figure 3.15 Verification of the Cx43 / pBi5 clone 
The Cx43 / pBi5 clone (calculated to be 7.357 kb) designated Clone 20 was 
verified using restriction enzyme analyses. In (A), the single cutter AatII gave a linear 
band around the predicted band size of 7.357 kb, whilst Asel (cuts twice) produced two 
fragments of approximately 1.235 kb and 6.122 kb as expected. The AatII I Asel 
restriction produced three bands which approximated the predicted fragment sizes of 
5.359 kb, 1.234 kb and 0.764 kb. 
The Sphl and Sphl I BamHI restrictions are shown in (B). Sphl produced a 
linear band of about 7.357 kb. The Sphl I BamHI restriction produced three of the 
predicted four bands as the 0.018 kb band was too small to be visualized on an agarose 
gel. 
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electrophoresis, the DNA was dephosphorylated and purified before repeat 
electrophoresis. 
3.6.1.2 Preparation of the Cx43 / pBi5 plasmid 
The Cx43 / poly A signal fragment was excised from 2.5 µg of the Cx43 / pBi5 
plasmid in a large restriction digest with BamHI, Asel and Sphl. The DNA was 
checked, and the fragment isolated and purified. 
3 .6.1.3 Cloning of the insert into the vector 
After the BamHI I Asel I Cx43 I poly A insert was ligated into the BamHI I 
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SM22a / pBs KSII- vector, the 3' ends were filled-in with Klenow. The sample was 
purified and assessed by agarose gel electrophoresis, before another 1 µl of T4 DNA 
Ligase was added to the mix, followed by overnight ligation at 16°C. The vector was 
transformed and resulting colonies screened by cracking. Five positive SM22a / Cx43 / 
polyA I pBs KSII- (SM22a / Cx43 / pBs KSII-) clones were chosen for verification by 
PCR screening, restriction enzyme analyses, and bi-directional sequencing using a 
variety of primers (SM22exlf, SM22exlr, CnxF, CxF, Cx43F, Cx43R2, pBi5 3', 
HOTT3 and HOTT7) so that each base was determined at least twice. The construct 
was evaluated in cell cultures of murine smooth muscle cells and embryonic fibroblasts 
using immunohistochemistry. 
3.6.1.4 Preparation and electroporation of the SM22a / Cx43 / pBs KSII-
Kpnl (a single cutter in pBs KSII- at position 759) and Pvul (a double cutter in 
pBs KSII- at positions 500 and 2416, and a non-cutter in the SM22a promoter and Cx43 
gene fragment) excised the SM22a / Cx43 / poly A signal insert from 4 µg of the SM22a 
I Cx43 I pBs KSII- plasmid (Figure 3.5). After isolation, purification and assessment by 
agarose gel electrophoresis, 6 µg of the fragment was co-electroporated into BALB/c 
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(white) murine embryonic stem (ES) cells with a circular resistance plasmid pMClNeo, 
and subsequently selected with G4 l 8. 
The seven antibiotic resistant colonies (diluted in T10Eo.1 to give a final 
concentration of 20 ng / µl of which, 5 µl was used in each PCR) were screened by PCR 
using gene specific primers to confirm which clones possessed a stably incorporated 
copy of the gene. Two new primers were designed and synthesized to maximize the 
sensitivity of the PCR for the SM22a promoter: mSM22exlf (re-synthesized), 
mSM22exlfb and mCnx43R (see Table 2.2). 
3 .6.1.5 Screening of the progeny 
Progeny were screened by PCR. To test whether the SM22a promoter was 
present but truncated in the mice, three new forward primers in the SM22a promoter 
region were designed and synthesized, mSM22F2, mSM22F6 and mSM22F7 (see 
Figure 3.6; Table 2.2), and one reverse primer in the Cx43 gene (mCx435'R). 
3.7 Results 
3.7.1 Cloning of SM22a I Cx43 
(a) PCR screening 
The PCRs showed that for all five clones, the insert was present and in the 
correct orientation, which was quite surprising as the cloning was not directional (Figure 
3.16). Briefly, the SM22exlf and pBi5R primers amplified a band around the predicted 
size of 1.99 kb, the SM22exlf and Cx43R2 primers amplified a band around the 
predicted size of 1.47 kb, the SM22exlf and HOTT7 primers (to screen the whole insert 
from the promoter through the gene and into pBluescript) amplified a band about 3.5 kb 
as expected, and the HOTT3 and Cx43R2 primers (to screen from pBluescript to the 
start of the Cx43 gene) amplified a band size of around the predicted 1.4 kb. 
Figure 3.16 PCR screening of SM22a / Cx43 / pBs KSII- colonies 
In (A), Lanes 3 to 7 contain the five colonies that were screened by the ensuing 
PCRs. The SM22exlf and Cx43R2 PCR produced the expected 1.47 kb band size. The 
HOTT3 and Cx43R2 PCR (B) produced a band which approximated the predicted band 
size of 1.4 kb, whilst the SM22exlf and HOTT7 PCR amplified a fragment of about 3 
kb. The water control was in Lane 3. The apparent upward slope of the bands in Lanes 
4 to 7 inclusive, was due to gel artifact. The relative positions of the primers is shown 
in (C), which is not drawn to scale. 
(A) 
the colonies (no PCR) SM22exlf and Cx43R2 
5.581 kb • 
3.574 kb • 
2.720 kb 
• 2.180 kb • 
1.444 kb • • 
1.47 kb 
band 
(B) HOIT3 and Cx43R2 SM22exlf and HOIT? 
5.581 kb • 
• 
3.0 kb 
3.574 kb • band 
2.720 kb • 2.180 kb 
• 
1.444 kb 
• • 
1.4 kb 
band 
(C) 
HOIT3 HOTT? 
in pBs KSII- SM22a I Cx43 fragment in pBs KSII-
-----------
-----------
SM22exlf / HOTD 
-----------
---HOTT3 I Cx43R2 PCR 
PCR 
-----------
-SM22exlf I Cx43R2 PCR 
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(b) Restriction analyses 
Restriction analyses confirmed that for all clones, each segment of the construct 
was present in the clones. The single cutters Sphl ( cuts in the SM22a restricted 
promoter) and BamHI ( cuts in pBi5) each gave a single band around the predicted band 
size of 5.9 kb (Figure 3.17). A single Natl restriction produced a linear band of 
approximately 5.9 kb as expected, and when combined withXhaI (a single cutter in pBs 
KSII-) one band, assumed to be a doublet containing the predicted band sizes of 2. 7 kb 
and 2.9 kb, was produced. A BamHI ( a single cutter between the SM22a promoter and 
the Cx43 / poly A fragment) I SacIT restriction produced two bands which approximated 
the predicted band sizes of 3. 09 kb and 2. 81 kb. 
One colony (designated Clone #57) was chosen, based on band intensity, to be 
the stock colony. Kpnl and Pvul excised the SM22a I Cx43 I poly A insert from SM22a 
I Cx43 I pBs KSII- (Clone #57) generating three bands around the expected band sizes 
of 1.045 kb, 1.657 kb and 2.999 kb (the latter was the desired fragment), while the 
fourth and smallest band (0.199 kb) expected from this restriction digest, was not visible 
on the gel (Figure 3.18). 
( c) Sequencing 
The data showed that the restricted SM22a promoter and the Cx43 / poly A 
signal sequences did not differ from the published genomic sequences and the consensus 
sequence, apart from the three base pairs in the SM22a promoter as already noted ( see 
Figure 3.12). 
3.7.2 Testing in cell culture 
Data from the single transfections of SM22a I Cx43 I pBs KSII- in the aortic 
smooth muscle cells are presented in,Figure 3.19A and B. Expression was detected by 
immunohistochemistry. There was no expression in the fibroblasts (Figure 3 .19C) as 
(A) 
5.9 kb band 
(C) 
5.581 kb 
4.373 kb 
2.720 kb 
2.180 kb 
1.444 kb 
• 
(B) 
6.957 kb 
3.574 kb 
2.720 kb 
1.444 kb 
BamHI 
• 
= 
• 
Notll XhoI 
BamHI/ SacII 
• 
• 
NotI 
Figure 3.17 Restriction enzyme digests on the colonies 
• 
• 
6. 557 kb 
4.373 kb 
3.09 kb band 
2.8 kb band 
• 5.9 kb band 
Restriction enzyme analyses performed on five SM22a / Cx43 / pBs 
KSII- colonies (designated 11 , 19, 21 , 46 and 57) are shown (A), (B) and 
(C). In (A), BamHI gave a linear band around 5.9 kb for all clones. The 
BamHI I Sac II restriction (B) produced three bands, two of which 
corresponded with the predicted band sizes of 3.09 kb and 2.81 kb, with the 
third band representing uncut plasmid. The Natl I Xhol restriction produced 
two bands as expected around 2.7 kb and 2.9 kb (seen as a doublet), whilst 
Natl gave a linear band around the predicted band size of 5.9 kb (C). 
....... 
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6.957 kb • 5.581 kb • 
4.373 kb • 
3.574 kb • 
• Fragment 
2.720 kb • 
2.180kb • 
1.444 kb • 
Figure 3.18 Restriction enzyme digests using Kpnl and Pvul. 
The Kpnl restriction gave the predicted fragment size of 5 .9 kb 
whilst the Pvul restriction produced bands which corresponded with 
the predicted band sizes of 1.045 kb and 4.855 kb. Kpnl I Pvul 
effectively excised the SM22a / Cx43 / poly A signal fragment 
producing fragments which corresponded with the predicted band 
sizes of 1.045 kb, 1.657 kb and 2.999 kb (the desired fragment; 
approximate estimation), with the 0.199 kb not able to be visualized 
on the gel. 
Figure 3.19 Graph of the single transfections of the smooth muscle cells. 
Results from single transfections of the smooth muscle cells using the SM22a / 
Cx43 I pBs KSII- construct are shown (A) and (B). (B) is an enlarged version of (A). 
Single transfections of the fibroblasts are shown in (C). The pEGFP-NI (CMV-EGFP) 
plasmid was used as the control. Expression of the SM22a I Cx43 I pBs KSII- construct 
was detected by immunohistochemistry using commercial antibodies. The number of 
labelled cells counted was expressed as a percentage of the total cell count for each 
slide (n = 4 with 2 duplicates per experiment). Each point represents the mean and 
standard error of the mean. 
* Indicates significantly different from control 
~
 
0 =
 
r,J
. 
.
.
.
.
.
 
~
 
=
 
~
 
.
.
.
.
.
 
0 • 0 0 
SM
22
a/
C
x4
3/
 
pB
s 
K
SI
I-
C
M
V
-E
G
FP
 
N
oD
N
A
 
C
on
tr
ol
 
L
ab
el
le
d 
C
el
ls
 (%
 To
ta
l) 
0 N
 
U
l 
*
 0 • U
l 
0 
0 . ---
l 
U
l 
~
 
.
 0 0 
,,
.-
..
._
 
cc
 
"
-
"
'
 
.
.
.
 
(j
 
0 =
 
r,J
. 
.
.
.
.
.
 
~
 
=
 
~
 
.
.
.
.
.
 
>
 
,.
..
_
.,
, 
La
be
lle
d 
C
el
ls
 (%
 To
ta
l) ~ 
~
 
~
 
0 
~
 
N
 
~
 
~
 
U
l 
~
 
-
-
-
l 
~
 
~
 
0 
~
 
N
 
SM
22
a/
C
x4
3/
 
pB
s 
K
SI
I-
C
M
V
-E
G
FP
 
N
oD
N
A
 
C
on
tr
ol
 
*
 
(j
 
0 =
 
r:,
;. 
.
.
.
.
.
.
.
 
..
. =
 
r':
J 
.
.
.
.
.
.
.
 
SM
22
a/
C
x4
3/
 
pB
s 
K
SI
I-
C
M
V
-E
G
FP
 
N
o 
D
N
A
 C
on
tr
ol
 
L
ab
el
le
d 
C
el
ls
 (0
/o
 T
ot
al
) 
i,-
,-
Q 
i,-
,-
N
 
~
 
~
 
~
 
~
 
~
 
~
 
~
 
Q 
~
 
~
 
.
.
.
.
.
_
.
.
.
, 
78 
expected. There was a low level of expression in the aortic smooth muscle cells (0.20 + 
0.11 %; n = 4) which, when compared to the control plasmid (CMV-EGFP; Clontech), 
was significant (P < 0.05) but at a much lower level. 
3.7.3 Preparation and electroporation of the SM22a I Cx43 fragment into ES cells 
The eluted SM22a I Cx43 I poly A fragment was checked for sample purity and 
correct band size (Figure 3.20A) before co-electroporation into BALB/c ES cells. 
Residual DNA was PCR screened using the SM22exlf and Cx43R2 (amplified a 
fragment of about 1.2 kb), SM22ex 1 f and pBi5F ( as expected, no band was amplified) 
and SM22ex 1 f and pBi5R primers ( amplified a fragment of about 2 kb) (Figure 3 .20B; 
see Table 2.2). These PCRs confirmed the integrity and orientation of the fragment. 
3. 7 .4 Identification of positive clones 
Antibiotic resistant colonies were screened by PCR using the SM22ex 1 f and 
CnxR2 or Cnx43R (amplified bands of about 1.2 kb and 1.3 kb respectively) and CnxF 
and pBi5R primers ( amplified a fragment of about 1.5 kb) (Table 2.2). Only one clone 
( designated A2) was strongly PCR positive to both sets of primers. Another clone 
( designated C4) was strongly PCR positive for the CnxF / pBi5R primers but not for the 
SM22exlf / CnxR2 primers (Figure 3.21). The new primers synthesized to maximize 
the sensitivity of the PCR for the SM22a promoter (mSM22exlf, mSM22exlfb and 
mCnx43R) did not improve the PCR results already obtained. Thus, two clones 
(designated A2 and C4) were microinjected into the BALB/c murine blastocysts. 
3.7.5 PCR screening of the progeny 
Tail DNA from the white progeny of the mating of the chimaeras (from the A2 
and C4 clones) to their BALBI c counterparts were PCR screened using the mSM22ex 1 f 
and mCx43R ( expected band size of 1.3 kb) and the CnxF and pBi5R primers ( expected 
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Figure 3.20 The SM22a I Cx43 I poly A signal construct 
• 
• 
~1.9 kb band 
~ 1.3 kb band 
The isolated and gel purified Pvul I Kpnl I SM22a I Cx43 
fragment prior to electroporation into murine embryonic stem cells (A). 
In (B), the residual DNA was PCR screened with the SM22exlf and 
pBi5F primers(no band expected) followed by the SM22exlf and 
pBi5R primers (a band of 1.9 kb was expected) and the SM22exlf and 
CnxR2 primers ( expected a band about 1.3 kb). The plasmid (positive 
control) was Clone #57. 
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Figure 3.21 PCR testing of the clones 
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Antibiotic resistant colonies were screened by PCR using a 
variety of primer combinations. In this figure, the SM22ex 1 f and 
mCnx43R ( expected 1.3 kb band; A) and Cx43F and pBi5R ( expected 
0.9 kb band; B) primers were used. 
The positive control was Clone #57 and the negative control mouse 
genomic DNA. The A2 and C4 clones are marked. 
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band size of 1.5 kb). For the "C4" tail DNA samples, the mSM22exlf and mCx43R 
PCR did not amplify any product from the DNA samples, but the CnxF and pBi5R PCR 
did amplify a fragment which approximated the predicted band size of 1.5 kb (Figure 
3 .22). All "A2" tail DNA samples were PCR negative. As these results were 
unexpected, further PCR testing was undertaken using the mSM22ex 1 f and H OTT7 
primers followed by the mSM22exlf and pBi5R primers (expected band size of 2 kb). 
Both PCRs failed to amplify any fragments from the clones; only the positive control 
(Clone #57) produced a band of the correct size. Repetition of these PCRs using 
increased primer concentrations produced the same negative results, as did PCR 
analyses of a new batch of tail DNA samples using the mSM22exlf and mCnx43R, and 
CnxF and pBi5R primers. 
To test whether the SM22a promoter was present but truncated in the mice, 
PCRs using three new forward primers in the SM22a promoter region (mSM22F2, 
mSM22F6 and mSM22F7) were undertaken with the reverse primer mCx435'R. 
Preliminary testing on Clone #57 produced the appropriately sized bands: mSM22F2 
and mCx435'R primers (a band of about 0.633 kb was amplified), mSM22F6 and 
mCx435'R primers (a band of about 0.374 kb was amplified), and mSM22F7 and 
mCx435'R primers (a band of about 0.273 kb was amplified) (Table 2.2; Figure 3.23). 
Subsequent PCR testing of these primers on mouse DNA revealed that the majority of 
the restricted SM22a promoter was indeed absent (Figure 3.24). According to the PCR 
results using the mSM22F6 and mSM22F7 forward primers with a reverse primer, it 
was concluded that perhaps only 100 bp of the promoter was present in the construct. 
However, as no primers were synthesized between these two primers, the exact length of 
the truncated promoter is not known. 
Subsequently, the single transgenic-promoter transgenic mice were interbred to 
increase the gene dose rate (and hence Cx43 gene expression) and produce double 
transgenic mice. 
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Figure 3.22 PCR screening of the first batch of "C4" tail DNAs 
The tail DNAs were PCR screened with the mSM22exlf and 
mCnx43R primers (A) and the CnxF and pBi5R primers (B). The 
predicted band size for the mSM22exlf and mCnx43R PCR was 1.334 
kb. The CnxF and pBi5R PCR (B) amplified a fragment which 
approximated the predicted band size of 1.469 kb in Lanes 3, 4, 5 ,7 
and 11. The positive control was Clone #57 and the negative control 
was genomic DNA. 
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Figure 3.23 Diagnostic PCR testing using the new primers 
PCR screening of Clone #57 with the new primers mSM22F2, 
mSM22F6, mSM22F7 and the reverse mCx435'R primer. In (A), 
Clone #57 was screened with the mSM22F2 and mCx435'R (expected 
band size of 0.633 kb), mSM22F6 and mCx435'R (0.374 kb), and 
SM22F7 and mCx435'R (0.273 kb) primers. The mSM22F7 and 
pBi5R PCR ( expected band size of 1.598 kb) is shown in (B), with 10-
fold serial dilutions of Clone #57. The respective water controls are in 
Lanes 4, 6 and 8. The correct band size (predicted 1.598 kb) was 
amplified. 
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Figure 3.24 Final PCR screening of selected positive tail DNAs 
0.633 kb band 
1.5 kb band 
The tail DNAs were screened with the mSM22F2 and 
mCx435'R primers (A), and with the mSM22F7 and pBi5R priiners 
(B). The Clone #57 positive control had a band that approximated the 
predicted band size of 0.633 kb. The water and genomic DNA lanes 
were negative ( as expected). In (B), five tail DNAs were PCR 
positive with a band corresponding with the predicted band size of 
1.598 kb; thus showing that only a truncated SM22a promoter was 
present in the SM22a / Cx43 / poly A signal construct in the genome 
of these transgenic mice. 
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3.8 Generation of a Second SM22a I Cx43 Transgenic Mouse 
A new enzyme combination (Pvul I Pvull) was chosen to excise the SM22a I 
Cx43 I poly A signal from SM22a / Cx43 / pBs KSII-. By using Pvul with Pvull this 
time instead of Kpnl, 218 bases were added to the 5' end of the construct to prevent 
truncation of the promoter from recurring. After running a small restriction digest to 
check the efficiency of the Pvul and Pvull enzymes, a large restriction digest was set up 
to excise the SM22a / Cx43 / poly A signal from 30 µg of SM22a / Cx43 / pBs KSII-. 
The fragment was isolated, purified and subsequently co-electroporated into prepared 
BALB/c embryonic stem cells with pMCl Neo as previously described. After selection, 
resistant (surviving) colonies were analyzed by PCR screening. One antibiotic resistant 
colony (designated B7) was identified by PCR using the mSM22exlf and mCx435'R, 
and mSM22F7 and pBi5R primers, and subsequently microinjected into the C57BL/6 
blastocysts. Resulting chimaera were mated with BALB/c mice, and the progeny 
analyzed by PCR which identified the presence of the entire SM22a / Cx43 construct. 
A double transgenic mouse line was then established. 
3. 9 Discussion 
The SM22a promoter and Cx43 gene fragment were successfully amplified from 
a mouse genomic library and cloned into pBs KSII-. The sequencing data revealed that 
Pfu DNA polymerase had made three base errors in the reading of the SM22a promoter 
DNA and no errors in the reading of the Cx43 cDNA. Pfu DNA polymerase exhibits 
the lowest error rate of any of the commercial DNA polymerases (Life Science 
Catalogue, 2000) ( eg. Taq DNA polymerase) and thus, would be used again in a similar 
context. Both SM22a / pBs KSII- and Cx43 / pBs KSII- were then ready to be used in 
the generation of the SM22a I Cx43 I pBs KSII- construct. 
The SM22a / Cx43 / pBs KSII- construct was successfully cloned from the 
SM22a I pBs KSII- (Clone #137) and Cx43 / pBi5 (Clone C20) plasmids. Testing of 
the construct in vitro in murine aortic smooth muscle cells showed low levels of Cx43 
expression, which were similar to background levels. It was concluded that, for the 
SM22a I Cx43 I pBs KSII- construct, virtually no expression was evident in vitro. 
81 
There are a variety of methods for introducing DNA into mammalian cells -
transfection is reputably the most convenient and reproducible method. Preliminary 
experiments using electroporation to transform the fibroblasts showed that transfection 
would be the best method for the current study (data not shown). Transfection is, 
however, associated with a high DNA mutation frequency of approximately 1 % per 
gene; supercoiled and relaxed DNA are mutated at equal frequencies, whilst linearized 
DNA leads to a greatly elevated frequency of deletions (Miller et al. 1984). This may, 
in part, explain the low expression rates recorded in the current study. 
DNA transfection may be mediated by calcium phosphate, DEAE dextran, 
electroporation and cationic phospholipids (Kaufman, 1997) - the method of choice 
being determined by the one most suited to a particular cell type. Lipofectamine Plus 
Reagent, a cationic lipid reagent with improved transfection efficiency for many 
adherent cells and with a broader cell type range than the widely used Lipofectamine 
Reagent (Clontech, 2000), was the transfection reagent of choice for the present study. 
This reagent was recommended for the murine fibroblasts (Clontech, 1997), although no 
published data existed for the murine smooth muscle cells. In contrast, in rat smooth 
muscle cells, Lipofectamine Reagent was recommended (Clontech, 1997, 2000). 
Although the control experiments in this study showed that for the cultured aortic 
smooth muscle cells the Lipofectamine Plus Reagent was the best transfection reagent, it 
may be that the ideal transfection reagent for the combination of these cells and 
constructs is not as yet established. 
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Another factor to be considered is the differentiation state of the smooth muscle 
cells. As these cells are known to readily de-differentiate in vitro (Moessler et al. 1996), 
procedural modifications were made to confirm the status of the cells in the current 
study and to promote differentiation by using insulin for example ( data not shown). 
However, the expression levels for the construct did not improve. In contrast, the 
CMV-EGFP transfection rates remained relatively constant and at an acceptably high 
level throughout the experiments. Although it is difficult to determine the 
differentiation state of the smooth muscle cells, further consideration of this factor 
would be important in future studies. 
The observed low expression levels of the construct are in contrast with the good 
transfection rates obtained with the CMV-EGFP plasmid. It is now recognized that 
various promoters are capable of producing different expression levels of genes 
(Gerolami et al. 2000). For example, the CMV promoter can produce high expression 
levels of many genes in a wide variety of cells after transfection (Almouzni and Wolfe, 
1993), but the same situation does not exist for the tissue specific SM22a promoter. 
The expression levels obtained using the modified SM22a / Cx43 / pBs KSII-
construct are clearly much lower than those for other constructs already published ( c.f. 
Kemp et al. 1995; Solway et al. 1995; Li et al. 1996; Moessler et al. 1996). However, 
direct comparisons cannot be made for several reasons: firstly, the current study used 
primary cultures of murine aortic smooth muscle cells and murine embryonic fibroblasts 
in which to test the restricted SM22a promoter (the first such study to do so). Published 
data concerning the culture and transfection of these cells in vitro is lacking. At present 
there is no recommended transfection reagent for murine aortic smooth muscle cells. 
However, in the current study, CMV-EGFP was shown to express equally well in both 
the smooth muscle cells and the fibroblasts . Secondly, all studies so far have used 
different plasmids, which affect transf ection efficiency and thus gene expression. 
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Linearization of the plasmid, for example, increases the efficiency of integration 
(Buttner et al. 1981; Potter et al. 1984 ). Also, different transfection reagents were used 
on different cell types. The efficacy, sensitivity and toxicity of a transfection reagent are 
known to depend on a variety of parameters, some of which have already been 
discussed. These include, for example, growth rates of cells (Pickering et al. 1996), cell 
type (smooth muscle cell versus endothelial cell, for example) and cell species (rat 
versus human, for example), absence of serum (Escriou et al. 1998), and DNA purity 
(Clontech, 2000)- which was the same for the constructs in the current study. 
The majority of transfection studies thus far have been performed on animal cells 
but unfortunately, and not surprisingly, not all cell types have been studied. To date, 
there is a paucity of published data examining the efficient transfection of primary 
murine smooth muscle cells. The success and effectiveness of the new liposomal and 
non-liposomal transfection reagents remains to be elucidated. Recently, Hamm et al. 
(2002) demonstrated the effectiveness of the Nucleofectortrade mark technology 
developed by amaxa biosystems, in the transfection of various primary human cells and 
stem cells, including human coronary smooth muscle cells. Clearly, more work needs to 
be undertaken to ascertain the optimal culture conditions and transfection efficiencies of 
murine embryonic fibroblasts and aortic smooth muscle cells in vitro. 
Although the SM22a / Cx43 / pBs KSII- construct was shown to be virtually 
non-functional in vitro, it was still possible that the SM22a / Cx43 / pBs KSII- construct 
would be viable in vivo. Therefore, the linear DNA constructs (Pvul I Kpnl I SM22a I 
Cx43 and Pvul I PvuIT I SM22a I Cx43) were electroporated into the BALB/c 
embryonic stem cells (where they would recombine with the genome) with a circular 
selection plasmid (pMCl Neo). Most of the markers confer resistance to the antibiotic 
neomycin (Gassler et al. 1986; Robertson et al. 1986). 
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DNA introduced into embryonic stem (ES) cells can either randomly integrate, 
where the entire construct enters the genome stably but non-specifically, or can be 
subject to homologous (specific) recombination (Roth and Wilson, 1985; Roth et al. 
1985). Generally, DNA has a two to three-fold higher propensity for random integration 
(Roth and Wilson, 1985). The ES cell route to transgenesis provides the opportunity to 
screen for the desired genetic alteration/s before the reintroduction of the ES cells into 
the mouse (Gossler et al. 1986). In the current study, PCR screening of the clones 
showed that only two colonies were positive for the Pvul I Kpnl I SM22a I Cx43 
construct (first transformation) and one for the Pvul I PvuII I SM22a I Cx43 construct 
(second transformation). From previous experience in this laboratory, more positive 
colonies had been anticipated (Matthaei pers com). The reasons for this observation are 
unknown but it may be due to problems with the construct itself, the ES cells, or a 
combination of both factors. 
Two methods currently exist for the production of ES cell chimaeras: 
microinjection and aggregation/ co-culture of which, the former is reputedly the more 
successful (Gossler et al. 1986). In aggregation, the zona pellucida (outer layer) is 
removed from morulae-stage embryos, and the morulae allowed to aggregate ( co-
culture) on a lawn of targeted ES cells. After co-culture, the embryos with the ES cells 
attached develop into blastocysts before implantation into pseudo-pregnant females 
(Wood et al. 1993a). A comparison of both aggregation and blastocyst injection 
methods by Wood et al. (1993b ), however, showed that there was no significant 
difference in the number of germ-line chimaeras produced by either method. 
Consequently, in the current study, the two colonies from the first attempt, and the 
colony from the second attempt, were microinjected into recipient blastocysts. 
As most ES cell lines have an XY karyotype, the sex ratio among the chimaeras 
is biased towards male mice (Robertson et al. 1986). Male ES cell lines have the 
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advantage that the resulting germ-line chimaeras are normally male and so, can father a 
large number of offspring in a short period of time. In the current study, each male 
chimaera with a coat colour of any variation of black and white was mated to two 
female BALB/c mice, and each female chimaera was mated to one male BALB/c 
mouse. Germ-line transmission has been achieved using male chimaeras with much less 
than 10% coat colour change (Matthaei pers com). PCR analysis using DNA isolated 
from the tails of three week old mice was used in the current study and if time had 
permitted, Southerns would also have been done, as they have been suggested to be a 
better approach (Hogan et al. 1994). 
PCR analyses of the tail DNAs from the first microinjection, revealed the 
presence of a truncated form (103 to 204 bp only) of the original restricted SM22a 
promoter. The exact length of the truncated promoter was not known as no further 
primers were synthesized. The stage at which the 5'-end of the restricted SM22a 
promoter was lost is open to speculation. Since the promoter was intact in Clone #57, it 
is possible that it occurred during electroporation of the construct into the ES cells or, 
that not all of the promoter was integrated into the genome. Electroporation is known to 
cause mutations in the DNA. The PCR analyses performed on the A2 clone showed that 
the entire construct was present, whilst the colony designated C4 was only weakly PCR 
positive to the SM22a forward and Cx43 reverse primers, compared with the strong 
band obtained by PCR using the Cx43 forward and pBi5 reverse primers. The A2 clone 
was equally PCR positive for both sets of primers. Consequently, it is possible that the 
C4 clone had a truncated-promoter, as the positive PCR result was not entirely 
convincing. This is supported by the observation that when the C4 clone was 
incorporated into the germ-line, the resulting progeny contained a truncated-promoter. 
Although chimaeric mice from microinj ection of the A2 clone were produced, 
none were germ-line. This may be because the A2 colony was a combination of 
transgenic and non-transgenic ES cells, with only the non-transgenic cells being 
incorporated into the germ-line. In addition, the A2 ES cells were co-transfected with 
the pMCl Neo transiently and the selective pressure could not be maintained. 
In contrast, the colony designated B7 from the second microinjection attempt 
produced chimaeric pups. Their progeny were identified by PCR screening as 
possessing the entire DNA construct. Interbreeding of the single transgenic offspring 
from both the truncated-SM22a I Cx43 and full-SM22a / Cx43 transgenic mouse lines 
produced double transgenic mice. 
In conclusion, the SM22a / Cx43 / poly A fragment was successfully cloned. 
Although in vitro testing of the construct in smooth muscle cells was inconclusive, it 
was subsequently used to generate two transgenic mouse lines: one with a truncated 
SM22a promoter in the germ-line and one with the full construct in the germ-line. 
Interbreeding of each mouse produced double transgenic offspring. Two transgenic 
mice lines had been successfully generated. 
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Chapter 4 - Analysis of the SM22a I Cx43 Mouse 
4.1 Introduction 
Genetically modified mice are increasingly being used to extend the study of the 
activity of a particular molecule or gene in vivo, following cellular studies that were 
initiated in vitro. In vivo studies are particularly relevant for the investigation of 
vascular function and associated disease states (Christ et al. 1996). A distinct advantage 
of a transgenic mouse that survives to and throughout adulthood, is that the potential 
effect of the removal or modification of a single gene or molecule on mouse physiology 
and behaviour can be examined using a wide variety of experimental procedures. 
Various experimental paradigms can, and have been, examined using transgenic and 
knockout mice. 
The phenotypes of transgenic mice can be studied at many levels from behaviour 
to physiology to cell biology and biochemistry. In this Chapter, studies were undertaken 
on mice transformed either with a truncated-promoter SM22a / Cx43 mouse (single and 
double transgenic) or a full-promoter SM22a / Cx43 mouse (single transgenic) to 
investigate their phenotypes. The expression level of Cx43 in the vasculature, 
specifically in the aorta and tail artery, was determined using Western blots. The effect 
of overexpressing Cx43 in the vasculature on blood pressure was also examined. 
4.2 Results 
4.2.1 General observations 
PCR analyses of tail DNA using the mSM22exlfb / mSM22F7 and mCx435'R 
primers, and CnxF and pBi5R primers (Table 2.2) identified positive and control mice 
from the respective litters (single transgenic truncated-promoter, double transgenic 
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truncated-promoter, single transgenic full-promoter and double transgenic full-
promoter). For all groups, there were no obvious phenotypic abnormalities at birth and 
all were viable, surviving into adulthood. Neo-natal and post-natal deaths were rare. 
Either a two- or three-way analysis of variance (ANOVA), or a one-way 
ANOV A followed by individual pairwise t tests with Bonferroni correction for multiple 
group comparisons, was performed on the data. 
4.2.2 Litter sizes and pup gender 
The litter sizes and pup genders were recorded for each group (Table 4.1 ). 
Interestingly, the full-promoter mice, both single and double transgenic, had slightly 
smaller litter sizes than did the single and double transgenic truncated-promoter mice 
(P > 0.05). All groups had an approximately equal number of male and female pups. 
Single Double Single Full- Double Full-Truncated- Truncated- Promoter Promoter Promoter Promoter 
5.77 ± 0.47 6.36 ± 0.47 4.69 ± 0.66 4.50 ± 0.53 
Litter Size 
n = 31 n = 14 n = 16 n = 14 
2.91 ± 0.54 c3' 3 .46 ± 0.45 c3' 2.23 ± 0.33 c3' 1.86 ± 0.59 c3' 
c3' 1¥ 
3.02 ± 0.39 ¥ 3.00 ± 0.38 ¥ 2.67 ± 0.29 ¥ 2.29 ± 0.47 ¥ 
Table 4.1 Litter sizes and numbers of each sex per group 
(n = number of litters) 
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4.2.3 Body weights 
A two-way analysis of variance with gender and treatment as explanatory 
variables was used to examine body mass variation at the end of experiments. Males 
were significantly heavier (26.35 ± 0.36 g) than females (21.60 ± 0.35 g) (F [I ,33] = 121.2, 
P < 0.0001). Transgenic mice were lighter than their non-transgenic litter mates (F[s,33] 
= 12.6, P < 0.0001), and there was an interaction between transgenic and gender as well 
(F[5,331 = 4.07, P = 0.0055) as the difference between male and female weight varied 
with various transgenic treatments (Figure 4.1 ). For example, mean weights of males 
and females of the double truncated-promoter mice were within 1 gram, but all other 
treatments had at least 2 to 3 grams difference between mean weights of males and 
females. Comparing only the transgenic groups, the single truncated-promoter mice 
were heavier (25.0 ± 0.48 g) than both the single full-promoter (22.4 ± 0.58 g) and 
double truncated-promoter (21.2 ± 0.52 g) mice, although most of the latter change 
resulted from much smaller male mice. 
4.2.4 Organ weights 
At the end of the experiments, all mice were weighed and their hearts, lungs, left 
and right kidneys, livers, spleens, stomach, intestines were removed and the wet weights 
recorded, to see if there was any difference between the transgenic mice groups and the 
control mice. As it is known from murine cardiovascular studies that in transgenic and 
gene targeted mouse lines, the heart and body weights may either increase or decrease 
(Milano et al. 1994; Hein et al. 1995; Doevendans et al. 1998), changes in other organs 
would not be unexpected. Wet weights of the various organs are shown in Table 4.2 as 
absolute weights and relative to body weight. 
The single transgenic truncated-promoter male mice had larger hearts, kidneys 
and livers, but smaller spleens and lungs than the controls. Conversely, the transgenic 
females had smaller hearts and kidneys, but larger livers, spleens and lungs than 
Figure 4.1 Body weight measurements. 
The body weight measurements (g) for each mouse group are shown. Each 
point represents the mean and standard error of the mean. 
* Indicates significantly different from control 
KEY: 
Single Trunc Male/Female= Single transgenic truncated-promoter male/ female mice 
Double Trunc Male/Female= Double transgenic truncated-promoter male/ female 
rmce. 
Single Full Male/Female = Single transgenic full-promoter male/ female mice. 
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Table 4.2 Absolute and relative weights of selected organs 
The absolute and relative weights of the hearts, left and right kidneys, livers, spleens and lungs from the control mice, the single and 
double transgenic truncated-promoter mice, and the single transgenic full-promoter mice are shown. All values represent the mean and 
standard error of the mean. Significant values are indicated (* P < 0.05). 
TISSUE 
GROUP 
Heart Left Kidney Right Kidney 
absolute relative absolute relative absolute relative 
Control male 0.15 ± 0.04g 5.52 ± 1.22 0.26 ± 0.0lg 9.77 ± 0.31 0.28 ± 0.03g 10.24 ± 0.82 
(n = 16) 
Control female 0.12 ± 0.03g 5.74 ± 1.30 0.15 ± 0.04g 6.94 ± 1.52 0.15 ± 0.04g 7.02 ± 1.86 
(n = 11) 
Single 0.15 ± 0.02g 5.61 ± 1.52 0.27 ± 0.02g 10.07 ± 0.70 0.30 ± 0.0lg 11.06 ± 0.60 
TruncProm 
male (n = 11) 
Single 0.10 ± 0.02g 5.03 ± 0.57 0.12 ± 0.03g 5.41 ± 0.61 0.17 ± 0.03g 6.87 ± 0.71 
TruncProm 
female (n = 11) 
Double 0.15 ± 0.03g *6.17 ± 1.09 0.21 ± 0.02g 8.45 ± 0.42 0.24 ± 0.02g 9.70 ± 0.39 
TruncProm 
male (n = 5) 
Double 0.095 ± 0.003g *4.64 ± 0.16 0.11 ± 0.0lg 5.39 ± 0.40 0.13 ± 0.02g 6.27 ± 0.70 
TruncProm 
female (n = 3) 
Single 0.12 ± 0.003g *4.89 ± 0.16 0.26 ± 0.0lg 10.30 ± 0.45 0.25± 0.0lg 10.02 ± 0.47 
FullProm 
Male (n = 5) 
Single 0.10 ± 0.006g 5.08 ± 0.18g 0.11 ± 0.003g 5.45 ± 0.28 0.12 ± 0.007g 5.94± 0.28 
FullProm 
Female (n = 4) 
KEY: 
trunc/fullprom = truncated-or full-promoter ; * P < 0.05; n = number of individual 1nice. 
TISSUE 
GROUP 
Liver Spleen Lung 
absolute relative absolute relative absolute relative 
Control male 1.48 ± 0.08g 55.41 ± 2.21 0.10 ± 0.0lg 3.55 ± 0.15 0.22 ± 0.03g 8.16 ± 0.89 
(n = 16) 
Control female 1.05 ± 0.05g 50.24 ± 0.93 0.09 ± 0.002g 4.58 ± 0.07 0.21 ± 0.03g 9.98 ± 1.12 
(n = 11) 
Single 1.49 ± 0.02g 59.32 ± 1.81 0.10 ± 0.002g 3.51 ± 0.10 0.22 ± 0.0lg 9.02 ± 1.06 
TruncProm 
male (n = 11) 
Single 1.03 ± 0.05g 52.60 ± 0.98 0.09 ± 0.0lg 4.84 ± 0.11 0.21 ± 0.02g 9.99±1.16 
TruncProm 
female (n = 11) 
Double 1.54 ± 0.06g *63.59± 0.99 0.08 ± 0.0lg 3.38 ± 0.09 0.22 ± 0.03g 9.06 ± 1.03 
TruncProm 
male (n = 5) 
Double 1.09 ± 0.03g 53.90 ± 1.80 0.09 ± 0.002g 4.58 ± 0.07 0.21 ± 0.03g 9.98 ± 1.12 
TruncProm 
female (n = 3) 
Single 1.48 ± 0.03g 58.75 ± 0.67 0.09 ± 0.0lg 3.70 ± 0.37 0.25 ± 0.03g 10.01 ± 1.15 
FullProm 
Male (n = 5) 
Single 1.01 ± 0.06g 51.20 ± 1.91 0.08 ± 0.003g 4 .24 ± 0.15 0.20 ± 0.003g 10.36 ± 0.25 
FullProm 
Female (n = 4) 
KEY: 
trunc/fullprom = truncated-or full- promoter; * P < 0.05; n = number of individual mice. 
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controls. The double truncated-promoter mice had smaller hearts (females only), 
kidneys and spleens and larger livers than did the controls. The relative lung weights for 
the control and transgenic mice were almost identical. In the single transgenic full-
promoter males, all relative organ weights ( except the heart) were increased over 
control, whilst in the females, only the liver and lung weights were increased over 
control. 
Although variation in the carcase weights for each group were observed for the 
two sexes, the differences were not significant at the 5% level. In general, the female 
carcase weights for all groups were less than the male carcase weights. In the transgenic 
double truncated-promoter mice, for example, the female relative carcase weight was 
648.7 ± 3.85 g compared to the males' 653.8 ± 4.80 g, whilst in the control single full-
promoter mice, the female relative carcase weight was 645 ± 2.44 g and the male 
relative carcase weight 654.5 ± 4.16 g. 
4.2.5 Blood pressure measurements 
Data from the blood pressure measurements ( as systolic blood pressures) are 
presented in Figures 4.2 and 4.3. The mice in Figure 4.2 (single transgenic truncated-
promoter) were not acclimatized to the equipment prior to the start of the blood pressure 
recordings, as were the other groups (Figure 4.3). A three-way analysis of variance 
using the extent of acclimatization to the cuff, transgenic and gender as the major 
explanatory variable, indicated that none of these variables had a significant effect on 
blood pressure directly. However, two interactions were significant. The interaction 
between acclimatization and gender showed that acclimatization affected male mice 
more than female mice (F [I ,S&] = 11.44, P < 0.002) as mean male blood pressure 
decreased from 111 ± 2.7 mm Hg to 99 ± 2.4 mm Hg with acclimatization. In contrast, 
female blood pressure actually increased from 101 ± 2.8 mm Hg to 109 ± 2.4 mm Hg 
with acclimatisation. There was also a weak interaction between the acclimatization 
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Figure 4.3 Blood pressure measurements. 
The blood pressure measurements (mmHg) for each mouse group are shown. 
Each point represents the mean and standard error of the mean. 
* Indicates significantly different from control 
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and whether mice were transgenic or not (F[l ,58] = 4.55, P = 0.038). Non-acclimatized 
transgenic mice had the highest blood pressure measurements (111 ± 3.4 mm Hg), while 
control (106 ± 2.6 mmHg) and transgenic acclimatized (102 ± 2.8 mmHg) and control 
non-acclimatized (101.6 ± 3.2 mmHg) mice all had lower blood pressure measurements. 
The variability in the individual blood pressure recordings necessitated several 
readings on each animal. Examples of the variability are given in Table 4.3, using a 
selection of individuals from all groups sampled in the current study. There was no 
correlation between blood pressure and body weight for any group. 
The body weights of randomly selected individuals from the single and double 
transgenic truncated-promoter mice, and single transgenic full-promoter mice were 
recorded at defined time periods to assess the level of stress and adaptive response to the 
recording procedure, and hence influence on the blood pressure measurements. Body 
weight in animals is known to decrease as a stress response (Ettinger, 1989). Body 
weights were recorded six days prior to the handling / acclimatization period, on the first 
three days of the recordings and then every second day for six measurements, and on the 
day of euthanasia ( one week after cessation of the blood pressure recordings). 
Between the first and second body weight measurements ( at the start of the 
handling/ acclimatization period and the blood pressure measurements respectively), 
both the control and transgenic mice had a slight decrease in body weight (average 0.2 ± 
0.0lg; n = 25). 
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Mouse ID Initial 2
na 3ra 4th 5th 6th 7th 
reading reading reading reading reading reading reading 
Single 
1 transgenic 115.0 88.0 93.0 80.0 110.0 94.0 Not 
truncpromoter* recorded 
male 
Single 
2 transgenic 153.0 95.0 105.0 113.0 89.0 87.0 Not 
truncpromoter* recorded 
female 
Double 
3 transgenic 76.3 123.3 104.8 106.8 108.3 98 111.8 
truncpromoter* 
male 
Double 
4 transgenic 104.5 95.0 113.3 101.8 103.8 106.5 113.8 
truncpromoter* 
female 
Single 
5 transgenic 79.3 129.75 113.75 80.0 113.0 153.3 46.0 full promoter* 
male 
Single 
6 transgenic 77.25 93.0 91.75 121.5 104.5 90.25 121.50 fullpromoter* 
female 
7 
Control 
contro lfemale 105.0 123.5 107.5 114.0 101.0 106.5 113.8 
8 Control contro lmale 126.25 117.25 109.75 82.75 103.0 108.5 140.5 
Table 4.3 Individual Blood Pressure Measurements in mmHg 
*trunc/fullpromoter = truncated- or full-promoter mouse 
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The mice not handled nor acclimatized ( control), did not lose any weight during 
this period. After the first blood pressure measurement, most mice lost an average of 
0.8 ± 0.05 g which equated to 3-4% of their total body weight. This was not fluid loss 
as the weight had not been regained by the following day. By the third to fifth blood 
pressure reading all mice groups except the double transgenic truncated-promoter males 
and females were regaining their pre-experimental weight, indicating a reduction in the 
level of stress experienced by the mice. The double transgenic truncated-promoter 
males and females started regaining weight by the sixth blood pressure reading. 
Thereafter, all groups gained weight until euthanasia. All mice not handled gained 
weight during the experimental period. 
4.2.6 Determination of Cx43 expression 
The aortae and tail arteries of the transgenic mice ( single and double transgenic 
truncated-promoter and single transgenic full-promoter) were observed during the 
dissections, to be very fragile when compared to the control vessels. Although the 
dissections proceeded with great care, homogenisation of the tissues was considerably 
easier than for the control vessels. Whilst this may have artificially increased the 
protein values to some degree, the data (presented below) indicate that the magnitude of 
such an increase was negligible. A more extensive network of connective tissue 
consistently surrounded the tail arteries in the control mice. 
Western blots were used to investigate the protein level of Cx43 in the tail artery 
and aorta of both control and transgenic mice of either sex. Protein assays were 
conducted so that equal amounts of protein were loaded per lane, that is 1 mg for the 
aortae and 12 mg for the tail arteries. Results from the W estem blots for Groups 2 to 4 
(single transgenic truncated-promoter, double transgenic truncated-promoter, and single 
transgenic full-promoter mice) are shown in Figure 4.4A to D and presented in Tables 
4.4 and 4.5. Data from Group 1 (single transgenic truncated-promoter mice) were 
Figure 4.4 Western blot analyses of Cx43 in the aortae and tail arteries 
Representative portions of W estem blot gels from the aortae and tail arteries of 
the single and double transgenic truncated-promoter mice, and the single transgenic 
full-promoter mice. The blots were detected with the Cx43 antibody, followed by the ~-
actin antibody (as indicated). The actin antibody was supplied by Dr MF Crouch, 
Division of Neuroscience, John Curtin School of Medical Research, ANU. 
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analyzed separately due to different experimental conditions. The data presented are 
estimates of signal intensity (relative optical density x mm2), as determined using AIS 
(Analytical Imaging System) 
For Group 1 (single transgenic truncated-promoter mice) Tris-buffer was used to 
homogenize the aortae (individually processed) and the tail arteries ( combined into 
control and transgenic). There was no significant difference in the aortic Cx43 levels 
between the control (37.80 ± 16.71; n = 8) and transgenic (27.66 ± 10.27; n = 9; P > 
0.05) mice. Similar results were obtained for Cx43 levels in the tail arteries for the 
control (2.5 x 10-4 ± 5.0 x 10-5; n = 2) and transgenic (3.5 x 10-4 ± 5.0 x 10-5; n = 2; P > 
0.05) mice. In the latter, the n values refer to data from two groups of mice. There was 
no significant sex difference at the 5% level for the aortae. 
For the second group of single transgenic truncated-promoter mice, and also the 
double transgenic truncated-promoter and single transgenic full-promoter mice, all 
tissues were homogenized in sodium bicarbonate buffer and the aortae paired, whilst the 
tails were combined to give a minimum final concentration of 12 mg wet weight/ 10 µl 
Ix sample buffer. The Western blots were again analysed using AIS to determine the 
respective Cx43 and actin quantitative gel values. Significant values when compared to 
control are indicated. 
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Aorta Aorta Tail Artery Tail Artery 
TREATMENT 
Cx43 level Actin level Cx43 level Actin level 
56.56 ± 8.72 0.09 ± 0.02 0.25 ± 0.05 5.95 X 104 ± 8.5 X 10-5 
Control 
n=7 n=7 n=2 n=2 
Sgl Transgenic 63.38 ± 10.30 0.11 ± 0.04 0.38 ± 0.08 1.20 X 10-J ± 0.0002 
Trunc. Prom. n=5 n=5 n=2 n=2 
173.3 ± 16.97 0.13±0.03 0.38 ± 0.005 9. 80 x 10-4 ± 6. o x 10-5 Dbl 
n=4 Transgenic 
n=4 n=2 n=2 Trunc. Prom. P < 0.05 
135.0 ± 8.02 0.15 ± 0.02 0.44 4.98 X 10-4 Sgl Transgenic 
n=5 Full Promoter 
n=5 n=l n=l P < 0.05 
·Table 4.4 Combined Cx43 and actin quantitative gel values for the aortae and tail 
arteries. 
(n = number of samples analyzed; data presented are estimates of signal 
intensity (relative optical density x mm2)). 
Briefly, the aortic Cx43 protein values for the single transgenic truncated-
promoter mice were not significantly different from the control mice (P > 0.05) and 
similarly for the actin protein values. There was, however, a significant 3 fold 
difference in the quantity of Cx43 expressed in the double transgenic truncated-
promoter mice versus control (P < 0.05). The corresponding actin value was not 
significantly increased (P > 0.05). In the aortae of the single transgenic full-promoter 
mice, the Cx43 protein level increased by 2.4x over control values (P < 0.05). The 
slight increase in the transgenic mice actin levels was not significant (P > 0.05). The 
Cx43 protein levels in the single and double transgenic truncated-promoter tail arteries 
showed a trend towards an increase (P > 0.05), with a similar trend in the single 
transgenic full-promoter mice. 
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No definitive conclusions could be drawn from the tail artery data due to the 
small sample sizes. However, it would seem that the pattern was consistent with that 
observed with the aortae. 
There was a significant sex difference in Cx43 protein (P < 0.05) with males 
consistently having 20 - 30% more Cx43 in the aortae than their female counterparts. 
There was no corresponding increase in the actin values, as expected. Representative 
mice from the aortic control, double transgenic truncated-promoter and single transgenic 
full-promoter mice are shown in Table 4.5. In the tail arteries of the single transgenic 
truncated-promoter mice, there was a much smaller increase in the Cx43 protein values, 
3 % between males and females. 
TREATMENT Connexin value Actin value 
(aorta) 
Control 65 0.185 
(n = 4; o) 
Control 53 0.167 
(n = 4; Si?) 
Dble TruncProm 206 0.09 
(n = 1; o) 
Dble TruncProm 157 0.15 
(n = 2; Si?) 
Single FullProm 143 0.16 
(n = 2; o) 
Single FullProm 119 0.14 
(n = 2; Si?) 
Table 4.5 Representative semi-quantitative aortic Cx43 protein and actin data 
(TruncProm/Ful1Prom =Truncated-or Full-promoter) 
(n = number of samples analyzed; data presented are estimates of signal 
intensity (relative optical density x mm2) ). . 
4.2. 7 Immunohistochemistry 
Immunohistochemical staining indicated no qualitative change in Cx43 levels 
between the single transgenic truncated-promoter mice and controls in any tissues 
examined - the thoracic aorta, mesenteric artery, abdominal aorta, tail artery, ventricle 
and vena cava. No immunohistochemistry was undertaken on the double transgenic 
truncated-promoter and single transgenic full-promoter mice because of time 
constraints. 
4.3 Discussion 
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Interbreeding of the single transgenic offspring of both the truncated SM22a / 
Cx43 (truncated-promoter) and entire SM22a / Cx43 (full-promoter) transgenic mouse 
lines, produced double transgenic truncated-promoter and double transgenic full-
promoter mice. Phenotypic and molecular genetic analysis of transgenic mouse lines 
has revealed a high level of stability of the transgene integration sites in mice (Aigner et 
al. 1999) and so, upon the establishment of double transgenic lines, breeding programs 
can be continued to a large number of generations without the need for further stringent 
molecular genetic analyses. 
Interpretation of data obtained from transgenic mice should take into 
consideration that, in the case of microinjection of DNA into pronuclei (usually the male 
pronuclei) of mouse zygotes as established by Gordon et al. (1980), multiple copies of 
the transgene are usually integrated in large arrays (Palmiter and Brinster, 1986). 
However, transgene expression may not necessarily correlate with copy number 
(Fishman, 1998). The exceptions are the few transgenes which contain all of the 
elements necessary for position-independent expression, such as the locus control region 
(LCR) in human ~-globin genes (Grosveld et al. 1987; Ryan et al. 1989), the chicken 
lysosome locus (Bonifer et al. 1994, 1996) and ovine B-lactoglobulin locus (Whitelaw 
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et al. 1992). LCRs, however, have not been determined for most genes. A method of 
identifying sites permissive for transgene expression and their use for efficient 
introduction of single copy genes by homologous recombination has recently been 
described (Wallace et al. 2000). 
General physical observations revealed that the single transgenic full-promoter 
mice had significantly smaller litter sizes than either the single transgenic truncated-
promoter or double transgenic truncated-promoter mice. This may represent lowered 
fertility and/or fecundity rates in this group. The sex ratios were equal in each group, 
which is consistent with Mendelian ratios, and the neo-natal mortality rate was within 
normal population limits. 
Interestingly, all the transgenic mice were lighter (in bodyweight) than their non-
transgenic litter mates, with the double transgenic truncated-promoter males being the 
lightest. The difference between the male and the female bodyweights in the latter 
group was almost negligible compared to that recorded for the single truncated- and full-
promoter mice. Although the body weights were recorded at the same time each day, 
the influence of unknown recent feeding on the body weight needs to be considered. 
Individual weights obtained for the entire digestive tracts, however, indicated that this 
was not likely to be a problem (data not shown). The bodyweight differences may 
reflect the presence of the construct, including increased gene copy number, or may be 
the direct result of the transgene integration site (Milano et al. 1994; Hein et al. 1995; 
Doevendans et al. 1998). 
There were differences in the relative organ weights (heart and kidneys) for the 
single truncated-promoter mice. The relative lung weight for the control and transgenic 
mice was almost identical, whilst the transgenic male mice had larger livers than did the 
control mice. The reason for this is unknown. In the single transgenic full-promoter 
males, all relative organ weights were increased over control, whilst in the females, only 
the liver and lung were increased over control. This may simply be a sex-difference. 
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The value of using the relative weight of a particular tissue rather than absolute weight 
is evident, allowing more accurate interpretation of the data to be made. The variation 
in the organ weights, although not statistically significant, is most likely a strain 
difference and represents no pathological or physiological change. It is known from 
murine cardiovascular studies, for example, that in transgenic and gene targeted mouse 
lines, the heart weight and body weight may either increase or decrease (Milano et al. 
1994; Hein et al. 1995; Doevendans et al. 1998), and thus changes in other organs 
would not be unexpected. 
There are two methods of obtaining blood pressure measurements in the mouse: 
indirect (tail-cuff plethysmography) and direct (intra-arterial; telemetry). A close 
correlation between the two methods in conscious mice and rats exists, with systolic 
blood pressure as measured by the tail-cuff method, being only 1-9 mmHg higher than 
intra-aortic measurements (Pfeffer et al. 1971; Ikeda et al. 1991 ; Krege et al. 1995). 
Tail-cuff plethysmography allows accurate and reproducible measurements of systolic 
blood pressure to be obtained (Hoit, 2001 ), without the surgical invasiveness required 
for telemetry and the associated anaesthetic complications. Anaesthesia should be 
avoided where possible as its deleterious effects on blood pressure can last from 24 
hours to 4 days post-administration (Janssen et al. 1997). Direct intra-arterial 
assessment in unrestrained and unanaesthetized animals is, nevertheless, regarded as the 
most physiologically appropriate method of determining the blood pressure (Bunag, 
1983; Ferrari et al. 1986; Kurtz and St Lezin, 1992; Sponer et al. 1993; Mills et al. 
2000; Butz and Davisson, 2001; Schyvens et al. 2001). 
Although the blood pressure measurements were quite variable, they were still 
within the normal limits for mice. Individual tail-cuff measurements are always subject 
to variability due to animal movement (mice are very active animals compared to rats), 
stress and associated excessive vasoconstriction. Stress is a major factor in the 
variability of tail-cuff plethysmography measurements. The heart rate, for example, in 
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the unanaesthetized resting mouse, varies between 480 and 540 beats per minute (bpm) 
but during light exercise, the heart rate increases to 600-650 bpm in the BALB/c mouse 
and during stressful events such as hand restraint, to 750-800 bpm (Kramer et al. 1993). 
As the heart rate varies, concomitant changes occur in blood pressure. It had been 
hoped in the current study, albeit unsuccessfully, to reduce or even eliminate the 
variability by extending the number of blood pressure measurements to a total of 16 
over 4 weeks. Previous studies have used 60 to 100 tail-cuff measurements for each 
mouse (Krege et al. 1995), which is in direct contrast to those who claim a stable blood 
pressure measurement with four or five readings (Johns et al. 1996). Recently, Janssen 
and Smits (2002) concluded that the tail-cuff method is more practical when blood 
pressures between groups have to be compared over long periods. 
Although the majority of mice in the current study were handled for three to four 
days prior to acclimatization on the base-plate, there was still a stress response as 
determined by the 4% loss in body weight after the first recording. The initial blood 
pressure recordings were often higher than those subsequently obtained and there was 
also a noticeable post-recording change in temperament in the mice. They became 
unco-operative with increased vocalization, until they adjusted to the tail-cuff 
plethysmography equipment. According to the body weight measurements, this 
occurred after the third to fifth reading with attainment of the pre-recording weights 
occurring relatively slowly, indicating a slow adaptive response. 
The difference in the blood pressure measurements between the single transgenic 
truncated-promoter mice in Groups 1 and 2 may be attributed to the lack of handling of 
by Group 1 prior to commencement of the measurements. An ANOVA on all groups, 
showed that acclimatization affected male mice more than the female mice, with male 
blood pressures decreasing whilst the females increased. Non-acclimatized transgenic 
mice had the highest blood pressures. The reasons for these differences have yet to be 
elucidated. 
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In order for definitive results to be obtained, many more mice need to be tested 
with an increased number of blood pressure recordings for each individual. However, it 
may be better to utilize the direct intra-arterial (telemetry) method for recording blood 
pressure in future. This would also eliminate the stresses inherent in handling and 
restraint. 
The increased tissue fragility of the aortae, tail arteries and associated connective 
tissue of all the transgenic mice was not expected. Similar findings with other 
transgenic mice have not, as yet, been reported. This may be partly due to lack of study 
on the vasculature of normal and transgenic mice. The systemic influence of selectively 
overexpressing the Cx43 gene in the murine vasculature should not be overlooked, nor 
should the possibility that the insertion of foreign DNA into the genome may have 
disrupted the function of one or more endogenous genes (Babinet et al. 1989). Clearly, 
the nature and extent of this tissue phenomenon, and its likely systemic effects, need to 
be ascertained. 
Although a larger number of samples for each group must be studied for more 
conclusive results, some generalizations can be drawn from the Western blot protein 
data. The slight increase in Cx43 expression in the single transgenic truncated-promoter 
mice was not statistically significant but the trend suggested an increase, which will 
require further testing of the mice to establish its significance. It appears unlikely that 
the truncated promoter is capable of full function, but it may retain minimal function. 
In the double transgenic truncated-promoter mice, an increased gene copy 
number significantly increased aortic Cx43 protein levels with little increase in the tail 
artery Cx43 protein levels. This indicates that the truncated-promoter appears to be 
tissue specific. It may also indicate that the construct has been incorporated into the 
genome in a way that allows overexpression of Cx43 in the elastic vessels in the 
vasculature. Estimates of the gene copy number would have been obtained by either 
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Southern blot analysis or dot-blot hybridisation assay (Hogan et al. 1994) had time 
permitted. 
The single transgenic full-promoter mice had a 3-fold increase in Cx43 protein 
levels in the aortae compared to the control mice, with a trend towards increased Cx43 
protein levels (2-f old) in the tail arteries. This trend may become significant with 
further testing as only one sample containing five tails was analyzed. This indicates that 
the full SM22a promoter is providing tissue specificity for Cx43 overexpression in the 
aorta ( elastic artery) and perhaps in the tail artery (muscular artery). Conclusive 
evidence will be provided by continuing studies on a range of blood vessels from these 
transgenic mice. 
The control actin values for the aortae and tail arteries remained relatively 
constant both within and between groups, making this a suitable standard for use in the 
vasculature of mice. A relationship has been proposed to exist between actin 
microfilaments and gap junctions (Larsen et al. 1979; Hitt and Luna, 1994; Murray et al. 
1997) due to their close anatomical positioning. However, the data obtained so far 
would not support such a contention. Ongoing testing by other methods such as 
immunohistochemistry and mRNA analysis will help to verify the data obtained from 
the Western blots. Future research will be discussed in detail in Chapter 5. 
Both the blood pressure recordings and the Western blots, indicate that there is 
no correlation between blood pressure and Cx43 protein expression levels. In addition, 
two mice (one in the double transgenic truncated-promoter group and one in the single 
transgenic full-promoter group) that consistently had high blood pressure measurements 
did not have increased Cx43 expression in either the aorta or tail artery. Although it 
would seem likely that increased Cx43 expression does not pre-dispose the mouse to 
hypertension at this age, it may be that these mice may develop hypertension or even 
hypotension later in life as has been noted for other hypertensive models (McGuire and 
Twietmeyer, 1985; O'Sullivan and Harrap, 1995; Hill et al. unpublished results). 
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Differences due to strain are not applicable in the current study as all mice used were 
BALB/c - only the chimaeras had a mixed BALB/c x C57BL/6 background. 
The data obtained from the preliminary analyses in the current study showed that 
there was a difference both between and within the transgenic truncated and full-
promoter mouse lines. However, more work is required to fully elucidate these 
differences and correspondingly, the phenotypes. In terms of the Cx43 expression data 
and the blood pressure measurements, it would seem that increased Cx43 expression 
does not cause hypertension or hypotension in the mouse. However, no definite 
conclusions can be drawn at this stage without further study, and perhaps even repeating 
the microinjection protocol so that comparisons with other full-promoter transgenic 
mice can be made. The significance of much of the available data with respect to 
vascular function remains to be elucidated. 
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Chapter 5 - General Discussion 
Gene technology developed over the last ten to fifteen years, has allowed the 
introduction of foreign gene/s into the germ-line of mice, permitting new insights into a 
wide variety of biological mechanisms. This has resulted in biomedical research 
making use of transgenic mice which are specific to a particular molecular genetic 
question (Jaenisch, 1988; Hanahan, 1989; Babinet, 2000; Janssen and Smits, 2002). 
This methodology has a wide range of applications (Connelly et al. 1989; Babinet, 
2000), from the regulation of gene expression in vivo and analysis of gene manipulation, 
to the establishment of disease models for the study of pathogenesis. 
The primary aim of this thesis was to determine the role of Cx43 in hypertensive 
states by producing a transgenic mouse model that would selectively overexpress Cx43 
in the arterial system. Two genetically modified mice were in fact produced: one 
containing a truncated form of the restricted SM22a promoter coupled to the Cx43 gene, 
and the other containing the entire restricted SM22a promoter coupled to the Cx43 
gene. Preliminary studies were undertaken on the mice to investigate their phenotypes 
and the level of Cx43 expression in the vasculature. 
Briefly, the tail artery tissues of all transgenic mice were more fragile than the 
control mouse, and the blood pressures of all mice were within the normal range. The 
Cx43 protein levels in the aortae and tail arteries of the single transgenic-promoter mice 
were not significantly increased, but in the double transgenic truncated-promoter mice, 
the Cx43 protein levels were significantly increased in the aorta, with no change in the 
tail artery. This indicated that the truncated-promoter was minimally functional. In the 
single transgenic full-promoter mice, aortic Cx43 protein levels were significantly 
increased with a trend towards increased Cx43 in the tail arteries, which demonstrated 
that the SM22a / Cx43 construct may be functional in vivo. 
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A number of germane areas were identified during the preliminary studies: the 
transient transfection system, the low expression level of the SM22a construct and the 
subsequent analysis of Cx43 expression by Western Blotting. These will now be 
discussed. 
Data presented from the transfections of the construct in Chapter 3, showed that 
the SM22a / Cx43 construct was tissue specific. The low expression rates for the 
construct in the smooth muscle cells are of concern when viewed in conjunction with 
the expression rates for the control CMV -EGFP plasmid, and results from previous 
papers utilizing SM22a promoter constructs (Kemp et al. 1995; Solway et al. 1995; Li 
et al. 1996; Moessler et al. 1996). Solway et al. (1995) found that in both primary rat 
aortic smooth muscle cells and the smooth muscle cell line A 7r5, the transfected murine 
482 bp SM22a promoter (bp --441 to +41) was active and increased transcription of the 
luciferase reporter gene to a high level. Passage three cells were used, together with 
Lipofectin Reagent (Life Technologies). The 493 bp SM22a promoter (bp -438 to +56) 
used in the current study was based on this promoter. 
Several SM22a promoter constructs of varying lengths have been transfected 
into primary cultured rabbit aortic cell lines, both with and without 10% serum, and 
using the Lipofectamine Reagent (Moessler et al. 1996). The best transfection rates (3-
fold increase in expression of ~-galactosidase) were with the 510 bp promoter (bp -445 
to +65) which was again longer, by-seven bases at the 5' (proximal) end and seven at the 
3' (distal) end, than the promoter used in the current study. Expression was reduced 
when using promoters of a shorter length (417 bp; bp -352 to +65) and absent (low 
background only) when at 271 bp (bp -206 to +65). The truncated-promoter in the 
current study contained somewhere between 204 and 103 bp of the restricted 493 bp 
SM22a promoter and consequently, based on the above study, would not be capable of 
directing transcription in vivo. In comparison, Solway et al. (1995) showed that in 
transfections of their 482 bp promoter (bp -441 to +41 ), expression of luciferase was 
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increased by 250-300 fold compared to control, especially in the smooth muscle cell 
line, whilst no expression was detected in all non-smooth muscle cells. This represents 
a considerable difference in expression levels. Shorter promoter lengths of 3 65 bp (bp -
300 to +65; 50% reduction) and 227 bp (bp-162 to +65; 90% reduction) were also 
transfected, with only background expression levels being observed for the latter. This 
again suggested that the truncated-promoter in the present study would not be functional 
in vivo. Actually, the truncated-promoter was found to have tissue specificity in vivo 
(Chapter 4), despite these previous studies suggesting that no expression would occur. 
The only difference between the 482 bp promoter used by Solway et al. (1995) 
and the one used in the current study, is the absence of five bases at the 5' end of the 
promoter, and an extra fifteen bases on the 3' ( exon 1) end. The omission of three bases 
(AGT) in the design of the construct was not thought to be of concern as they form part 
of the Pstl restriction enzyme site only. However, as two more bases at the forward end 
were lost during the cloning of the respective constructs, the possible functional 
significance of these missing bases needs to be considered when reviewing the results 
presented herein. 
Similar results to that of Solway et al. (1995) were observed in the cloning and 
analysis of the promoter region of the rat SM22a gene by Kemp et al. (1995) which has 
98% homology with the mouse SM22a protein (Li et al. 1996). Promoters of similar 
length to those already made in the mouse, were coupled to the reporter CAT 
( choramphenicol acetyltransferase) gene and transfected by electroporation into cultured 
adult rat aortic vascular smooth muscle cells and Rat-1 fibroblasts. The highest 
expression levels were recorded for the 368 bp promoter (bp -303 to +65; 295%) in 
both cell types, followed by the 258 bp promoter (bp -193 to +65; 44% in vascular 
smooth muscle cells) and the 182 bp promoter (bp -117 to +65; 3 9% in vascular smooth 
muscle cells). For both the 258 and 182 bp fragments, no CAT activity was detected in 
the fibroblasts. The residual promoter activity for the smallest promoter suggested that 
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factors binding to the proximal 182 bases of the SM22a promoter play an important role 
in restricting the expression of the SM22a gene to smooth muscle cells. Interestingly, 
these results differ from the data presented for the mouse promoter in vitro (Moessler et 
al. 1996). 
Direct comparisons between the expression levels for the different promoter 
lengths are difficult to substantiate, as different plasmids, cell lines and types ( which 
affect transfection efficiency and thus gene expression), detection methods and 
transfection reagents and methods were used. In the literature, murine aortic smooth 
muscle cells have not been chosen as the vehicle in which to study the murine SM22a 
. promoter constructs. One mitigating factor could be that, as the current study 
determined, published data concerning the culture and transfection of these cells in vitro 
is lacking and at present, there is no recommended transfection reagent for murine aortic 
smooth muscle cells. Hamm et al. (2002) have recently reported on the successful use 
of the Nucleofectortrade mark technology in the transfection of human coronary smooth 
muscle cells, but its applicability to murine smooth muscle cells remains to be 
ascertained. 
The differentiation state of the smooth muscle cells was of the utmost 
importance, and the most difficult to determine. As discussed in Chapter 3, Solway et 
al. (1995) used rat aortic cells at passage three, together with Lipofectin Reagent, whilst 
Moessler et al. (1996) tested the same promoter region in primary cultured rabbit aortic 
smooth muscle cells, both with and without 10% serum and using the Lipofectamine 
Reagent. In the latter, high-level expression was detected in the absence of serum 
( differentiated cells) with a 3-fold lower expression in the cells cultured with 10% 
serum (proliferating cells). As smooth muscle cells are known to readily de-
differentiate in vitro (Moessler et al. 1996), procedural modifications were invoked to 
confirm the status of the cells and to promote differentiation by the use of insulin, for 
example. However, no improvement in expression levels for any construct was 
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observed. This indicates that the experimental conditions were still not optimal for 
expression of the SM22a construct, especially as the CMV-EGFP transfection rates 
remained relatively constant and at an acceptably high level throughout the experiments. 
Interestingly, it has recently been shown that the SM22a promoter activities in canine 
tracheal myocytes were decreased by 8-fold in long-term serum deprived smooth muscle 
cells compared with serum-fed cells, whilst the activity of a viral promoter was not 
affected (Camoretti-Mercado et al. 2000). 
These points raise the question about the possible effect of the coupling of the 
SM22a promoter to various reporter genes. It is possible from the data in the current 
study to hypothesize that the coupling of the SM22a promoter to the Cx43 gene, may 
have affected the performance of the promoter. However, it may simply reflect the 
differences in detection sensitivity or alternatively, the CMV promoter may be more 
effective than the SM22a promoter. The data in the present study as well as from other 
studies (Gerolami et al. 2000; Ribault et al. 2001) would support either tenet. 
In terms of coupling and expression levels, it is possible that combined, the 
omission of the seven bases at the 5' end of the SM22a promoter fragment ( compared to 
other promoters where no bases, and fourteen bases, were missing), and the loss of 
seven bases at the 3' end ( compared to the optimally expressing promoter lengths), 
affected the functioning of the SM22a promoter when it was coupled to the Cx43 gene. 
As all published work to date has included all of exon 1 in the cloning of the SM22a 
promoter, it would be advisable to include this entire region in future cloning exercises 
involving the murine SM22a promoter. The inclusion of more bases at the forward end 
of the restricted SM22a promoter region is recommended to ensure adequate and high 
expression levels of the gene of interest. Nevertheless, overexpression of Cx 4 3 in the 
aortae of single transgenic full-promoter mice was observed in the current study and it is 
likely that with further testing, the 2-fold trend towards increased Cx43 expression in 
the tail arteries, will also prove to be significant. 
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In vivo data from the single transgenic truncated-promoter and the double 
transgenic full-promoter mice did not support the in vitro evidence presented above by 
Solway et al. (1995) and Kemp et al. (1995) that the truncated-promoter (between 204 
and 103 bp) could not function in either of its tissue specific or gene-driving roles in 
vivo. The data indicated that truncated-promoter was minimally functional, especially in 
driving tissue specificity which, until the number of bases present is accurately 
determined, either extends or confirms the findings by Kemp et al. (1995) who found 
residual promoter activity with a 182 bp SM22a promoter fragment. If the construct had 
been incorporated into the genome and was under the control of another promoter, 
tissue-specificity would have been lost. 
The increased Cx43 expression in the aorta and the trend towards increased 
Cx43 expression in the tail artery of the single transgenic full-promoter mice, indicate 
that the SM22a / Cx43 construct is functional in vivo, though to what extent remains to 
be determined by the ongoing studies. Tang et al. (2000) found a 76% increase in the 
GF A (glutamine:fructose-6-phosphate amidotransferase) single transgenic mice 
compared to the littermate controls. Others, such as Wang et al. (1997), reported a 3.5 
to 4-fold to 10-fold increase over controls in transgenic mice overexpressing IGF-I. The 
trend towards increased Cx43 expression in the tail arteries for the single and double 
transgenic truncated-promoter mice and the single transgenic full-promoter mice, may 
simply be a reflection of the relatively small sample sizes. Perhaps as only one single 
transgenic full-promoter founder mouse was made, compared to the norm of four or 
five, it is possible that due to gene copy number and position effects in this mouse, this 
mouse is not capable of giving the best result in terms of Cx43 expression. 
Three problems were identified in the analysis of Cx43 expression levels in the 
aortae and tail arteries of the transgenic and control mice using Western blots. Firstly, 
the tissue extraction component of the procedure needs to be considered. The basic 
assumption in this procedure was that each sample ( artery) gave an equal amount of 
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membrane protein. So for four mice tails, this would equate to 12 mg wet weight / 10 µl 
( 4 tails combined); the minimum amount of tissue required for visualization on a gel. 
However, after determining the wet weight of each sample, it is impossible to control 
the tissue extraction so that complete homogenization of each tissue sample occurs. I 
only used visual observation for determining when homogenization of the tissue was 
complete, although in the future, spectrophotometry could be used. Tissues that are 
easier to homogenize such as those with less connective tissue, are more likely to have 
higher membrane protein values. All the transgenic mice in the current study were 
observed to have fragile aortae and tail arteries compared to the controls and this may 
have influenced the Cx43 protein values to some degree. Anatomical studies are needed 
to ascertain the cause of the fragility. 
There did not appear to be any difference in the intensity of the actin bands 
between groups macroscopically, but when the bands were analyzed with the AIS 
program slight, though non-significant, differences were observed. This highlights the 
fact that for actin, the value of W estem blots for detecting change in protein expression 
is limited when the gels are viewed by ' eye' only. The same however cannot be said for 
detecting Cx43 expression in the aortae, where gross changes in bandwidth and intensity 
could be seen. For the tail artery, changes observed macroscopically became more 
significant when assessed with the AIS program. 
The consistent variation in the Cx43 values between the groups and the constant 
actin values give credibility to the results presented in this work. It also points to the 
role of actin as an important and conserved entity in vascular smooth muscle. The value 
of using a control such as ~-actin is evident. However, as the values were derived from 
relatively small ( combined) sample sizes, especially for the double transgenic truncated-
promoter and single transgenic full-promoter mice, it is recommended that further 
experiments be conducted using this standard to confirm the trends seen in the current 
study. In addition, protein assays cannot be viewed as a strictly valid determinator of 
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the membrane protein, and hence Cx43 protein present, in the tissue samples due to the 
presence of other proteins such as enzymes, that may not be directly present in smooth 
muscle. 
The data from this thesis indicate that increased Cx43 expression can occur 
without a concomitant increase or decrease in blood pressure. Both the double 
transgenic truncated-promoter mice, and the single transgenic full-promoter mice, had 
increased Cx43 expression in the aortae with a trend towards increased Cx43 expression 
in the tail arteries, without any increase or decrease in blood pressure. This opens up a 
wide variety of opportunities for future studies on these mice, with potentially important 
implications for the study of hypertension, as increased blood pressure has traditionally 
been associated with an increase in Cx43 expression (Blackburn et al. 1997; Donaldson 
et al. 1997, Haefliger et al. 1997a,b; Haefliger and Meda, 2000). Recently, however, a 
decrease in Cx43 expression in the aorta ofL-NAME hypertensive rats has been 
reported (Haefliger et al. 1999). Exactly what causes increased expression of Cx43 in 
hypertension is open to speculation, whilst the effect of increased Cx43 expression on 
vascular function remains to be elucidated. This represents an exciting area of further 
investigation. 
Future Studies 
It is unfortunate that time restrictions prevented the realisation of a more 
definitive picture of the characteristics of the mice produced - particularly the double 
transgenic full-promoter mice. My work has indicated several directions for future 
study, including immunohistochemistry and semi-quantitative mRNA using reverse 
transcription PCR (RT-PCR). This is work that should be included in a series of further 
studies. 
To assess the effect of the increased Cx43 expression on the vascular responses 
physiological experiments such as electrophysiology and myography, should also be 
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undertaken. This work has demonstrated that not only must a substantial number of 
mice need to be subjected to blood pressure recordings, but also an increased number of 
recordings for each individual must be employed. This latter requirement suggests that 
it would be worthwhile trialling telemetry for continuous recording of blood pressure in 
future studies. This would also have the benefit of eliminating, or at least minimising, 
blood pressure altering stresses inherent in handling and restraint. 
Comparison of data from ongoing studies using such techniques as 
immunohistochemistry, dye-tracer studies and I or calcium imaging of gap junction 
activity on both the control and transgenic mice should yield, for example, information 
on age-related and disease-related alterations in second messenger levels, metabolism 
and diffusion, sympathetic and sensory innervations, and neurotransmitter receptors. 
A further area of interest for continuing study, and an alternative method for 
producing transgenic mice, is the use of the Tetracycline Expression System (Tet) to 
control the temporal expression of Cx43. To accomplish this, both tissue specific 
activity (using the restricted portion of the SM22a promoter) and temporal specific 
activity (using Tet to tum the Cx43 gene on in adulthood) must be present. Briefly, the 
transgenic mice separately produced by injection of these constructs, would be 
intercrossed to produce a doubly transgenic mouse line in which both constructs were 
present in the same cell. It would be hoped that Cx43 expression will be driven by the 
SM22a promoter under the temporal control of tetracycline. More detail is provided in 
Appendix II which also describes the work accomplished on this exciting area. 
Conclusion 
Finally, the results of this study should provide the groundwork for further 
experimentation into the physiological effects of Cx43 overexpression in the vasculature 
and changes in vascular reactivity. 
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Appendix I - Methods 
This Appendix supplements the information presented in Chapter 2 - Materials 
and Methods. 
AI.1 Restriction endonuclease digests 
Restriction endonuclease digests were undertaken to verify the plasmids and the 
DNA constructs. Each was carried out in the appropriate NEB buffer (see Table AI.1) 
for each enzyme selected. 
NEBuffer 1 
NEBuffer 2 
NEBuffer 3 
NEBuffer4 
10 mM Bis Tris Propane-HCl, 10 mM MgCh and 1 mM 
dithiothreitol pH 7. 0 at 25°C. 
10 mM Tris-HCl, 10 mM MgCh and 1 mM dithiothreitol pH 
7.9 at 25°C. 
50 mM Tris-HCl, 10 mM MgCh, 100 mM NaCl and 1 mM 
dithiothreitol pH 7 .9 at 25°C. 
20 mM Tris-acetate, 10 mM magnesium acetate, 50 mM 
potassium acetate and 1 mM dithiothreitol pH 7 .9 at 25°C. 
Table AI.1 NEBuffers used in the restriction digests 
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AI.2 Analytical and preparative separation of DNA fragments 
Lambda phage DNA digested with Accl or Hindill or pTz I Alul were 
electrophoresed with the DNA samples as molecular size markers (see Table AI.2). The 
ADNA EcoRI I Hindill marker was also used. 
lAccl 
l Hindlll 
13 .070 kb, 11.828 kb, 6.957 kb, 5 .5 81 kb, 3 .57 4 kb, 2. 720 kb, 
2.180 kb, 1.444 kb, 0.639 kb and 0.499 kb. 
23 .130 kb, 9.416 kb, 6.557 kb, 4.373 kb, 2.322 kb, 2.027 kb, 0.564 
kb and 0.125 kb. 
l DNA I EcoRI 24.756 kb, 21.226 kb, 5.148 kb, 4.973 kb, 4.268 kb, 3.530 kb, 
I HindIIT 
pTz I Alul 
2.027 kb, 1.904 kb, 1.584 kb, 1.375 kb, 0.947 kb, 0.831 kb, 0.564 
kb and 0.125 kb. 
0.621 kb, 0.521 kb, 0.257 kb [x2] , 0.226 kb, 0.215 kb, 0.136 kb, 
0.118 kb, 0.100 kb, 0.095 kb, 0.093 kb, 0.064 kb, 0.063 kb, 0.049 
kb and 0.045 kb. 
Table AI.2 The molecular weight DNA standards 
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AI.3 Smooth muscle cell specificity 
Positive staining with antibodies against smooth muscle cell myosin was used to 
confirm the specificity of these cultures. The method is tabulated below. 
1. Aspirate DMEM from the adhered cells and rinse 3 times in PBS. 
2. Fix in 4 % (w/v) paraformaldehyde in 0.1 M sodium phosphate buffer pH 7.3, for 30 
minutes at room temperature. 
3. Rinse in PBS, then wash 3 times in PBS; 5 minutes each. 
4. Add primary antibody (rabbit anti-myosin; 1: 1000) diluted in PBS containing 10 mg 
I ml BSA, 0.4 mg I ml sodium azide and 30 µl / ml 10% Triton X-100, and incubate 
overnight at room temperature in a humidified chamber. 
5. Rinse in PBS, then wash 3 times in PBS; 10 minutes each. 
6. Incubate with fluorescein (FITC)-conjugated affinity-purified donkey anti-rabbit 
(1 :40; Dako) or goat anti-rabbit oregon green (1: 100; Molecular Probes) diluted in 
PBS, for one hour at room temperature in a humidified chamber. 
7. Rinse in PBS, then wash 3 times in PBS; 10 minutes each. 
8. Mount in buffered glycerol and store at -20°C. 
Table AI.3 Immunohistochemical protocol for smooth muscle culture 
specificity using myosin antibody. 
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AI.4 Protocol for fresh tissue immunohistochemistry 
1. Pre-chlll chuck in a sluny of 95% ethanol and dry ice. Add embedding compound (Cryo-M-Bed; 
Bright Instrument Company Ltd. , England) to the chuck's surface just before placing the tissue on 
the chuck. 
2. Place dissected tissue into cold 30% sucrose in PBS for 5 to 10 minutes, and then into 1: 1 mixture of 
30% sucrose and embedding compund for 5 to 10 minutes until tissue sinks. 
3. Remove tissues and place on a microscope slide (max. 3 per slide). Cover preparations with chllled 
embedding compound. Place on dry ice to freeze whllst prepare the chuck (see point 1). 
4. Invert slide on chuck and freeze completely. Then remove slide by gently warming the surface 
5. Keep chuck with tissue preparations on dry ice until sectioning. 
6. Section tissue at a thlckness of 10 µm on cryostat, and place sections on microscope slides. 
7. Section tissue at a thlckness of 10 µm on cryostat, and place sections on microscope slides. 
8. Fix in cold acetone for 7 minutes and air dry the slides. 
9. Make circle around tissue with pap pen and pre-incubate sections in 2% BSA / 0.2% Triton-X / 
0. 04 % sodium azide for 3 0 minutes. 
10. Add primary antibody: anti-rabbit Cx43 antibody (1 :250; Zymed, California) diluted in 2% BSA / 
0.2% Triton-X / 0.04% sodium azide in PBS for 1 hr at room temperature in a humidified container. 
11. Rinse quickly with PBS, and then wash in PBS 3 x 10 minutes. 
12. Apply secondary antibody (1: 100; Cy3-conjugated anti-rabbit immunoglobulins, Jackson 
Immunoresearch Laboratories Inc. , PA) diluted in PBS / 0.01 % Triton-X for one hour at room 
temperature in a humidified container. 
13. Rinse quickly with PBS, then wash in PBS 3 x 10 minutes. 
14. Mount in buffered glycerol and examine using a fluorescence microscope fitted with the appropriate 
filters. 
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AI.5 Western blots 
The solutions used in the Western blots are shown below. 
Running Buffer 28.8 g glycine, 6 g Tris-base, 2 g SDS in 2 L distilled water. 
Lower Tris Buffer 15.4 g Tris-base, 3.7 g Tris-HCl in 100 ml distilled water; pH 
8.8. 
Anode Buffer #1 100 ml Tris-base, 33.3 ml Methanol, 33.3 ml distilled water; 
pH 10.4. 
Anode Buffer #2 10 ml Tris-base, 80 ml Methanol, 310 ml distilled water; pH 
10.4. 
Cathode Buffer 10 ml 500 mM Tris-base, 310 ml distilled water, 2.099 g 
aminohexanoic acid, 80 ml Methanol; pH 9.4. 
Tris-base 500 mM- 30.25 g I 500 ml distilled water; pH 7.4. 
Table AI.4 Western blot solutions 
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Appendix II - Generation of the Tetracycline Response Constructs 
AILJ Introduction 
A major limitation in the use of genetically modified mice for various studies is 
the lack of tissue and temporal control of gene expression. To date, much work has 
been undertaken using transgenes that are controlled by either tissue-specific promoters 
or promoters that are expressed in a wide variety of tissues with no temporal control of 
expression. In the ideal situation, control of the expression of individual genes would 
also allow expression at defined levels, as well as mediating on / off expression. 
In the tetracycline regulatory ( expression) system, target genes are placed under 
the control of a regulatory sequence (tetO) from the tetracycline-resistance operon of 
Tnl 0. This short sequence is bound by the tetracycline repressor protein (tetR) in 
bacteria (Hillen and Wissmann, 1989). In the presence of the tetracycline antibiotic, 
tetR does not bind to its operators located within the promoter region of the operon, 
allowing transcription to occur (Gossen and Bujard, 1992). A hybrid transactivator 
(tTA), as in the plasmid system used in the current study, stimulates transcription from a 
minimal promoter sequence, which is virtually silent in the presence of low 
concentrations of tetracycline. This system is called TetOff. There are in fact two 
complimentary versions of the Tet system: TetOff and TetOn. 
The TetOn system (Figure All.I) is based on the reverse tTA (rtTA), which 
differs from tTA by four amino acid changes in the TetR protein (Clontech, 1997), and 
activates transcription in the presence of the tetracycline antibiotics, tetracycline or 
doxycycline ( the latter being the drug of choice as it is known that the rtT A responds 
poorly to tetracycline; Gossen and Bujard, 1992). Two plasmids are needed: a regulator 
plasmid and a response plasmid. In this thesis, the regulator plasmid was pTetOn 
(Clontech; Figure AII.2A) which contained the rtTA coding region, a CMV promoter (to 
rtetR VP16 
rtTA 
Doxycycline • 
Transcription 
p minCMV 
Figure All.I The Tetracycline Expression System 
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be replaced by the restricted SM22a promoter) and a SV40 polyadenylation site. The 
response plasmid was pBi5 (Figure AII.2B) with a silent, minimal CMV promoter, the 
tetracycline response element (TRE) and multiple cloning site (MCS) into which the 
selected Cx43 gene region was cloned (see Chapter 3). 
The two DNA constructs described above would be used to generate two 
transgenic mouse lines. One would contain the smooth muscle specific construct in 
which the restricted SM22a promoter would provide tissue specificity for the expression 
of the tetracycline transactivator protein (rtTA; SM22a / pTetOn), and the other would 
contain the Cx43 temporal specific construct in which the tetracycline response element 
would provide temporal control of Cx43 gene expression (Cx43 I pBi5; EGFP I Cx43 I 
pBi5). The transgenic mice separately produced by injection of these two constructs, 
would be intercrossed to produce a doubly transgenic mouse line in which both 
constructs would be present in each cell so that Cx43 expression would be driven by the 
SM22a promoter under the temporal control of doxycycline (Figure AII.3). 
This Appendix describes the cloning of the SM22a / pTetOn, and EGFP / Cx43 / 
pBi5 constructs. All constructs were evaluated in vitro in cultured murine embryonic 
fibroblasts and murine aortic smooth muscle cells. 
AII.2 Additional Methods 
AII.2.1 Cloning of SM22a / pTetOn 
AII.2.1.1 Preparation and verification of the pTetOn plasmid 
The pTetOn plasmid (7.4 kb; 500 ng / µl) was diluted in MilliQ water and a 
small aliquot electroporated into TOP 1 OF' cells. Colonies were screened for the insert 
by cracking and one positive colony was chosen to form the stock sample. After 
purification, the DNA was checked by agarose gel electrophoresis and quantified by 
spectrophotometric analysis, before verification by restriction enzyme digests. 
Figure AII.2 The TetOn plasmids 
Shown are the two TetOn vectors, pTetOn (7.4 kb; A) and pBi5 (6.083 kb; B) 
with selected restriction enzyme sites. Neor and Ampr refer to the neomycin and 
ampicillin resistance genes respectively. 
In p TetOn, the generalized promoter (P CMV) which produces the viral products 
rtetR and VP 16 ( together forming the tetracycline transactivator; rtT A), was removed 
and replaced with the SM22a promoter; thus giving tissue specificity to the construct. 
The tetracycline response element (TRE), to which the rtT A binds when doxycycline is 
added, is shown in the pBi5 plasmid. After binding, the TRE activates the minimal 
promoter (Phi-I promoter) to drive transcription of the luciferase gene as well as the 
Cx43 gene, which was cloned into the multiple cloning site. 
Xhol 2 
871 
SV 40 poly A signal 
Xhol 4461 
Figure AII.2A The pTetOn plasmid 
Pstl 1 
L ucif erase gene 
Pbi-1 
Multiple cloning site 
~-Globulin 
Xbal 4350 SV 40 poly A signal 
~ ~~~ poly A signal 
. ~- :;. 
Asel 1827 
Asel 3062 
Figure AII.2B The pBi5 plasmid 
Figure AII.3 Tissue and temporal specificity in the same cell 
The tissue specific construct with the SM22a promoter (A) and the temporal 
specific construct with the Cx43 gene (B). Mice overexpressing A and Bare required. 
KEY: 
SM22 
rtetR/VP16 
Luc 
Pmin 
TRE 
Cx43 
the restricted SM22a promoter 
rtTA (tetracycline transactivator) 
lucif erase gene 
minimal promoter 
tetracycline response element 
Cx43 gene 
A . ..) ..... 
~ 
' 
• 
" 
a SM22 rtetR VP16 
a 
. ;ii 
163 
Briefly, the single cutters EcoRI and Spel each gave band sizes around the 
predicted band size of 7 .4 kb, whilst the combined Eco RI I Spel restriction removed the 
CMV promoter (663 bp) leaving a fragment of around 6.7 kb. PvuIT, cut pTetOn five 
times to give the predicted fragment sizes of 3.0 kb, 2.6 kb, 0.7 kb, 0.57 kb and 0.5 kb. 
Hindill was specifically chosen to verify the plasmid as pTetOn and not pTetOff, as it 
has the unique feature of being a single cutter in pTetOff and a double cutter in pTetOn. 
Two fragments of about 1.3 kb and 6.1 kb were produced (Figure AII.4). 
The CMV promoter was excised from 2 µg of the plasmid using EcoRI and Spel, 
and then isolated and purified before assessment by agarose gel electrophoresis. 
AII.2.1.2 Preparation of the SM22a I pBs KSII- plasmid 
The SM22a promoter was excised from 400 ng of SM22a I pBs KSII-
( designated Clone #121; Chapter 3) with EcoRI and Spel. This would ensure that even 
with a 50% recovery rate from the gel purification, 200 ng (the calculated amount 
needed for subsequent cloning into pre-restricted pTetOn) would be available for 
cloning. After isolation and purification, the SM22a fragment was assessed by agarose 
gel electrophoresis. 
AII.2.1.3 Cloning of SM22a I pTetOn 
The Spel I EcoRI I SM22a fragment was directionally cloned into the EcoRI I 
Spel I pTetOn plasmid. The DNA was subsequently transformed, and cracking 
identified clones possessing an insert. Six positives were purified and assessed by 
agarose gel electrophoresis. Verification was by restriction enzyme digests, and bi-
directional sequencing with the SM22exlr and SM22exlf primers (see Section AII.3). 
PCR screening was not undertaken, as it was deemed unnecessary due to the satisfactory 
results already obtained. 
9 .416 kb -~•--
6.557 kb-----1•-
5. 5 81 kb---•-
2.720 kb-----1•a-
2.180 kb-~•--
1.444 kb -----1•a-
0.639 kb 
0.564 kb 
• 
• 
-
\.) 
\.) 
~ 
-
-°B ~ s;: 
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Figure AII.4 Verification of pTetOn 
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3.0 kb band 
2.6 kb band 
4•a---- 1.3 kb band 
-•- - 0.663 kb band 
Both EcoRI and Spel linearized pTetOn, giving bands of about 7.4 kb. 
The combined EcoRI I Spel restriction removed the CMV promoter (663 
bp ). Hindfil gave two fragments of approximately 1.3 kb and 6.1 kb, 
thereby verifying the plasmid as pTetOn and not pTetOff. PvuIT produced 
five bands which corresponded to the predicted fragment sizes of 3 .0 kb, 2.6 
kb, 0.7 kb, 0.57 kb and 0.5 kb. 
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Ail.2.2 Cloning of Cx43 / pBi5 
This construct was cloned in Chapter 3. 
Ail.2.3 Cloning of EGFP / Cx43 / pBi5 
As the EGFP expression data from in vitro testing of the DNA constructs 
revealed that immunohistochemical detection was not as sensitive as direct detection of 
EGFP, the luciferase gene in the Cx43 / pBi5 construct was replaced with the EGFP 
gene from pEGFP-Nl (4.733 kb; Figures AII.5 and AII.6). Briefly, the luciferase gene 
was excised from pBi5 with Pstl I Spel and the Pstl I Natl I EGFP gene from pEGFP-NI 
inserted, as the polyadenylation site in the pBi5 plasmid could be used by the EGFP 
gene. The Natl and Spel sites were filled in with Klenow for the blunt-end cloning. 
Ail.2.3.1 Preparation of the pEGFP-Nl plasmid 
The pEGFP-Nl plasmid (4.733 kb; CMV-EGFP) was quantified by 
spectrophotometric analysis at OD260 and then verified by restriction analyses. The 
single cutter Natl (cuts pEGFP-Nl at 1.402 kb) produced a linear band around the 
expected size of 4.7 kb. Pstl, also a single cutter (at 0.639 kb), gave a linear band 
around 4. 7 kb. The Natl I Pstl double restriction removed the EGFP gene giving band 
sizes corresponding with the predicted sizes of 0.763 kb and 3.97 kb. Xbal (single 
cutter at 1.412 kb) did not cut the plasmid (expected a linear band of 4.7 kb). BamHI 
cuts once at 663 bp and thus, gave a linear band approximating the predicted value of 
4.7kb. 
Ail.2.3.2 Preparation of the Cx43 / pBi5 plasmid 
Additional restriction digests were undertaken for further verification of the 
Cx43 I pBi5 plasmid, and to confirm the viability of the proposed cloning strategy. Pstl 
(a single cutter in Cx43 / pBi5, specifically pBi5) gave a linear band around the 
Asel 8 
Multiple cloning site/ 
SV 40 poly A signal 
Figure AII.5 The pEGFP-NI plasmid 
EGFP 
~Natl 1402 
Xbal 1412 
The pEGFP-NI plasmid (4.7 kb) is shown with selected 
restriction enzyme sites pertinent to this study. Kanr / Neor refer to 
the kanamycin / neomycin resistance gene. The Natl site follows the 
EGFP stop codon. The pUC origin is the origin of replication for 
propagation in E. coli. P CMV is the promoter. 
Figure AII.6 Schematic diagram of the cloning of EGFP / Cx43 / pBi5 
The cloning of the EGFP / Cx43 / pBi5 construct is shown in (A), (B) and (C). 
The luciferase gene was excised from Cx43 / pBi5 with Pstl and Spel (A), whilst the 
EGFP gene was excised from EGFP-NI with Pstl and Natl (B). The Pstl I Natl I EGFP 
gene was then cloned into Pstl I Spel I Cx43 I pBi5 (C). The figures are not to scale. 
(A) 
Luciferase gene 
(1.727 kb) 
(B) 
(C) 
EGFP gene 
Pstl 1 
Cx43 I pBi5 
7.357 kb 
SV40 polyA signal 
~ 
Spel 
Spel 
pEGFP-NI 
4.7kb 
Xbal 1412 
Natl 1402 
Pstl 1 
EGFP I Cx43 I pBi5 
6.393 kb 
5.630 kb 
Pstl 639 
EGFP gene 
0.763 kb 
Cx43 / pBi5 
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predicted band size of 7.4 kb, Spel (a single cutter in Cx43 / pBi5, specifically pBi5) 
produced a linear band around the predicted band size of 7 .4 kb, Pstl I Spel ( cuts twice 
in Cx43 / pBi5, specifically pBi5) removed the luciferase gene, producing bands which 
corresponded to the predicted bands of 5.673 kb and 1.727 kb, and a third band which 
was some remaining linear plasmid. Asel ( cuts pBi5 twice) generated two bands that 
were about the predicted sizes of 1.235 kb and 6.165 kb. 
AII.2.3.3 Preparation of the Cx43 / pBi5 vector 
The luciferase gene was excised from 2 µg of Cx43 / pBi5 in a four hour 
restriction digest using Pstl followed by Spel with fresh NEBuffer, BSA and MilliQ 
water. The efficiency of the Pstl restriction was assessed by agarose gel electrophoresis 
prior to restriction with Spel. The sample was re-checked before the fragment was 
isolated and purified. 
AII.2.3 .4 Preparation of the EGFP gene insert 
Pstl and Notl excised the EGFP gene from the pEGFP-NI plasmid. After 
isolation, the insert was purified and assessed by agarose gel electrophoresis. 
AII.2.3 .5 Cloning of the insert into the vector 
The Pstl I Notl I EGFP insert was ligated into the Pstl I Spel I Cx43 I pBi5 
vector with a 5:1 insert to vector ratio to maximize the cohesive (sticky-end) ligation 
(Pstl I Pstl). The non-ligated Spel and Notl recessed ends were filled in with Klenow, 
and the mix subsequently purified. The efficacy of the sticky-end ligation was assessed 
by agarose gel electrophoresis before adding another 1 µl of T 4 DNA Ligase to the 
ligation mix (for the Spel I Notl ligation), which was then incubated as before. The 
sample was then transformed into TO Pl OF' cells with seventy-three colonies screened 
by cracking. The single colony containing an insert ( designated C 16) was purified and 
checked by agarose gel electrophoresis. 
The EGFP / Cx43 / pBi5 clone was then verified by PCR screening using the 
pEGFPR and mCx435 'R, and pEGFP and CxF primer combinations (Tables 2.2 and 
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AIL 1 ), and by restriction enzyme digests. Two new primers were synthesized: CMVF 
(24 bp; Tm of72°C; GCA GTA CAT CAA TGG GCG TGG ATA) and pEGFPR (22 bp; 
Tm of 70°C; GTC AGC TTG CCG TAG GTG GCA T). The new construct was 
evaluated in cell cultures of murine aortic smooth muscle cells and embryonic 
fibroblasts. 
Primer Annealing Extension Predicted Chapter Gene I Plasmid temperature Time (s) / Fragment Pair Reference TA (°C) (ruins) size (kb) 
CxF EGFP/Cx43/pBi5 65 2.20 1.0 kb All pEGFPR 
mCx435'R EGFP/Cx43/pBi5 65 2.20 none All pEGFPR 
Table All.I PCR conditions for specific primer pairs 
AII.2.4 Immunohistochemistry 
Immunohistochemical studies were undertaken using antibodies against VP 16 
and Cx43 in order to detect the products of the individual constructs. The protocol was 
as described in Section 2.3.5 but with the following alterations. The primary antibodies 
used were either mouse anti-Cx43 (1 :250; Chemicon or rabbit anti-Cx43, 1 :250, 
Zymed) or rabbit anti-VPl 6 (1 :50 or 1: 100, Clontech) or combined). After primary 
incubation the cells were rinsed as before, and the pTetOn samples were incubated with 
fluorescein (FITC)-conjugated affinity-purified donkey anti-rabbit (1 :40, Jackson 
Immuno-Research Laboratories Inc, PA, USA) whilst the Cx43 samples were incubated 
with biotinylated horse anti-mouse (1 :500, Jackson Immuno-Research Laboratories Inc, 
PA, USA) or biotinylated donkey anti-rabbit mouse (1 :500, Jackson Immuno-Research 
Laboratories Inc, PA, USA) at room temperature for one hour in a humidified chamber. 
The cells were rinsed again. 
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The single pTetOn transfections were mounted in buffered glycerol (glycerol: 0.5 
M sodium carbonate buffer (2: 1) containing 0.6% (w/v) phenylenediamine, whilst the 
double transfections and single Cx43 transfections were incubated in Texas Red 
conjugated to streptavidin (1 :200, Amersham, USA) for 60 minutes at room temperature 
in a humidified chamber. The cells were washed and mounted in buffered glycerol. 
Preparations were examined using a fluorescence microscope (BH2-RFL, 
Olympus) fitted with the appropriate filters for fluorescein (excitation filter IF-190 + 
EY455, dichroic mirror DM500, barrier filter 0-515) and Texas Red (excitation filter IF-
545 + BG-36, dichroic mirror DM580, barrier filter R-610), and a confocal laser 
scanning microscope (Leica TCS 4D), and the number ofVP16, Cx43 and EGFP 
labelled cells counted. Total cell counts and statistical analyses were performed as 
described in Section 2.3.5. 
AII.3 Results 
AII.3.1 Cloning of SM22a I pTetOn. 
The SM22a I pTetOn clones (expected plasmid size was 7.255 kb) were verified 
by restriction analyses using Spel I EcoRI, PvuIT, Sacl and.Kha! (Figure AII.7). The 
Spel I EcoRI double restriction digest (both enzymes cut in the multiple cloning site of 
pTetOn) removed the SM22a promoter, giving the predicted band sizes of 6.737 and 
0.518 kb. PvuIT, a non-cutter in the restricted SM22a promoter, cuts pTetOn five times 
so five fragments were expected, although one was too small to visualize on a gel. Sacl, 
a single cutter in pTetOn and a non-cutter in the restricted SM22a promoter, gave a 
linear band of about 7.3 kb, whilst.Kha! (cuts once in pTetOn and once in the restricted 
SM22a promoter fragment) generated two fragments of approximately 6.9 kb and 0.4 
kb. Unfortunately, the print resolution in Figure AIL 7 precluded clear visualization of 
all 0.4 kb bands. 
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Figure Ail.7 Verification of the SM22a I pTetOn colonies 
XbaI 
The SM22a I pTetOn clones were verified using the Spel I EcoRI, 
PvuII, Sacl and Xbal restriction enzymes. The expected plasmid size was 
7.255 kb. The Spel I EcoRI double restriction digest removed the SM22a 
promoter, giving bands corresponding to the predicted band sizes of 6.737 
and 0.518 kb (the latter just being visible on the gel). They also confirmed 
the forward orientation of the SM22a promoter in the pTetOn plasmid. 
PvuII cut pTetOn five times so five fragments were expected, although one 
was too small to visualize on a gel. Sac I, gave a linear band of about 7 .2 kb 
whilstXbaI generated two fragments of predicted lengths 6.9 kb and 0.4 kb. 
Unfortunately, the print resolution precluded visualization of the later band. 
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The clone giving the strongest bands on the gel (designated# 47) was chosen for 
bi-directional sequencing. Apart from the three base changes in the SM22a promoter 
already noted in Chapter 3, the sequence did not vary from the published sequence. 
AII.3.2 Testing of the constructs in cell culture 
AII.3 .2.1 Electroporation experiments 
Preliminary electroporative experiments were undertaken with the fibroblasts 
and the control plasmid pJWLacZ, followed by X-gal staining (Allen et al. 1988) to 
determine the number of transformed fibroblasts, and hence luciferase activity. As this 
method produced low numbers of positive healthy cells ( data not shown), which meant 
that the luciferase activity could not be measured, it was decided to change to 
transfection using one of the commercial available reagents in order to introduce the 
DNA into the cultured fibroblasts and smooth muscle cells. 
AII.3 .2.2 Single and double transfections of the fibroblasts 
(a) Single transfections 
In the single transfections of the fibroblasts, without DNA, there were no 
positive CMV-pTetOn cells present and no intense staining of Cx43. Both CMV-
pTetOn and Cx43 / pBi5 were expressed singly in the fibroblasts forty-eight ( 48) hours 
after transfection (Figures AII.8 and AII.9). Expression of Cx43 / pBi5 was attributed to 
either random integration of the plasmid or to residual basal activity of the TRE 
(leakiness). 
The slight increase in CMV-pTetOn expression from 0.64 + 0.05% to 0.85 + 
0.07% (n = 5) with the addition of doxycycline to the medium, was not statistically 
significant (P > 0.05). There was little change in Cx43 / pBi5 expression with 
doxycycline (0.338 + 0.028%; n = 5) or without (0.339 + 0.034%; n = 5). CMV-EGFP 
expression ( 4.24 + 0.41 %; n = 5) was significantly different to CMV-pTetOn expression 
Figure AII.8 Single transfections of the fibroblasts. 
Confocal images of two murine embryonic fibroblasts after transfection with 
CMV-pTetOn (A) and Cx43 / pBi5 (B). Expression of both constructs was detected 
using immunohistochemistry. CMV-pTetOn expression was detected using a 
commercial antibody against VP16 (FITC; fluoresces green) (A) whilst Cx43 / pBi5 
(Cx43) expression was detected using a commercial antibody against Cx43 (Texas Red; 
fluoresces red) (B). Scale bar represents 500 µm. 
(A) 
(B) 
Figure AII.9 Graph of single transfections of fibroblasts. 
Results from single transfections of the fibroblasts using the CMV-pTetOn and 
Cx43 I pBi5 plasmids, both with ( + dox) and without (-dox) the addition of doxycycline 
to the medium are shown. The pEGFP-NI (CMV-EGFP) plasmid was used as the 
control. Expression of the CMV-pTetOn and Cx43 / pBi5 constructs was detected by 
immunohistochemistry using commercial antibodies, whilst CMV-EGFP expression 
was detected by direct fluorescence microscopy. The number of labelled cells counted 
was expressed as a percentage of the total cell count for each slide ( n = 5 experiments 
with duplicate wells per experiment). Each point represents the mean and standard 
error of the mean. 
* Indicates significantly different from control 
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(P < 0.05) and Cx43 / pBi5 expression (P < 0.05). As expected, there was no 
expression of SM22a / pTetOn in the fibroblasts. 
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Expression of CMV-pTetOn, Cx43 / pBi5 and CMV-EGFP following 
transfection was measured at 6 hourly intervals over four 48 hour periods (n = 4; Figure 
All.IO). For both CMV-pTetOn and CMV-EGFP, expression was observed in some 
cells at 6 hours. There was no significant change in the expression levels of CMV -
pTetOn over the 48 hour period (P > 0.05), with expression being maximal at 12 hours. 
In contrast, induction of Cx43 / pBi5 was not recorded until 18 hours post-transfection. 
The slight variation in number of labelled cells from 18 to 24 to 48 hours was not 
statistically significant (P > 0.05), indicating that the maximum induction level of Cx43 
/ pBi5 had already occurred by 18 hours post-transfection. A similar time frame was 
obtained for double transfections using CMV-pTetOn and Cx43 / pBi5 + doxycycline (n 
= 3) where complete expression occurred 24 hours after the addition of the doxycycline 
to the medium. 
(b) Double transfections 
The results of the double transfections are presented in Figure AII.11 for cells 48 
hours after transfection. In the CMV-pTetOn - doxycycline, CMV-pTetOn + 
doxycycline, Cx43 / pBi5 - doxycycline and Cx43 / pBi5 + doxycycline columns, the 
total number of cells stained with either VP16 or Cx43 were counted. As expected, 
doxycycline did not have an effect on CMV-pTetOn expression (1.30 + 0.15% (without) 
and 1.23 + 0.03% (with); P > 0.05; n = 5) but it did increase Cx43 expression (0.80 + 
0.07% (n = 5; without doxycycline) and 1.65 + 0.10% (n = 5; with doxycycline)). The 
increase was statistically significant (P < 0.05). 
When counts were made of cells expressing both CMV-pTetOn and Cx43 / 
pBi5, the numbers were reduced, suggesting that the CMV-pTetOn was inhibiting Cx43 
expression, but there was still a doubling with doxycycline (0.18 + 0.023% (n = 5; 
Figure AII.10 Data on induction of construct expression. 
Single transfections (n = 4) of the fibroblasts using CMV-pTetOn, Cx43 / pBi5 
and CMV-EGFP were undertaken to determine the induction level for each. Data was 
collected at 6 hourly intervals over a 24 hour period and then at 48 hours. Expression of 
the CMV-pTetOn and Cx43 / pBi5 constructs was detected by immunohistochemistry 
using commercial antibodies, whilst CMV-EGFP expression was detected by direct 
fluorescence microscopy. The number of labelled cells counted was expressed as a 
percentage of the total cell count for each slide. Triplicate slides were made in each 
experiment for all time intervals. Each point represents the mean and standard error of 
the mean. 
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Figure AII.11 Double transfections of fibroblasts. 
Results from the double transfections of the fibroblasts are shown opposite. 
Transfections were performed using the CMV-pTetOn and Cx43 / pBi5 plasmids, both 
with(+ dox) and without (- dox) the addition of doxycycline to the medium. 
Expression of the constructs was detected by immunohistochemistry using commercial 
antibodies. CMV-pTetOn expression was detected using a commercial antibody against 
VP 16 (FITC; fluoresces green), whilst Cx43 / pBi5 (Cx43) expression was detected 
using a commercial antibody against Cx43 (Texas Red; fluoresces red). 
In the first four columns, only cells expressing either CMV-pTetOn or Cx43 / 
pBi5 were counted. The number of labelled cells expressing both CMV-pTetOn and 
Cx43 I pBi5 are shown in the last two columns. The number of labelled cells counted 
was expressed as a percentage of the total cell count for each slide (n = 6). Each point 
represents the mean and standard error of the mean. 
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without doxycycline) to 0.53 + 0.03% (n = 5; with doxycycline)). The increase was 
significant (P < 0.05). The expression of the constructs in different parts of the same 
cell is shown in Figures AII.12 and AII.13. 
AII.3 .2.3 Single and double transfections of the smooth muscle cells 
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In the single transfections of the smooth muscle cells, without DNA, there were 
no CMV-pTetOn cells present and no intense expression of Cx43. Results from the 
single and double transfections are shown in Figure AII.14. All data was obtained by 
counting Cx43 expressing cells. In the single transfections (Cx43 / pBi5 + doxycycline) 
there was no significant difference between Cx43 / pBi5 - doxycycline (1.12 + 0.61 %; n 
= 4) and Cx43 / pBi5 + doxycycline (1.02 + 0.42%; n = 4) (P > 0.05). However, in the 
double transfections, doxycycline increased Cx43 expression both with CMV-pTetOn & 
Cx43 I pBi5 (0.93 + 0.17% (without; n = 4) to 2.57 + 0.81 % (with; n = 4; P > 0.05) and 
SM22 I pTetOn & Cx43 / pBi5 (0.13 + 0.02% (without; n = 4) to 0.63 + 0.015% (with; 
n = 4; P < 0.05). EGFP expression was significantly different ( 4.68 + 0.42%; n = 4; P < 
0.05) when compared to all groups. Figure AII.15 shows the distribution of the 
constructs ( double transfections) within the same smooth muscle cells. 
AII.3 .2.4 Cloning of EGFP I Cx43 I pBi5 
As the EGFP expression data from the in vitro testing of the DNA constructs had 
revealed that the imrnunohistochemical detection was not as sensitive as the direct 
detection ofEGFP, the luciferase gene in the Cx43 / pBi5 construct was replaced with 
the EGFP gene from pEGFP-NI (4.733 kb; Figures AII.6 and AII.7). 
Figure AII.12 Confocal images of doubly transfected fibroblasts 
Fibroblasts were transfected with both CMV-pTetOn and Cx43 / pBi5 using 
Lipofectamine Plus, and with the addition of doxycycline to the medium. Expression of 
each construct was detected by immunohistochemistry using commercial antibodies 
against VP16 (FITC; fluoresces green) and Cx43 (Texas Red; fluoresces red). The 
expression of the constructs in different parts of the same cell as seen using the confocal 
microscope is shown (A) and (B). Scale bar represents 500 µm. 
(A) 
(B) 
Figure AII.13 Confocal images of doubly transfected fibroblasts 
Superimposed confocal images of some transfected fibroblasts are shown at high 
power magnification. Immunohistochemistry to detect expression of each construct 
was undertaken using comm~rcial antibodies, as previously mentioned. All images 
saved from the confocal microscope were imported into Photoshop, where images of 
the same cell were superimposed on each other. Cx 4 3 shown in red and VP 16 shown in 
green. The expression of the constructs in different parts of the same cell is shown. 
Scale bar represents 500 µm. 

Figure AII.14 Graph of single and double transfections of murine smooth muscle cells 
Single and double transfections of the murine smooth muscle cells were 
undertaken using the CMV-pTetOn, SM22a/ pTetOn, Cx43 / pBi5 and CMV-EGFP 
plasmids, both with ( + <lox) and without (- <lox) the addition of doxycycline to the 
medium. Expression was detected using commercial antibodies against VP 16 (FITC) 
and Cx43 / pBi5 (Texas Red), with EGFP expression detected by direct fluorescence 
. 
microscopy. 
Single transfections are in columns one and two on the graph, and column seven. 
Columns three to six contain data from the double transfections. The number of 
labelled cells counted was expressed as a percentage of the total cell count for each 
slide (n = 4). Each point represents the mean and standard error of the mean. 
* Indicates significantly different from control. 
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Figure AII.15 Confocal images oftransfected smooth muscle cells 
Superimposed confocal images of two transfected smooth muscle cells 
transfected with both CMV-pTetOn and Cx43 / pBi5, are shown at high power 
magnification (A) and (B). Immunohistochemistry, using the previously mentioned 
commercial antibodies, detected expression of the two constructs within the same cells. 
VP16 shown in green and Cx43 shown in red. All images saved from the confocal 
microscope were imported into Photoshop, where images of the same cell were 
superimposed on each other. Scale bar represents 500 µm. 
(A) 
(B) 
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AII.3 .3 Cloning of EGFP / Cx43 / pBi5 
(a) Restriction analyses 
The potential positive EGFP / Cx43 / pBi5 clone (C16; plasmid size 6.393 kb 
c.f. 7.357 kb for Cx43 / pBi5) was verified by restriction analyses using the Xbal , Asel, 
Pvul, Xmnl and Agel enzymes (Figure AII.16A). 
Xbal, a double enzyme cutter in pBi5 gave one band which, due to the increased 
bandwidth and intensity, was assumed to be a doublet and thus did not correspond with 
the predicted band sizes of 3.671 kb and 2.722 kb. In view of the other results, it was 
judged not to have worked. Pvul, a non-cutter in the EGFP and Cx43 genes, and a 
single cutter in pBi5, only partially cut the construct, indicating that more enzyme was 
needed to achieve the desired linear band. Asel, a non-cutter in both the EGFP and 
Cx43 genes, gave two bands which corresponded to the predicted fragment sizes of 
5.158 kb and 1.235 kb. Xmnl, which cuts once in both Cx43 and pBi5 but not in the 
EGFP gene, also produced two bands which were around the predicted band sizes of 
3.306 kb and 3.087 kb. Agel, a single cutter in EGFP and a non-cutter in the Cx43 gene 
and pBi5 plasmid, generated a linear band which approximated the calculated size of 
6.393 kb. 
Correct insert orientation in the vector was confirmed by a BamHl restriction 
(Figure AII.16B). BamHI cuts EGFP once and pBi5 twice, producing three fragments 
that corresponded to the predicted band sizes of 5.028 kb, 0.692 kb and 0.673 kb. 
(b) PCR screening 
The clone was screened by PCR using the pEGFPR and mCx435'R primers 
(amplified a band around the predicted 1 kb), and the pEGFPR and CxF primers (no 
band was amplified) (Figure AII.17). Thus, in this clone, the EGFP insert had ligated 
into the Cx43 / pBi5 plasmid in the correct orientation. 
AII.3.4 Testing of the construct in cell culture 
The new construct was evaluated in combination with CMV-pTetOn, SM22a / 
pTetOn and EGFP-NI in murine fibroblasts and smooth muscle cells using 
Figure AII.16 Restriction enzyme verification of pEGFP-NI and Cx43 / pBi5 
Restriction enzyme verification of pEGFP-NI is shown in (A). The single 
cutters Natl and Pstl each gave a linear band of around the predicted band size of 4.7 
kb. The Natl I Pstl restriction removed the EGFP gene, giving bands which 
corresponded to the predicted band sizes of 0.763 kb and 3.937 kb (Lane 5). Xbal did 
not cut the plasmid ( expected a linear band of 4. 7 kb if it had) and BamHI gave a linear 
band around 4.7 kb. 
Cx43 I pBi5 was again verified using restriction enzyme digests (B). The single 
cutters Pstl and Spel produced linear bands which corresponded with the predicted band 
size of 7 .4. The Pstl I Spel restriction produced two fragments around the calculated 
fragment sizes of 5.673 kb and 1.727 kb (Lane 6) and also some linear plasmid. Lastly, 
Asel gave two bands of approximately 1.235 kb and 6.122 kb. 
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Figure AII.17 PCR verification of EGFP / Cx43 / pBi5 clone 
PCR screening of the EGFP / Cx43 / pBi5 clone using the pEGFPR and 
mCx435'R, and pEGFPR and CnxF primers (A). The amplified band (pEGFPR and 
mCx435'R; Lane 1) showed that in this clone, the EGFP insert had ligated into Cx43 / 
pBi5 in the correct orientation ( expected band size of about 1 kb). The pEGFPR and 
CnxF PCR did not amplify any fragment, as expected (Lane 2). The water control was 
in Lane 3. 
A schematic diagram of the pEGFPR and mCx435'R PCR is shown in (B). 
Here, the Cx43 gene and EGFP gene are marked, together with appropriate restriction 
enzyme sites for reference. The mCx435'R primer (\V) direction is indicated by an open 
arrow, as is the pEGFPR primer (x) direction. The diagram is not to scale. 
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Lipofectamine Plus, both with and without the addition of doxycycline to the medium. 
In the fibroblasts, both doxycycline free serum and foetal calf serum were used, whilst 
only the doxycycline free serum was used in the smooth muscle cell transfections. 
Expression was detected by direct fluorescence microscopy. 
AII.3 .4.1 Single and double transfections of the fibroblasts 
(a) Single transfections 
Results from the single transfections of the fibroblasts are presented in Figure 
AII.18. When the expression level for EGFP / Cx43 / pBi5 without doxycycline (0.22 ± 
0.06%; n = 5) was compared to that obtained for Cx43 / pBi5 without doxycycline (0.34 
± 0.07%; n = 5), it was not significantly different (P > 0.05). Similarly with EGFP / 
Cx43 I pBi5 with doxycycline (0.23 ± 0.07%; n = 5) and Cx43 / pBi5 with doxycycline 
(0.34 ± 0.06%; n = 5) (P > 0.05). There was no significant difference between the 
expression levels for EGFP / Cx43 / pBi5 without doxycycline and EGFP / Cx43 / pBi5 
with doxycycline (n = 5; P > 0.05). 
The differences between the modified Cx43 / pBi5 construct with foetal calf 
serum (PCS) compared to doxycycline free serum (DPS), with and without the addition 
of doxycycline to the medium, were not significant (P > 0.05; n = 5 and P > 0.05; n = 5, 
respectively). In both the DPS and PCS groups, the addition of doxycycline to the 
medium had no effect on Cx43 expression (P > 0.05), as expected. 
The control CMV-EGFP plasmid did not have a significantly different 
expression level (P > 0.05) compared to the earlier experiments (5.74 ± 1.26%; n = 5, 
and 4.24 ± 0.41 %; n = 5, respectively). CMV-EGFP expression was significantly 
different to all EGFP / Cx43 / pBi5 transfection groups (P < 0.05). 
Figure AII.18 Single transfections of fibroblasts using the modified construct. 
Single transfections of the fibroblasts using the EGFP / Cx43 / pBi5 plasmid, 
both with ( + dox) and without (-dox) the addition of doxycycline to the medium 
containing either the doxycycline free serum (DFS) or foetal calf serum (FCS). The 
CMV-EGFP plasmid was used as the control. Expression ofEGFP I Cx43 I pBi5 and 
CMV-EGFP was detected using direct fluorescence microscopy. Results are expressed 
as the number of labelled cells counted as a percentage of the total cell count for each 
slide. Each point represents the mean and standard error of the mean. 
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(b) Double transfections 
Data from the double transfections of the fibroblasts with CMV-pTetOn and 
EGFP I Cx43 I pBi5 with ( + dox) and without (- dox) the addition of doxycycline to the 
medium containing either doxycycline free serum (DFS) or foetal calf serum (FCS) is 
presented in Figure AII.19. A comparison between DFS and FCS in the medium did not 
reveal any significant difference between the different groups (P > 0.05). The data also 
show that the addition of doxycycline to either medium induced expression of the EGFP 
I Cx43 I pBi5 construct; a difference that when compared to the doxycycline-free state 
was significant (P < 0.05). For DFS this was 4.60 ± 0.63% (FCS 4.74 ± 0.56%); n = 4, 
and 1.62 ± 0.09% (FCS 1.65 ± 0.16%); n = 4, respectively. Compared to earlier 
experiments, this represented a significant increase at the 5% level. The control CMV-
EGFP plasmid again showed a consistent expression level when compared to previous 
transf ections. 
AII.3.4.2 Single and double transfections of the smooth muscle cells 
All single and double transfections were undertaken in medium containing 
doxycycline free serum to abrogate the possibility of residual doxycycline in the foetal 
calf serum. CMV-EGFP, EGFP / Cx43 / pBi5, CMV-pTetOn and SM22a / pTetOn 
were transfected into the murine aortic smooth muscle cells using Lipofectamine Plus 
(Figure AII.20). 
In the single transfections, except for CMV-EGFP, both EGFP / Cx43 / pBi5 -
doxycycline and EGFP / Cx43 / pBi5 + doxycycline had low expression levels (0.26 ± 
0.07%; n = 4, and 0.18 ± 0.04%; n = 4, respectively) especially when compared to the 
previous single transfections with Cx43 / pBi5 (av: 1.0 ± 0.05%; n = 4). This was not 
statistically significant (P > 0.05). The CMV-EGFP expression level was significantly 
different to both EGFP / Cx43 / pBi5 ± doxycycline (P < 0.05). 
Figure AII.19 Double transfections of fibroblasts using the modified construct. 
Double transfections of the fibroblasts using the EGFP / Cx43 / pBi5 and CMV-
pTetOn plasmids, both with ( + dox) and without (-dox) the addition of doxycycline to 
the medium containing either the doxycycline free serum (DFS) or foetal calf serum are 
shown opposite. The CMV-EGFP plasmid was used as the control. Expression of 
EGFP I Cx43 I pBi5 and CMV-EGFP was detected using direct fluorescence 
microscopy. Results are expressed as the number of labelled cells counted as a 
percentage of the total cell count for each slide. Each point represents the mean and 
standard error of the mean. 
* Indicates significantly different from control 
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Figure AII.20 Single and double transfections of smooth muscle cells using the 
modified construct. 
Single and double transfections of the smooth muscle cells using the EGFP / 
Cx43 I pBi5 plasmid with ( + dox) and without (-dox) the addition of doxycycline to the 
medium containing doxycycline free serum. The CMV-EGFP plasmid was used as the 
control. Expression ofEGFP I Cx43 I pBi5 and CMV-EGFP was detected using direct 
fluorescence microscopy. The number of labelled cells counted is expressed as a 
percentage of the total cell count for each slide. Each point represents the mean and 
standard error of the mean. 
* Indicates significantly different from control 
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The CMV-pTetOn and EGFP / Cx43 / pBi5 double transfections showed 
significantly increased expression of EGFP ( and hence inferred Cx43 expression) with 
the addition of doxycycline to the medium (0.27 ± 0.03%; n = 4, and 1.37 ± 0.11 %; n = 
4, respectively; P < 0.05). The expression of CMV-EGFP was significantly different to 
CMV-pTetOn and EGFP / Cx43 / pBi5 ± doxycycline expression (P < 0.05). 
In the double transfections with SM22a I pTetOn and EGFP / Cx43 / pBi5, 
doxycycline increased expression ofEGFP from 0.22 ± 0.08% (n = 4) to 0.62 ± 0.14% 
(n = 4). The increase was statistically significant (P < 0.05). Although the expression 
levels were similar to those observed for the SM22a I pTetOn and Cx43 / pBi5 double 
transfections, the increase in expression with doxycycline was more marked this time, 
indicating that direct EGFP detection was more sensitive than immunohistochemical 
detection. CMV-EGFP expression was constant at 8.2 ± 1.0% (n = 4) and significantly 
different when compared to the other transfection groups (P < 0.05). 
AIL4 Discussion 
The three constructs SM22a I pTetOn, Cx43 I pBi5 and EGFP / Cx43 / pBi5 
were successfully cloned, and subsequently verified using a combination of restriction 
analyses, PCR screening and bi-directional sequencing. The sequencing data from each 
construct showed that apart from the base changes already noted in the SM22a 
promoter, no other base changes had occurred in any construct during the cloning 
process and therefore, the constructs were ready for testing in vitro in murine embryonic 
fibroblasts and aortic smooth muscle cells. 
The CMV-pTetOn, SM22a / pTetOn, Cx43 / pBi5, EGFP / Cx43 / pBi5 and 
CMV-EGFP plasmids were transfected into the fibroblasts and smooth muscle cells 
using the Lipofectamine Plus Reagent, albeit at varying efficiencies. CMV-pTetOn 
expression was detected using a commercial antibody against VP 16 (FITC; fluoresces 
green) whilst Cx43 / pBi5 (Cx43) expression was detected using a commercial antibody 
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against Cx43 (Texas Red; fluoresces red). Expression of CMV-EGFP and EGFP / Cx43 
/ pBi5 was detected by direct fluorescence microscopy. 
In the single transfections of both the fibroblasts and smooth muscle cells, 
without DNA, there were no CMV-pTetOn (VP16 positive) cells present and no intense 
staining of Cx43. CMV-pTetOn expression was observed both with and without the 
addition of doxycycline to the medium, albeit at low rates when compared to the control 
plasmid CMV-EGFP. Even lower rates of expression were observed for Cx43 / pBi5 
both with and without the addition of doxycycline to the medium. In both the CMV -
pTetOn and Cx43 / pBi5 single transfections, the addition of doxycycline to the medium 
did not increase expression levels as was expected. 
The observation that there was some Cx43 expression in the single transfections 
of Cx43 I pBi5 suggested that there had been random integration of the plasmid. Also, 
as the Cx43 / pBi5 construct was not expected to show any expression, it was likely that 
there was some 'leakiness' of the TRE ( tetracycline response element) or that there was 
some residual doxycycline present in the foetal calf serum. The latter possibility was 
ruled out by further experimentation using the doxycycline free serum, the results of 
which showed that there was no difference in the number of labelled cells for any 
transfection in the fibroblasts whether or not DFS (doxycycline free serum) or FCS 
( foetal calf serum) had been used. A similar result was also noted by another group 
working with the TetOn system in vitro (Ranu Mital , pers com). These results are 
further substantiated by the fact that doxycycline is rarely used in the bovine industry 
due to cost; tetracyclines being the drug of choice to treat bacterial infections and to 
increase carcase weight. Therefore, the calf and foetal calf serums used in cell culture 
are not likely to retain much, if any, residual doxycycline. Residual tetracycline is not 
likely to be of concern in the pTetOn system as the rtTA responds minimally to it 
(Gossen and Bujard, 1992). It has recently been stated that the pTetOn system is 
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responsive only to doxycycline and not to tetracycline (Gossen and Bujard, 1995; 
Clontech, 2000). 
'Leakiness ' is defined by Bujard (1996) as the intrinsic activity of the minimal 
promoter upon transfer into cells; the activity varying between different cell types. It is 
not uncommon in transient expression systems because the rtTA (or tTA) responsive 
transcription unit is in a non-integrated state in the cell. Whenever integration of genes 
responsive to either tT A or rtT A does not occur at a chromosomal site or at suitable 
chromosomal sites, unregulated basal transcription may be observed (Freundlieb et al. 
1999). Some applications are known to be hampered by this residual basal activity 
(Furth et al. 1994; Howe et al. 1995; Kistner et al. 1996). 
The residual activity of the minimal promoter in the current study was 
considered acceptable, especially as it is known that when a transcription unit controlled 
by a minimal promoter-tet operator sequence is integrated into the chromosome, the 
residual activity is drastically reduced (Bujard, 1996). If the background expression had 
indeed been excessive, a different minimal promoter would most likely have been 
selected, such as a Tk-based promoter. Recently, problems due to high background 
expression from tetracycline responsive promoters have been ameliorated by the use of 
tetracycline-sensitive transcriptional repressors I silencers (tTS) (Forster et al. 1999; 
Freundlieb et al. 1999; Rossi and Blau, 1998). The tTS bind promoters responsive for 
rtT A in the absence of the effector doxycycline, causing a ten to two hundred fold 
repression in transient expression systems (Freundlieb et al. 1999). 
In the double transfections of both the fibroblasts and smooth muscle cells, the 
modified pBi5 plasmids responded to CMV-pTetOn (VP16) and doxycycline (Figures 
AII.11 and AII.14). Cx43 expression was increased in the double transfections of the 
smooth muscle cells using SM22a / pTetOn and Cx43 / pBi5, and with doxycycline 
added to the medium. Consequently, it was inferred that the SM22a / pTetOn construct 
had been successfully transfected into the smooth muscle cells. Also, as no expression 
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of this construct was detected in the fibroblasts, the tissue specificity of the construct 
was confirmed. 
Data obtained from the time course study of the induction of expression of the 
CMV-pTetOn, Cx43 I pBi5 and CMV-EGFP constructs, showed a bell-shaped curve for 
CMV-EGFP expression, in contrast to the apparent steady-states of CMV-pTetOn and 
Cx43 I pBi5. This may be attributed to the more sensitive EGFP detection method 
compared to immunohistochemical detection; a contention which is supported by the 
fact that Cx43 / pBi5 expression was not detected until 18 hours post-transfection ( even 
though the plasmid had not been expected to express at all, as previously discussed). 
Furthermore, low rates of expression were recorded for CMV-pTetOn compared with 
those for CMV-EGFP. 
The results presented above suggest that immunohistochemical detection was not 
as sensitive as the direct EGFP detection method. The CMV-EGFP control was 
continually producing high levels of expression in both the fibroblasts ( about 7%) and 
the smooth muscle cells ( about 8% ), compared to the other constructs. Consequently, 
the Cx43 I pBi5 construct was modified by replacing the luciferase gene with the EGFP 
gene (EGFP I Cx43 I pBi5). EGFP measurement is renowned for being easy to monitor 
by using standard fluorescein microscope excitation / emission filters. 
Green fluorescent protein (GFP), originally isolated from the jellyfish Aequorea 
victoria, has been fused to many proteins in a range of species ( eg. mice; Chiocchetti et 
al. 1997; Jordan et al. 1999) to produce stable chimaera which retain their normal 
biological activity as well as retaining the fluorescent properties of native GFP (Prasher 
et al. 1992; Chalfie et al. 1994; Stearns, 1995). This allows a diverse range of 
biological functions to be studied in vivo. As GFP is distributed throughout the cell, 
both in the nucleus and cytoplasm, it is widely used as a reporter for gene expression 
and as a fusion tag to monitor protein localization in vivo (Misteli and Spector, 1997). 
The autofluorescing EGFP is a red-shifted eukaryotic cytoplasmic mutant of GFP that 
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fluoresces thirty-five times more intensely than the wild-type GFP (Cormack et al. 
1996), and thus has greater potential as a reporter system. As there are no mammalian 
homo logs to EGFP, there is no specific fluorescence from endogenous GFPs in 
mammalian cells, although there is variable non-specific autofluorescence (Kisseberth et 
al. 1999). 
Giaretta et al. (2000), in their comparative study of gene transfer into blood cells, 
concluded that EGFP marker genes are useful for rapid, safe and non-toxic detection of 
transduced cells; EGFP appearing particularly useful in the optimisation of gene transfer 
protocols in vitro. Similar in vitro conclusions have been drawn by others (Casey et al. 
2000). Duprex et al. (2000) and Henry et al. (2000), for example, have also reported on 
the efficacy of using EGFP coupled to measles virus and murine cytomegalovirus 
respectively, both in vivo and in vitro. However, Stripecke et al. (1999), have shown 
that in mice, the immune response against EGFP and GFP is high, indicating that their 
widespread application in vivo is potentially premature. 
EGFP has now been successfully fused to the TetR / VP16 DNA in order to 
rapidly select tetracycline-controlled inducible cell lines (Callus and Mathey-Prevot, 
· 1999). Recently, EGFP has been coupled to the Cx43 gene to study the formation, 
turnover and function of this connexin in in vitro mammalian cells (Jordan et al. 1999; 
Bukauskas et al. 2000). 
By using EGFP coupled to Cx43 / pBi5 in the current study, the number of 
labelled cells counted in the single transfections of the fibroblasts was decreased 
considerably compared to that of previous experiments, whilst in the double 
transfections, the number of labelled cells counted increased. The decrease in 
expression in the single and double transfections of the smooth muscle cells, may have 
been attributable to the use of the new serum (DFS) and not to any intrinsic property of 
the EGFP gene. However, it is more likely due to the elimination of false positives from 
the immunohistochemical detection of increased Cx43 expression, as was the case for 
179 
the single transfections of the fibroblasts. These results illustrate the effectiveness of the 
direct EGFP detection method compared to immunohistochemical methods for studies 
of this type. 
The lower expression levels of Cx43 in the double transfections with SM22a / 
pTetOn compared with those with CMV-pTetOn may be attributable to the nature of the 
DNA constructs or to the CMV promoter. The cytomegalovirus promoter is known to 
be a promoter capable of producing high expression levels of many genes in a wide 
variety of cells (Almouzni and Wolfe, 1993), and especially after transfection. The 
same situation does not exist for the tissue specific SM22a promoter. 
As discussed in Chapter 3, transient transfection of various SM22a promoter 
lengths has been previously reported. The expression levels obtained using the modified 
SM22a / pTetOn construct are clearly much lower than those for other constructs 
already published ( c.f. Kemp et al. 1995; Solway et al. 1995; Li et al. 1996; Moessler et 
al. 1996). However, direct comparisons cannot be made for several reasons as 
discussed in Chapter 3. 
Furthermore, it is possible that the coupling of the restricted SM22a promoter to 
the pTetOn plasmid in some way affected the performance of the promoter. 
Alternatively, the ubiquitous nature of the CMV promoter in pTetOn may be solely 
responsible. Both hypotheses could be supported by the data from the current study, 
where higher levels of Cx43 expression were detected when the modified pBi5 plasmids 
were transfected with the CMV-pTetOn plasmid compared with the SM22a / pTetOn 
plasmid. However, in view of the fact that several studies have shown that the CMV 
promoter allows a higher degree of expression of a gene compared with other 
promoters, such as the phosphoglycerolkinase promoter, for example (Gerolami et al. 
2000), the latter would seem to be more plausible. 
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The activity ( or expression) of a gene regulated by the tetracycline expression 
system also depends on the number of copies of the gene in the cell, which depends on 
the amount of DNA used for transfection (Bujard, 1996). Control experiments tested 
varying concentrations of CMV-EGFP and Lipofectamine Plus in the cell cultures; the 
optimal levels being 0.4 µg DNA and 4 µl Lipofectamine Plus in 25 µl serum free 
medium for each transfection ( data not shown). Double transfections were performed 
with increased D,NA concentrations (double) for each co-transfected construct, and also 
by maintaining each at 0.4 µg. 
Transfections in the current study were undertaken with equal amounts of each 
vector which, in hindsight, may not have been ideal.. This contention is supported by 
Bujard (1996), for example, who states that the ratio of the rtTA producing plasmid 
verses the response plasmid is critically important, with an excess of rtT A over response 
( up to 100-fold) being advisable to ensure high intracellular concentrations of rtT A. 
However, the fact that the transactivator may be toxic, thus imposing a growth 
disadvantage on cells expressing them at high levels, also needs to be considered (Saez 
et al. 1997; Strathdee et al. 1999). Hence, based on data obtained from this study, an 
initial titration of the regulator and response plasmids to determine the optimal ratio of 
the two plasmids would be recommended .. 
The nature of the double transfections raises another issue, that of co-
transfection. Co-transfection of the regulator plasmid (CMV-pTetOn or SM22a / 
pTetOn) and the response plasmid (Cx43 / pBi5 or EGFP / Cx43 I pBi5) can result in 
high background expression of the regulated gene (Cx43), which is not affected by the 
presence or absence of the antibiotic (tetracycline or doxycycline; Gossen and Bujard, 
1992). This is especially the case in stable co-transfections. Recently, in the Tet 
S stems User Manual (Clontech, 2000), it was recommended that that the regulator and 
response plasmids not be co-transfected for two principle reasons. Firstly, due to the 
induced basal expression levels as mentioned abo e and also, as the response plasmid 
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generally will not co-integrate with the regulator, giving cells with very low or no 
expression of the gene of interest. The background expression levels detected in the 
current transient experiments were relatively low but, as discussed previously, all 
expression levels were below that achieved by other studies using different constructs. 
In future experiments it would be advisable to trial separate transfections of the response 
and regulator plasmids, and compare the results with the data obtained in the current 
study. This would, of course, necessitate the use of stably transfected cells. 
Consequently, it would be recommended that for future studies of this type, or if 
the experiments were to be repeated, stably transfected cells be used. This would 
eliminate the basal expression levels of pBi5 alone and the spurious results emanating 
from using co-transfections. In co-transfections, the response plasmid will not generally 
co-integrate with the regulator giving cells with very low or no expression of the gene of 
interest (Clontech, 2000). 
The transient nature of the fibroblast and smooth muscle cell culture systems was 
not considered an important factor in the modulation of the various expression levels. It 
is recommended that the tetracycline expression system be tested first in a transient 
experiment with double transfections of the rtTA expression vector, an unregulated 
internal standard to examine the transfection efficiency and the response vector, in the 
absence or presence of 1 mg / ml doxycycline (Bujard, 1996). The latter factor leads to 
another area, which in hindsight, could have been exploited to optimize expression 
levels. 
The antibiotics tetracycline and doxycycline are known to enter vertebrate cells 
by passive diffusion and thus, the concentration inside the cells correlates with the 
amount added to the culture medium. Although the recommended concentration of 
doxycycline is 1 mg/ ml (Gossen and Bujard, 1992; Kringstein et al. 1998), it has been 
found that optimal concentrations for cells other than He La cells may vary. 
Furthermore, as the affinity of rtT A for doxycycline is lower than that for tT A, there is a 
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concentration of doxycycline at which rtTA will not bind DNA efficiently (Gossen et al. 
1995). The same is also applicable for tTA (Rossi and Blau, 1998). Consequently, 
varying concentrations of doxycycline should be trialled in cell culture to optimize the 
functioning of the tetracycline expression system. Also, although uptake of doxycycline 
is very fast, it would be interesting to pre-incubate cells with doxycycline prior to 
transfection, as it is known that some cell lines may behave differently in such 
circumstances (Gossen et al. 1995). To date, these antibiotics have been used for many 
years in both animals and humans, with deleterious effects only being detected at high 
dosages. 
A final consideration is that for all transfections, either single or double, the 
expression levels in the fibroblasts varied from those observed in the smooth muscle 
cells. This was not unduly surprising as the efficacy, sensitivity and toxicity of a 
transfection reagent was known to depend on a variety of parameters, some of which, 
have already been discussed. These include, for example, growth rates of cells 
(Pickering et al. 1996), cell type ( eg. smooth muscle cell versus endothelial cell) and 
cell species ( eg. rat versus human), absence of serum (Escriou et al. 1998), and DNA 
purity (Clontech, 2000)- which was the same for all constructs in the current study. 
The majority oftransfection studies so far have been performed on animal cells 
but unfortunately, and not surprisingly, not all cell types have been studied. To date, 
there is a paucity of published data examining the efficient transfection of primary 
murine smooth muscle cells. The success and effectiveness of the new liposomal and 
non-liposomal transfection reagents remains to be elucidated. 
A further factor to be considered in the interpretation of the increased double 
transfection expression levels in the fibroblasts compared with the smooth muscle cells, 
is the fact that the various plasmids may respond (ie: express) differently in the two cell 
lines. Howe et al. (1995), for example, found that tetracycline-sensitive inducible 
expression differed between two mammalian cell lines: GH3 cells derived from the rat 
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pituitary and HEK293 cells derived from the human embryonic kidney. They concluded 
that the inducible expression system does not function optimally in HEK 293 cells. 
Others have also shown that efficacy of tetracycline-controlled gene expression is 
influenced by cell type (Ackland-Berglund and Leib, 1995; Gossen and Bujard, 1995). 
Therefore, this aspect must also be considered when analyzing the results from the 
transfections and when comparing data from other studies. 
One of the advantages of the tetracycline expression systems is the high 
inducibility and response times. In contrast to other systems for mammalian expression, 
which may take up to several days, Clontech (2000) state that induction can be detected 
within 30 minutes in stably transfected cell lines (with doxycycline). In the current 
study, induction of CMV-pTetOn and CMV-EGFP expression had occurred by 6 hours 
post-transfection, with the maximum induction level peaking at 18 hours post-
transfection for CMV-EGFP. However, the Cx43 / pBi5 construct did not show any 
expression until 18 hours post-transfection. A similar time frame was obtained for the 
double transfections using CMV-pTetOn and Cx43 / pBi5 with doxycycline where 
complete expression occurred 24 hours after the addition of the doxycycline to the 
medium. For all constructs, the expression levels did not vary significantly from the 
time that expression was recorded. This is in accordance with other studies. These 
results indicate that the expression of the three plasmids occurs within 24 hours after 
transfection, making them relatively highly inducible. 
Kistner et al. (1996) showed that in transgenic mice, the administration of oral 
doxycycline rapidly induced synthesis of the indicator enzyme luciferase within the first 
four hours in some organs, with complete induction occurring after 24 hours in most 
organs studied. Longer induction times have, however, been recorded. Mansuy et al. 
(1998), for example, combined the rtTA with the CaMKIIalpha promoter and found that 
doxycycline induces maximal gene expression in neurons of the fore brain within six 
days. Hence, there exists a range of maximal induction times, depending on the organs 
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or tissues being targeted. Reversibility of the system is usually evident within 48 hours 
(Sturtz et al. 1998; Clontech, 2000). 
Generally, the basic premise with rtT A is that transient experiments are more 
complicated than with tTA. Recently, Paulus et al. (2000) reported higher regulation 
with the conventional tet system than with the reverse tet system (rtTA) in C6 glioma 
and rat-1 fibroblast clones. They also noted a very high variability in absolute 
expression levels in rat cells in vitro. A further limitation of the rtTA system, which 
was briefly alluded to, is the fact that the full potential of the rtT A regulation system can 
only be exploited in stably transfected cells since it relies on two sequential stable 
transfections for optimal inducibility (Gossen and Bujard, 1992; Bujard, 1996). 
Consequently, it is not ideal for use with primary cultures. 
Despite the limitations and problems inherent in the tetracycline expression 
system, especially with the rtTA, the data obtained in this study indicate the applicability 
of the system to studies involving gene manipulation. By careful adaptation of the 
expression vector to the host cell line, the full range of regulatory properties of 
tetracycline-controlled gene expression can be exploited (Hoffmann et al. 1997). 
At present, several inducible systems have been established in transgenic mice, 
but all have limitations. The various eukaryotic promoters used in the 1980s to control 
gene activity invariably suffered from leakiness of the inactive state (basal leakiness; 
Mayo et al. 1982) or from the wide variety of effects caused by the inducing agents 
themselves, such as toxicity, non-specific effects such as activation of endogenous 
genes, increased glucocorticoid activity or elevated temperature (Y arranton, 1992). 
Limited availability of cell specific promoters and low levels of gene expression were 
also problems (Y arranton, 1992). 
By the late 1980s, work on regulatory systems that do not rely on endogenous 
control elements had begun. This lead to the adoption of well-characterized regulatory 
systems from Escherichia coli for use in mammalian cells (Gossen et al. 1993). 
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Although transgenic systems based on the lac operon were unsatisfactory (Y arranton, 
1992), those which were based on the tetracycline-resistance operon tet from the E. coli 
transposon Tnl O enabled a new approach to be made in the control of transgene 
expression (Gossen and Bujard, 1992, 1993). The tetracycline regulatory system gives 
tight and reversible control of foreign gene activity in mammalian cells, permitting the 
study of particular gene functions in transfected cells (Buckbinder et al. 1994; Resnitzky 
et al. 1994; Yin et al. 1996) and in vivo gene transfer/ regulation studies (Fishman, 
1998). It has also been successfully used in transgenic mice to control expression of a 
transgene (Furth et al. 1994; Hennighausen et al. 1995; Kistner et al. 1996; Schultze et 
al. l 996; Chen et al. 1998; Sarao and Dumont, 1998; Tremblay et al. 1998; Bogeroger 
and Gruss, 1999 and Soulier et al. 1999). 
In conclusion, Cx43 expression was increased in the double transfections with 
SM22a I pTetOn (CMV-pTetOn) and Cx43_ / pBi5, and with SM22a / pTetOn (CMV-
pTetOn) and EGFP / Cx43 / pBi5, with doxycycline added to the medium. Although 
expression levels of Cx43 (inferred from EGFP expression) were lower than expected, 
and lower than those produced by the CMV-pTetOn and Cx43 / pBi5 ( or EGFP I Cx43 I 
pBi5) double transfections, the tetracycline expression system was shown to induce 
temporal and tissue specific expression of Cx43 in both the fibroblasts and smooth 
muscle cells. Thus, two constructs had been made which would form the basis of the 
temporal and tissue specific mouse. 
